

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/395, C07H 21/04, A01N 61/00, 37/18, 43/04, C12N 5/00, 15/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/10602</b> <b>(43) International Publication Date:</b> 2 March 2000 (02.03.00)
<b>(21) International Application Number:</b> PCT/US99/19068 <b>(22) International Filing Date:</b> 18 August 1999 (18.08.99) <b>(30) Priority Data:</b> 60/096,996 18 August 1998 (18.08.98) US 60/096,997 18 August 1998 (18.08.98) US <b>(71) Applicant (for all designated States except US):</b> YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> XU, Tian [US/US]; 149 Flag Marsh Road, Guilford, CT 06437 (US). TAO, Wufan [US/US]; 420 Delaware Street S.E., Box 806 Mayo, Minneapolis, MN 55455 (US). ST. JOHN, Maie, A., R. [US/US]; 2351 Camden Avenue, Los Angeles, CA 90064 (US). FEI, Xiaolan [US/US]; Apartment 21, 393 Mansfield Street, New Haven, CT 06511 (US). FUKUMOTO, Royd, K. [US/US]; P.O. Box 1266, Alea, HI 96701 (US). ZHANG, Sheng [US/US]; 146 Cottage Street S.E., New Haven, CT 06511 (US). TURENCHALK, Gregory, S. [US/US]; 820 Orange Street, New Haven, CT 06511 (US). STEWART, Rodney, A. [US/US]; Apartment B, 512 Whitney Avenue, New Haven, CT 06511 (US).	<b>(74) Agents:</b> ANTLER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> LATS KNOCK-OUT ANIMAL MODELS AND THEIR USES  <b>(57) Abstract</b>  A recombinant non-human animal having an inactivated <i>lats</i> gene is described. A <i>lats</i> knock-out mouse is exemplified. Because mice disrupted for the <i>lats</i> gene develop a variety of tumors, are susceptible to induction of skin tumors by exposure to carcinogens, and exhibit pituitary dysfunction, they have utility in screening for compounds effective to treat or prevent cancer or pituitary disorders. Compounds can be screened for activity in treating or preventing skin cancer in recombinant non-human animals which have an inactivated and in which skin tumors have been induced by exposure to carcinogens. Methods for treatment of cancers refractory to treatment with chemotherapy or radiation therapy by using a therapeutic that promotes <i>lats</i> function are also described. Additional methods are described for the treatment or prevention of diseases and disorders associated with aberrant levels of <i>cdc2</i> activity with a therapeutic that either promotes, inhibits or antagonizes <i>lats</i> function.		

ATTORNEY DOCKET NUMBER: 6523-020-999  
SERIAL NUMBER: 09/763,334  
REFERENCE: AJ

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## LATS KNOCK-OUT ANIMAL MODELS AND THEIR USES

5           This invention was made with Government support under Grant number NIH-NCI 1  
R01 CA 69408 awarded by the National Institutes of Health. The Government has certain  
rights in the invention.

RELATED APPLICATIONS

10           Priority is claimed to United States provisional application Serial Nos. 60/096,997  
and 60/096,996, both filed on August 18, 1998, both of which are incorporated by reference  
herein in their entireties.

FIELD OF THE INVENTION

15           The present invention relates to the use of lats proteins, derivatives and fragments  
for the treatment of cancer, particularly for the treatment of cancer that is refractory to  
treatment by standard chemotherapy and radiation therapy protocols. The present invention  
also relates to the use of lats proteins, derivatives and fragments for the treatment of  
diseases and disorders associated with an aberrantly high or aberrantly low level of cdc2  
20 activity. The present invention further provides complexes of lats and cdc2, and their  
production and uses. The present invention also provides an animal model for cancer,  
particularly for skin cancer, soft tissue sarcomas, and ovarian tumors, and for pituitary  
disorders. The animal model is preferably a mouse, in which a *lats* gene has been disrupted  
by homologous recombination, *e.g.*, a *lats* knock-out mouse. The present invention also  
25 provides methods of screening potential therapeutics for efficacy in the treatment and  
prevention of cancer and pituitary disorders using *lats* knock-out animals.

BACKGROUND OF THE INVENTION**Cancer**

30           A neoplasm, or tumor, is a neoplastic mass resulting from abnormal uncontrolled  
cell growth, which may cause swelling on the body surface, and which can be benign or  
malignant. Benign tumors generally remain localized. Malignant tumors are collectively  
termed cancers. The term "malignant" generally means that the tumor can invade and  
destroy neighboring body structures and spread to distant sites to cause death (for review,  
35 see Robbins and Angell, 1976, *Basic Pathology*, 2d Ed., W.B. Saunders Co., Philadelphia,  
pp. 68-122). Treatment options, such as surgery, chemotherapy and radiation treatment, are

either ineffective or present serious side effects. Thus, there is a need for development of new drugs for the treatment of cancer.

### **The Cell Cycle and Tumor Suppressors**

5 Many cancers have been linked to perturbations in the regulation of the cell cycle, resulting in deregulation of cell growth. Briefly, the cell cycle occurs in four stages: G1 (for Gap1), the resting stage prior to DNA synthesis; S (for synthesis) phase, in which DNA synthesis occurs; G2 (for Gap2), the resting stage after DNA synthesis and prior to mitosis; and M phase, mitosis, in which cell division occurs. Progression of the cell cycle is driven  
10 by a group of cyclin-dependent kinases (CDKs) (Elledge, 1996, Science 274:1664-1672; Nasmyth, 1996, Science 274:1643-1645). The kinase activities of CDKs require their positive subunits, the cyclins, and the activities of specific CDK/cyclin complexes are in turn positively and negatively regulated by phosphorylation events and CDK inhibitors (CKIs) (Hunter and Pines, 1995, Cell 80:225-236; Morgan, 1995, Nature 374:131-134).  
15 While the specific CDKs, CDK2, CDK4 and CDK6, along with Cyclins D and E, regulate the progression from G1 into S phase, cdc2, along with Cyclins A and B, regulate the cell cycle progression from G1 into mitosis (Hunter and Pines, 1995, Cell 80:225-236).

Human tumor suppressors often act as negative regulators of the cell cycle, and several tumor suppressors are known to affect the activities of the CDK/cyclin complexes.  
20 For example, p53 activates the transcription of the p21 (p21<sup>WAF1/CIP1</sup>) CDK inhibitor in response to DNA damage signals, and p21 in turn binds and inactivates the CDK4 and CDK6 cyclin D complexes (Gartel et al., 1996, Proc. Soc. Exp. Biol. Med. 213:138-149). Another CDK inhibitor, p16, is itself a potent tumor suppressor (Biggs and Kraft, 1995, J. Mol. Med. 73:509-514). Although multiple members of the p16 and p21 inhibitor families have been identified for other major CDKs, corresponding inhibitors that regulate the  
25 mitotic CDK, cdc2, have not previously been identified (Morgan, 1995, Nature 374:131-134).

### **Cancer Therapy**

Currently, cancer therapy may involve surgery, chemotherapy and/or radiation  
30 treatment to eradicate neoplastic cells in a patient (see, for example, Stockdale, 1998, "Principles of Cancer Patient Management", in Scientific American: Medicine, vol. 3, Rubenstein and Federman, eds., Chapter 12, Section IV). All of these approaches pose significant drawbacks for the patient. Surgery, for example, may be contraindicated due to the health of the patient or may be unacceptable to the patient. Additionally, surgery may not completely remove the neoplastic tissue. Radiation therapy is only effective when the  
35 neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue, and radiation therapy can also often elicit serious side effects.



With respect to chemotherapy, there are a variety of chemotherapeutic agents available for treatment of neoplastic disease. A significant majority of cancer chemotherapeutics act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of the deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division (see, for example, Gilman et al., Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Eighth Ed. (Pergamom Press, New York, 1990)). These agents, which include alkylating agents, such as nitrosourea, anti-metabolites, such as methotrexate and hydroxyurea, and other agents, such as etoposides, campathecins, bleomycin, doxorubicin, daunorubicin, etc., although not necessarily cell cycle specific, kill cells during S phase because of their effect on DNA replication. Other agents, specifically colchicine and the vinca alkaloids, such as vinblastine and vincristine, interfere with microtubule assembly resulting in mitotic arrest. Chemotherapy protocols generally involve administration of a combination of chemotherapeutic agents to increase the efficacy of treatment.

Despite the availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks (see, for example, Stockdale, 1998, "Principles Of Cancer Patient Management" in Scientific American Medicine, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10). Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous, side effects, including severe nausea, bone marrow depression, immunosuppression, etc. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even those agents that act by mechanisms different from the mechanisms of action of the drugs used in the specific treatment; this phenomenon is termed pleiotropic drug or multidrug resistance. Thus, because of drug resistance, many cancers prove refractory to standard chemotherapeutic treatment protocols. There is a significant need for alternative cancer treatments, particularly for treatment of cancer that has proved refractory to standard cancer treatments, such as surgery, radiation therapy, and chemotherapy.

### Pituitary Disorders

The pituitary regulates numerous biological functions through its secretion of different hormones. (For review see Frohman, "The Anterior Pituitary" in Cecil Textbook of Medicine, 18th Ed., Wyngaarden and Smith, eds. (W.B. Saunders Company, Philadelphia, 1988) pp. 1290-1305). In particular, the pituitary releases glycoprotein hormones, which include luteinizing hormone (LH) and follicle stimulating hormone (FSH); LH and FSH regulate ovarian and testicular development as well as reproductive functions such as ovulation and spermatogenesis. Disruption of LH or FSH secretion has dramatic consequences for reproductive function, particularly for ovulation in the female. The pituitary also releases somatomammotropic hormones, including growth hormone and

prolactin. Growth hormone promotes linear growth and is involved in the regulation of certain metabolic functions such as sugar and amino acid uptake and use of fat stores. Prolactin stimulates and maintains lactation in post-parturition females. Although an increase or decrease in prolactin levels does not appear to have significant biological consequences beyond an effect on lactation, disruption of growth hormone secretion stunts growth and has other metabolic effects. Other pituitary hormones include corticotropin (ACTH), thyroid stimulating hormone (TSH), and endorphins and related peptides. Although in some situations, hormone replacement therapy is available, there is a need for additional therapeutics to treat or prevent pituitary dysfunctions.

## 10 LATS

The *large tumor suppressor* or *lats* gene (also known as *warts*), a tumor suppressor gene, was previously isolated from *Drosophila* using a mosaic screen. Inactivation of *lats* in somatic cells causes dramatic overproliferation phenotypes (Xu et al., 1995, Development 121:1053-1063; Justice et al., 1995, Genes & Devel. 9:534-546). Somatic cells that are mutant for *lats* undergo extensive proliferation and form large tumors in many tissues of mosaic flies (Xu et al., 1995, Development 121:1053-1063). Tumors that result from inactivation of *lats* display many features of human neoplasms. *Lats* mutant cells grow aggressively, and a single mutant cell can develop into a tumor that is 1/5 the size of the animal, and these fly tumors are highly irregular in shape and size and are often poorly differentiated (St. John and Xu, 1997, Am. J. Hum. Genet 61:1006-1010). *Drosophila* that are homozygous for the various *lats* alleles display a wide range of developmental defects including embryonic lethality, overproliferation of both neural and epidermal tissues, rough eyes, and sterility. Molecular characterization of *lats* indicates that it contains a putative kinase domain (Xu et al., 1995, Development 121:1053-1063; Justice et al., 1995, Genes & Devel. 9:534-546).

Mouse and human homologs of the *Drosophila lats* have also been identified, and human *lats* was found to be down-regulated in a large number of human tumor cell lines. The nucleotide and amino acid sequences of human *lats* (h-*lats*), mouse *lats* (m-*lats*), mouse *lats2* (m-*lats2*) and *Drosophila lats* are provided herein in Figures 12-15, respectively (SEQ ID NOS:1-8, respectively), and are described in PCT Publication WO 96/30402, published October 3, 1996, which is incorporated by reference herein in its entirety.

Citation of references hereinabove shall not be construed as an admission that such references are prior art to the present invention.

## SUMMARY OF THE INVENTION

The present invention relates to therapeutic and prophylactic methods and compositions for the treatment and prevention of cancers based on *lats* proteins, and therapeutically and/or prophylactically effective analogs and fragments of *lats* protein. This is due to the fact that although most tumor suppressor genes regulate the G1/S phase of the

cell cycle, the lats protein interacts with the cell cycle-dependent kinase cdc2, which is involved in the regulation of the G2 to M transition of the cell cycle, and thereby provides a means to regulate the G2 to M transition of the cell cycle and to treat cancers that have proven refractory to other cancer treatments, including chemotherapy and radiation therapy treatments. The invention provides for treatment and prevention of cancer by  
5 administration of a therapeutic compound of the invention. The therapeutic compounds of the invention useful for treatment of cancer refractory to a chemotherapy and/or radiation therapy protocol include: lats proteins, and therapeutically effective analogs and derivatives (including fragments) of lats, nucleic acids encoding lats proteins and therapeutically effective analogs and derivatives of lats, and lats agonists.

10 The invention further provides assays, both *in vivo* and *in vitro*, for testing the efficacy of the therapeutics of the invention for treatment of cancer, particularly cancer that has been shown to be refractory to chemotherapy and radiation therapy treatments.

In another aspect, the invention provides compositions and methods of production of complexes of lats and cdc2 proteins ("lats-cdc2 complexes"), including complexes of lats  
15 analogs or derivatives and cdc2 analogs and derivatives (including complexes of lats proteins with cdc2 analogs and derivatives and vice versa), where the analogs and derivatives have the ability to interact with the other member of the complex.

The phosphorylated form of lats complexes with cdc2. Accordingly, in a preferred embodiment, the lats-cdc2 complexes contain phosphorylated lats protein, specifically lats protein phosphorylated on a serine or threonine residue within 20 residues upstream of an  
20 Ala-Pro-Glu consensus in subdomain eight of a lats kinase domain, *e.g.*, corresponding to serine 909 of human lats, as depicted in Figure 12 (SEQ ID NO:2). Alternatively, the lats protein in the lats-cdc2 complex has a glutamate or aspartate residue substituted for a serine or threonine residue within 20 residues upstream of an Ala-Pro-Glu consensus in subdomain eight of a lats kinase domain, *e.g.*, corresponding to serine 909 of human lats, as depicted in Figure 12 (SEQ ID NO:2).

25 In another embodiment, the lats-cdc2 complex contains a portion of lats protein corresponding to amino acids 15-585 of human lats, as depicted in Figure 12 (SEQ ID NO:2).

The invention further provides methods of modulating the activity of cdc2 using lats proteins, as well as lats derivatives and fragments able to interact with cdc2 protein, lats-  
30 cdc2 complexes, and antibodies against lats-cdc2 complexes. In particular, the invention provides methods for treating or preventing disorders involving an aberrant level of cdc2 in a subject. Therapeutically effective amounts of compounds are administered to promote or inhibit LATS function, as required.

The invention provides recombinant non-human animals in which a *lats* gene has been inactivated, preferably recombinant mice in which a *lats* gene (preferably a gene  
35 having lats coding sequence of SEQ ID NO:3) has been inactivated, *i.e.*, a *lats* knock-out mouse.

In a preferred embodiment, the invention provides a *lats* knock-out mouse in which the inactivated *lats* gene had the coding sequence of SEQ ID NO:3, prior to disruption, and in a more preferred embodiment, the inactivated *lats* gene is deleted for the Lats C-terminal domain 1 (LCD1), the Lats C-terminal domain 2 (LCD2), the Lats C-terminal domain 3 (LCD3), and all or a portion of the kinase domain, and retains the Lats flanking domain (LFD), the Lats split domain 1 (LSD1), the Lats split domain 2 (LSD2), and the putative SH3-binding domain, in a most preferred embodiment the *lats* gene is disrupted by replacement of a non-*lats* sequence for the sequence encoding the amino acids corresponding to amino acids 756 to 1130 of human *lats*, as depicted in Figure 12 (SEQ ID NO:2). In other embodiments, the inactivated *lats* gene is deleted for all or a portion of the kinase domain (*e.g.*, so as to inactivate kinase activity). A *lats* "knock-out" animal is an animal in which at least one genomic copy of a *lats* gene has been inactivated by insertional mutagenesis, *e.g.*, by homologous recombination, for example, as described and exemplified herein.

The invention further provides methods for screening potential therapeutics for activity in the treatment or prevention of cancer, preferably soft tissue sarcomas and ovarian tumors, using the *lats* knock-out animals of the invention. The invention also provides methods for screening potential therapeutics for activity in the treatment or prevention of pituitary dysfunctions, using the *lats* knock-out animals of the invention. In a preferred embodiment, the invention provides methods for screening potential therapeutics for activity in the treatment or prevention of skin cancer using a non-human *lats* knock-out animal, preferably a *lats* knock-out mouse, in which skin tumors have been induced with carcinogens.

### Definitions

As used herein, underscoring or italicizing the name of a gene shall indicate the gene, in contrast to its encoded protein product which is indicated by the name of the gene in the absence of any underscoring or italicizing. For example, "*lats*" shall mean the *lats* gene, whereas "lats" shall indicate the protein product of the *lats* gene.

ARN = After Removal of Nocodazole

CDK = Cyclin Dependent Kinase

mlats = mouse *lats*

### BRIEF DESCRIPTION OF THE FIGURES

Figures 1A-H. Human *lats* can functionally replace the fly gene. (A) Adult *Drosophila* in which *lats* homozygous mutant cells have been induced in the imaginal tissues of the *lats* heterozygous larvae, exhibit *lats* mosaic phenotype, and have mutant cells which have undergone extensive proliferation and formed tumors in various body parts of the mosaic adults. (B) Adult *Drosophila* that express human *lats* (hs-h-*lats*) completely do not exhibit tumor development (compare to A). (C, D) High magnification views of the

flies in panel (B) show *yellow* bristles (white arrows), indicating *lats* cells (genetically marked by the *yellow* mutation) were produced and that they have developed into normal structures. (E, F) *lats*<sup>e26-1</sup> homozygous mutants display giant pupae and disc-overproliferation phenotypes (left pupae in panels). Without heat-shock induction, the leaky expression of the *hs-h-lats* transgene partially suppressed the *lats*<sup>e26-1</sup> phenotypes (middle pupae in panels). Daily induction of the *hs-h-lats* gene completely rescued the mutant phenotypes (right pupae in panels). (G) Scanning Electron Micrograph view of a *lats* mosaic fly. (H) A *lats* tumor on the wing (indicated by an arrow in panel G) is enlarged, showing that cells in the overproliferated mutant clone have differentiated into wing cells with hair structures.

Figures 2A-E. Phosphorylation of *lats* oscillates with the cell cycle. (A) The phosphorylation of *lats* protein in HeLa cells after exposure of the cells to certain conditions was assayed by immunoprecipitation and blotted with an anti-h-*lats* monoclonal antibody. "CIP" indicates that the cells were incubated in calf intestinal phosphatase and "β-gp" indicates that the cells were incubated in β-glycerol phosphate. The "Time (min.)" indicates time in minutes of incubation. "⊖-h-Lats" and "h-Lats" indicate the phosphorylated and dephosphorylated forms of h-*lats*, respectively. *Lats* proteins from mitotic HeLa cell lysates (50 min. ARN (After Removal of Nocodazole)) display a slow-migrating form on SDS-PAGE (6%) (lane 1). The proteins are converted into a fast-migrating form when incubated with Calf Intestinal Phosphatase ("CIP") (lanes 2-4). When both CIP and a CIP inhibitor, β-glycerol phosphate ("β-gp"), are present, their mobility remains unchanged (lane 5). *Lats* proteins from 125 min ARN cells have both the slow-migrating and fast-migrating forms (lane 6) and CIP-treatment converts all *lats* proteins into the fast-migrating form (lanes 7-9). (B) Immunowestern blot shows that phosphorylation of the *lats* protein oscillates with the cell cycle. Cell cycle stages G0, G1, S, and G2, are indicated above each lane and cells in different mitotic stages (M) are indicated by min. (minutes ARN). The faint bands are degradation products of *lats*. The progression of the cell cycle was verified by DAPI staining. (C-E) These panels show fluorescent micrographs of DAPI staining for cells at three time points (50' (C), 75' (D), and 100' (E) ARN). Arrows indicate cells at metaphase (50' ARN (panel C)), anaphase (75' ARN (panel D)), or telophase (100' ARN (panel E)), respectively.

Figures 3A-E. *Lats* directly complexes with *cdc2* during mitosis and the *lats/cdc2* complex is inactive for H1 kinase activity. (A) *Cdc2* is co-immunoprecipitated with *lats* from mitotic CHO cell lysates (M) but not from quiescent CHO cell lysates (G0). Anti-h-*lats* polyclonal antibodies or anti-human cyclin B monoclonal antibodies were used for immunoprecipitation, and anti-human *cdc2* monoclonal antibodies were used to visualize *cdc2*. (B) *Cdc2* co-immunoprecipitated with human *lats* proteins at early mitosis. The stages of the cell cycle are indicated above each lane as "min. ARN" or "G0". *Lats* proteins were immunoprecipitated using anti-h-*lats* monoclonal antibodies and were separated on 8% SDS-PAGE. The western blot was sequentially probed with anti-human *cdc2*

monoclonal antibodies (lower panel, labeled "Cdc2"), anti-h-lats monoclonal antibodies (upper panel, labeled "h-lats"), anti-human cyclin B and cyclin A monoclonal antibodies (middle panels, labeled "Cyclin B" and "Cyclin A", respectively). (C) Co-immunoprecipitation of baculovirus-expressed human lats and cdc2 proteins. H-lats proteins were precipitated with anti-h-lats monoclonal antibodies and probed with anti-human cdc2 monoclonal antibodies (upper panel, labeled "Cdc 2") and cdc2 proteins were precipitated with anti-human cdc2 monoclonal antibodies and probed with anti-h-lats monoclonal antibodies (lower panel, labeled "h-lats"). (D) Lats-associated cdc2 is inactive for H1 kinase activity. Cdc2 proteins co-immunoprecipitated with either lats or cyclin B (indicated by "+" in the legend labeled "anti-Cyclin B" or "anti-h-lats") from 50 min. ARN HeLa cell lysates were divided for western quantification of cdc2 (upper panel, labeled "IP-Western") and for the histone H1 kinase assay (lower panel, labeled "H1 Kinase assay"), respectively. As a control, Protein G-agarose beads incubated with equal amounts of cell lysates only were also used for the H1 kinase assay (indicated by "-" in the legend). (E) Summarized are the results of yeast two-hybrid assays for interactions among full-length h-lats (h-lats), N-terminal region of h-lats (N-h-lats), C-terminal region of h-lats (C-h-lats), human cdc2, CDK2, and CDK4. +++, ++, +: indicate strong, intermediate, and weak interactions, respectively, while - and ND indicate no interaction and not determined, respectively.

Figures 4A-F. Genetic interaction between *lats*, *cdc2*, and *cyclin A* in *Drosophila*. (A) *lats*<sup>P8</sup>/*lats*<sup>P8</sup> homozygotes die at the pupal stage. (B) Removal of one copy of the *cdc2* gene rescues *lats*<sup>P8</sup> lethality (*lats*<sup>P8</sup>/*lats*<sup>P8</sup>; +/*cdc2*<sup>B47</sup>). (C) A typical rough, overproliferated eye dissected from a *lats*<sup>P8</sup>/*lats*<sup>P8</sup> dead pupa. (D) An eye from the fly in panel (B), showing that the eye phenotype has been almost completely suppressed. (E) *lats*<sup>e26-1</sup>/*lats*<sup>e26-1</sup> pupae (the pupa labeled 1) are much larger than wild-type (the pupa labeled 4). The giant-pupa phenotype is partially reduced by a *cdc2* temperature sensitive mutant at room temperature (pupa labeled 2) (*lats*<sup>e26-1</sup>/*lats*<sup>e26-1</sup>; *cdc2*<sup>E1-24</sup>/*cdc2*<sup>E1-24</sup>) or by removal of one copy of the *cdc2* gene ([i]a labeled 3) (*lats*<sup>e26-1</sup>/*lats*<sup>e26-1</sup>; +/*cdc2*<sup>B47</sup>). (F) The third instar larval wing discs dissected from animals of the same genotypes in (E) and labeled with the same number. The *lats* disc overproliferation phenotype (larva 1) is dramatically suppressed by mutations in the *cdc2* gene (larvae 2 and 3). Removal of one copy of the *cyclin A* gene resulted in a phenotypic suppression of the *lats* mutants in a manner similar to removal of one *cdc2* gene as shown above.

Figures 5A-N. Effect of inactivation and overexpression of *lats* on the cell cycle in *Drosophila*. (A) *Drosophila* third instar eye imaginal disc contains a homozygous *lats*<sup>x1</sup> clone (arrowhead indicates the lack of Myc staining) that crosses the morphogenetic furrow (MF) (arrow). (B) Cyclin A staining (indicated by arrowhead) in the clone exhibits expression that spans the MF (arrow). (C) Composite staining of the same disc shown in panels A and B showing Myc stains and propidium iodide staining which more clearly delineates the MF and the *lats* mutant clone (indicated by the arrow) that spans it. (D)

Composite staining magnification of the same *lats* mutant clone shown in panels A-C. Cyclin A staining clearly spans the MF region (arrow). (E) Composite staining of the same region shown in panel D viewed with Myc and propidium iodide. (F) Composite staining magnification of the same clone shown in panel E viewed with Cyclin A staining and propidium iodide. Cyclin A is degraded in *lats* mutant cells at late mitosis (as indicated by the arrowheads). (G) *Drosophila* third instar eye disc containing homozygous *lats*<sup>xl</sup> clones (lack of Myc staining is indicated by arrowheads) that span the MF region. (H) The third instar eye disc shown in panel G was also stained for Cyclin B. The MF (indicated by the arrow) is well defined and free of cyclin B staining. (I and J) Scanning electron micrograph of a wild-type *Drosophila* adult eye (I) in comparison to an eye (J) of a *GMR-d-lats* transgenic fly showing fewer and irregular ommatidia and missing bristles. (K) A section of a *GMR-d-lats* eye reveals that many pigment cells are missing, and that ommatidia occasionally lack a full complement of photoreceptor cells (arrow). (L) Propidium iodide staining of a *GMR-d-lats* third instar eye imaginal disc. A stripe of intensely stained nuclei which are tetraploid (indicated by the star) are seen in the region of the second mitotic wave, which is immediately followed posteriorly by apoptotic cells with fragmented nuclei (indicated by the small arrows). (M) BrdU labeling (green) of a *GMR-d-lats* third instar eye disc reveals that S phase occurs in the second mitotic wave (indicated by the star) posterior to the MF (indicated by the arrow) just as it would in wild type. (N) A *GMR-p21* eye disc is shown in which cell proliferation in the second mitotic wave is blocked before S phase and the stripe of BrdU labeling posterior to the MF (indicated by the arrow) is abolished.

Figures 6A-D. Targeting of the *lats* locus by homologous recombination. (A) Sequence alignment of human *lats* (h-*lats*) and mouse *lats* (m-*lats*, partial sequence). Arrow indicates the point at which the mouse *lats* gene was disrupted. (B) Targeting vector for positive-negative selection of homologous recombinants at the *lats* locus, with restriction map and the structure of the targeted *lats* locus. The vector is represented by the second line from the top, while the wild-type and mutant (i.e., disrupted) *lats* alleles are indicated by the top and bottom lines, respectively. The BamHI sites are indicated by "B", the EcoRI sites are indicated by "R", and the EcoRV sites are indicated by "RV". Exons are represented by filled rectangles. A BamHI/EcoRV double digest generates a 3.5 kb fragment from the wild-type allele and a 5.8 kb fragment from the disrupted allele, both of which are recognized by the probe shown, which is not contained in the targeting vector. In the vector and the mutant allele, the PGK-TK gene cassette and the PGK-neo fragment are denoted by open boxes labeled accordingly. (C) Southern blot of genomic DNA isolated from individual embryonic stem cell clones. The genotypes of the clones are indicated above the lanes with the "+/+" indicating wild-type clones, "+/-" indicating clones heterozygous for the mutant allele, and "-/-" indicating clones homozygous for the mutant allele. (D) Western blot using anti-h-*lats* polyclonal antibody on lysates from 13.5 dpc (days post coitus) mouse embryonic fibroblasts indicating the absence of *lats* protein in the knock-out mice. The genotype of the clones is indicated above the lanes as in panel C.

Figures 7A and B. Growth retardation of *lats*<sup>-/-</sup> mice. (A) Representative picture of a *lats*<sup>-/-</sup> mouse (agouti, the mouse on the right) with its wild-type littermate (black, the mouse on the left) (12-days-old). (B) Representative growth curve of *lats*<sup>+/+</sup>, *lats*<sup>+/-</sup>, and *lats*<sup>-/-</sup> mice. Mice were weighed (grams (g)) at intervals and plotted against age in days.

5      Figures 8A-D. Ovarian phenotypes of *lats*<sup>-/-</sup> mice. Histopathological sections of ovaries derived from *lats*<sup>+/+</sup> (panels A and C) and *lats*<sup>-/-</sup> (panels B and D) females. Overview images are in panels A and B while high magnification views are in panels C and D. The paraffin sections were stained with hematoxylin and eosin. An absence of corpora lutea (CL) is evident in the *lats*<sup>-/-</sup> ovary. Ovarian stromal cell tumors (SC) which obliterate the normal structure of the ovary, eliminating follicles (FC) progressively, are readily  
10    apparent.

Figures 9A-F. Absence of mammary gland development in *lats*<sup>-/-</sup> Mice. (A,B) *Lats*<sup>+/+</sup> female with normal mammary gland and nipple development. (D,E) *Lats*<sup>-/-</sup> female displaying absence of mammary gland and nipple formation. (C,F) Hematoxylin and eosin stained histopathological sections of mammary glands derived from *lats*<sup>+/+</sup> (C) and *lats*<sup>-/-</sup> (F) mice. The amount of breast epithelial tissue was markedly decreased in *lats*<sup>-/-</sup> females,  
15    resulting in mammary fat pads, devoid of an epithelial component.

Figures 10A-E. Pituitary hyperplasia and dysfunction in *lats*<sup>-/-</sup> mice. (A and B) Histopathological sections of pituitaries derived from *lats*<sup>+/+</sup> (A) and *lats*<sup>-/-</sup> (B) mice. The paraffin sections were stained with hematoxylin and eosin. The normal pituitary gland from a *lats*<sup>+/+</sup> mouse demonstrates the organized architecture of the gland. Hyperplastic  
20    changes are visible in *lats*<sup>-/-</sup> pituitaries. Multiple atypical cells showing irregularly shaped nuclei, and variability in shape and size are readily apparent. (C-E) The graphs indicate the amount of LH (C), PRL (D), and FSH (E) production in the mice. Hormone levels are plotted as ng/ml with the results from the *lats*<sup>+/+</sup> mice represented by the right bar of each bar graph and the results from the *lats*<sup>-/-</sup> mice represented by the left bar of each bar graph.

Figures 11A-C. Soft tissue sarcoma development in *lats*<sup>-/-</sup> mice. (A,B) Typical soft  
25    tissue sarcomas in *lats*<sup>-/-</sup> mice (A, 6.5 months old; B, 4.5 months old). (C) Histopathological section of the soft tissue sarcoma shown in panel B stained with hematoxylin and eosin revealing pleiomorphic, spindle-shaped cells characteristic of this tumor.

Figure 12. Nucleotide and amino acid sequences of human *lats* (h-*lats*) (SEQ ID NOS:1 and 2, respectively).

30    Figure 13. Nucleotide and amino acid sequences of mouse *lats* (m-*lats*) (SEQ ID NOS:3 and 4, respectively).

Figure 14. Nucleotide and amino acid sequences of mouse *lats2* (m-*lats2*) (SEQ ID NOS:5 and 6, respectively).

Figure 15. Nucleotide and amino acid sequences of *Drosophila lats* (SEQ ID  
35    NOS:7 and 8, respectively).



### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides lats-cdc2 protein complexes, including complexes that contain lats analogs and fragments and/or cdc2 analogs and fragments, as well as methods of producing these complexes and nucleic acids encoding the two members of the complex. The invention also provides antibodies that bind immunospecifically to a lats-cdc2 complex, but do not bind the individual binding partners immunospecifically.

The invention also provides methods for the modulation of cdc2 activity using lats proteins and lats analogs and derivatives that are able to interact with cdc2. In particular, methods are provided for treating or preventing diseases and disorders associated with aberrant cdc2 activity by administration of a therapeutic compound of the invention.

The present invention further provides recombinant non-human animals, preferably mice, having at least one copy of (preferably both copies of, *i.e.*, is homozygous for) an inactivated *lats* gene, *i.e.*, *lats* knock-out animals. Preferably, these *lats* knock-out animals are generated by homologous recombination, *i.e.*, have a gene disrupted by insertional mutagenesis induced by homologous recombination with a nucleic acid containing non-lats sequences flanked by *lats* genomic sequences. The invention further provides methods of screening for compounds effective to treat or prevent cancer, preferably soft tissue sarcomas or ovarian tumors, more preferably skin cancer, using the recombinant non-human animals of the invention. The invention also provides methods of screening for compounds effective to treat or prevent pituitary dysfunction using the recombinant non-human animals of the invention.

Therapeutics of the invention that can be used to treat or prevent diseases and disorders associated with an aberrant level of cdc activity include those therapeutics that promote lats function (*e.g.*, lats proteins and lats derivatives and analogs that supply lats function, nucleic acids encoding lats, lats derivatives and analogs, and lats-cdc2 complexes), and those therapeutics that inhibit or antagonize lats function (*e.g.*, lats derivatives and analogs that inhibit or antagonize lats function) and nucleic acids encoding these lats derivatives and analogs, anti-lats antibodies and anti-lats-cdc2 complex antibodies, lats antisense nucleic acids, and lats inhibitors and antagonists.

The present invention also provides therapeutic methods and compositions for the treatment and prevention of cancer based on lats proteins and therapeutically or prophylactically effective analogs and fragments of lats proteins. The invention provides for treatment and prevention of cancer by administration of a therapeutic compound of the invention. The therapeutic compounds of the invention that can be used to treat or prevent cancer include: lats proteins, including human lats proteins, therapeutically or prophylactically effective lats analogs and fragments, and nucleic acids encoding the lats proteins, analogs and fragments.

In a preferred embodiment, the invention provides therapeutic and prophylactic methods for the treatment or prevention of cancer that has been shown to be or may be

refractory to chemotherapy or radiation therapy treatments or treatments based on tumor suppressor genes other than lats.

Also included in the invention are methods of screening lats proteins and lats derivatives and analogs for activity in treating cancer that has been shown to be or may be refractory to chemotherapy or radiation therapy. Additionally, the invention provides methods of screening lats proteins, lats derivatives and fragments, anti-lats antibodies, lats antisense nucleic acids, lats antagonists and inhibitors, and lats-cdc2 complexes for activity in modulating the activity of cdc2.

### Therapeutic Uses

The invention provides for treatment or prevention of cancers refractory to chemotherapy or radiation therapy by administration of a therapeutic compound (termed herein "Therapeutic"). The invention also provides for treatment or prevention of diseases or disorders that can be treated by modulation of cdc2 activity by administration of a Therapeutic of the invention. Such "Therapeutics" include lats proteins and therapeutically or prophylactically effective analogs and fragments thereof; lats-cdc2 complexes; antibodies thereto; nucleic acids encoding the lats proteins, analogs, or fragments, and lats-cdc2 complexes; lats antisense nucleic acids, and lats agonists and antagonists.

In specific embodiments, the therapeutic is a lats protein or lats-cdc2 complex containing a lats protein that is phosphorylated, particularly a lats protein phosphorylated on a serine or threonine residue within 20 residues upstream of an Ala-Pro-Glu consensus in subdomain eight of a lats kinase domain, *e.g.*, a serine corresponding to serine 909 of human lats, as depicted in Figure 12 (SEQ ID NO:2). In another embodiment, the therapeutic is a lats derivative or lats-cdc2 complex containing a lats derivative, in which derivative a serine or threonine residue within 20 residues upstream of an Ala-Pro-Glu consensus in subdomain eight of a lats kinase domain is substituted with a glutamate or aspartate residue, preferably the serine corresponding to serine 909 of human lats is replaced with a glutamate residue. In a further embodiment, the therapeutic is a fragment of a lats protein or a lats-cdc2 complex containing a fragment of a lats protein comprising or consisting of the amino acid sequence of a lats protein corresponding to amino acids 15-585 of human lats, as depicted in Figure 12 (SEQ ID NO:2).

Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the subject is preferred. Thus, in a preferred embodiment, a human lats protein, derivative, or fragment, or nucleic acid, or an antibody to a human lats protein, is therapeutically or prophylactically administered to a human patient.

### Treatment and Prevention of Cancers Refractory to Chemotherapy or Radiotherapy

Cancers, including neoplasms, tumors, metastases, or any disorder characterized by uncontrolled cell growth, that have been shown to be refractory to a chemotherapy or

radiation therapy can be treated or prevented by administration of a Therapeutic of the invention that promotes (*i.e.*, increases or supplies) lats function.

Examples of such a Therapeutic include lats proteins, derivatives or fragments that are functionally active, particularly have a lats functional activity of inhibiting cell overproliferation (*e.g.*, as demonstrated in *in vitro* assays or in an animal model), and nucleic acids encoding a lats protein or a functionally active derivative or analog thereof (*e.g.*, for use in gene therapy). Other Therapeutics that can be used, *e.g.*, lats agonists, can be identified using *in vitro* assays or animal models, examples of which are described in Examples section.

That a cancer is refractory to chemotherapy or radiation therapy means that at least some significant portion of the cancer cells are not killed or their cell division arrested by the particular chemotherapeutic agent or combination of chemotherapeutic agents or the level of radiation employed in a therapeutic protocol. The determination of whether the cancer cells are refractory to the chemotherapy or the radiation therapy can be made either *in vivo* or *in vitro* by any method known in the art for assaying the effectiveness of treatment on cancer cells.

In various embodiments of the invention, cancer that is refractory to radiation therapy, chemotherapy or combination chemotherapy, or combination of radiotherapy and chemotherapy, is treated or prevented by administration of a Therapeutic of the invention. In a preferred embodiment, cancer that is refractory to treatment with a chemotherapeutic agent that is cell cycle specific, or said cancer is refractory to treatment with a chemotherapeutic agent that kills or arrests the cells in the S phase of the cell cycle, or said cancer is refractory to treatment with a chemotherapeutic agent that kills or arrests cells during the M phase of the cell cycle is treated using a Therapeutic of the invention. The Therapeutic of the invention can be administered along with radiation therapy and/or one or a combination of chemotherapeutic agents, or as an alternative to other forms of therapy.

The chemotherapy or radiation therapy administered concurrently with or subsequent to the administration of the therapeutic of the invention can be administered by any method known in the art. The chemotherapeutic agents are preferably administered in a series of sessions, any one or a combination of the chemotherapeutic agents listed above can be administered. With respect to radiation therapy, any radiation therapy protocol can be used depending upon the type of cancer to be treated. For example, but not by way of limitation, x-ray radiation can be administered; in particular, high-energy megavoltage (radiation of greater than 1 MeV energy) can be used for deep tumors, and electron beam and orthovoltage x-ray radiation can be used for skin cancers. Gamma ray emitting radioisotopes, such as radioactive isotopes of radium, cobalt and other elements may also be administered to expose tissues to radiation.

**Malignancies**

Malignancies and related disorders that may become refractory to chemotherapy and/or radiation therapy and that can be treated or prevented by administration of a Therapeutic that promotes lats function include blood-related cancers and solid tumors (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia).

**Treatment and Prevention of Diseases by Modulation of Cdc2 Activity**

In a specific embodiment of the invention, diseases and disorders associated with aberrant levels of cdc2 activity, e.g., aberrantly high or aberrantly low levels of cdc2 protein or activity, can be treated or prevented by administration of a therapeutic of the invention able to modulate the activity of cdc2. In particular, those diseases and disorders associated with an aberrantly high cdc2 activity are treated or prevented by administration of a Therapeutic that promotes lats activity. Alternatively, those diseases and disorders associated with an aberrantly low cdc2 activity are treated or prevented by administration of a Therapeutic that inhibits lats activity, e.g., lats derivatives and analogs that inhibit or antagonize lats activity, anti-lats antibodies, lats antisense nucleic acids, lats inhibitors and antagonists, antibodies that specifically recognize a lats-cdc2 complex, etc.

Because cdc2 promotes cell division, diseases and disorders that may be associated with an increased level of cdc2 activity, as compared with the levels of cdc2 in a subject not afflicted with such a disease or disorder, include diseases and disorders associated with increased cell proliferation, such as malignancies. Diseases and disorders that may be associated with a decreased level of cdc2 activity include diseases and disorders associated with decreased cell proliferation.

**Premalignant Conditions**

The Therapeutics of the invention that reduce cdc2 activity can be administered to treat premalignant conditions and to prevent progression to a neoplastic or malignant state. Such prophylactic or therapeutic use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred.

Alternatively or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed *in vivo* or displayed *in vitro* by a cell sample from a patient, can indicate the desirability of prophylactic/therapeutic administration of a Therapeutic that inhibits cdc2 activity. Some characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc.

### Treatment and Prevention of Disorders in Which Cell Proliferation Is Desired

Diseases and disorders involving a deficiency in cell proliferation (growth) or in which cell proliferation is otherwise desirable for treatment or prevention, are treated or prevented by administration of a Therapeutic that antagonizes (inhibits) *lats* function (in particular, *lats*-mediated inhibition of cell proliferation and/or *lats* binding to *cdc2*).  
5 Therapeutics that can be used include anti-*lats* antibodies (and fragments and derivatives thereof containing the binding region thereof), *lats* derivatives or fragments that are dominant-negative kinases, *lats* antisense nucleic acids, and *lats* nucleic acids that are dysfunctional (*e.g.*, due to a heterologous (non-*lats* sequence) insertion within the *lats* coding sequence) that are used to "knockout" endogenous *lats* function by homologous  
10 recombination (see, *e.g.*, Capecchi, 1989, *Science* 244:1288-1292), as described herein. Other Therapeutics that inhibit *lats* function can be identified by use of known convenient *in vitro* assays, *e.g.*, based on their ability to inhibit binding of *lats* to another protein (*e.g.*, *cdc2*), or inhibit any known *lats* function, as preferably assayed *in vitro* or in cell culture. Methods for screening for compounds that prevent or reduce *lats* binding to *cdc2* are  
15 described herein. Preferably, suitable *in vitro* or *in vivo* assays are utilized to determine the effect of a specific Therapeutic (*i.e.*, its ability to promote *cdc2* activity or increase *cdc2* levels) and whether its administration is indicated for treatment of the affected tissue.

Diseases and disorders involving a deficiency in cell proliferation or in which cell proliferation is desired for treatment or prevention, and that can be treated or prevented by promoting *cdc2* function, include degenerative disorders, growth deficiencies,  
20 hypoproliferative disorders, physical trauma, lesions, and wounds; for example, to promote wound healing, or to promote regeneration in degenerated, lesioned or injured tissues, etc.

### Gene Therapy

Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. In this embodiment of the invention, the nucleic acid produces its encoded protein  
25 that mediates a therapeutic effect by promoting *lats* function.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596; Mulligan, 1993, *Science* 260:926-932; and  
30 Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62:191-217; May, 1993, *TIBTECH* 11(5):155-215. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY; and Kriegler, 1990, *Gene Transfer and Expression*, A Laboratory Manual, Stockton Press, NY.

35 In a preferred aspect, the Therapeutic comprises a *lats* nucleic acid that is part of an expression vector that expresses a *lats* protein or fragment or chimeric protein thereof in a

suitable host. In particular, such a nucleic acid has a promoter operably linked to the *lats* coding region, said promoter being inducible or constitutive, homologous or heterologous, and, optionally, tissue-specific. In another particular embodiment, a nucleic acid molecule is used in which the *lats* coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the *lats* nucleic acid, as described (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438). In another embodiment, a nucleic acid or combination of nucleic acids containing both a *lats* and a *cdc2* nucleic acid, preferably where each is operably linked to a promoter, is delivered by gene therapy methods.

Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

Numerous techniques are known in the art for the introduction of foreign genes into cells (see e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618; Cohen et al., 1993, Meth. Enzymol. 217:618-644; Cline, 1985, Pharmac. Ther. 29:69-92).

In an embodiment in which recombinant cells are used in gene therapy, a *lats* nucleic acid or both *lats* and *cdc2* nucleic acids are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then

administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used, such as hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (PCT Publication WO 94/08598, dated April 28, 1994), neural stem cells (Stemple and Anderson, 1992, Cell 71:973-985), or epithelial stem cells (ESCs) (Rheinwald, 1980, Meth. Cell Bio. 21A:229; Pittelkow and Scott, 1986, Mayo Clinic Proc. 61:771).

### Antisense Therapy

*Lats* function may be inhibited by use of *lats* antisense nucleic acids. The present invention provides the therapeutic or prophylactic use of nucleic acids of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 200 oligonucleotides), that are antisense to a gene or cDNA encoding a *lats* protein, or portions thereof. A *lats* "antisense" nucleic acid as used herein refers to a nucleic acid capable of hybridizing to a portion of a *lats* nucleic acid (preferably mRNA) by virtue of some sequence complementarity. The antisense nucleic acid may be complementary to a coding and/or noncoding region of a *lats* mRNA. In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at any position (examples of such modifications can be found in: Bailey, Ullmann's Encyclopedia of Industrial Chemistry (1998), 6th ed. Wiley and Sons). Such antisense nucleic acids have utility as Therapeutics that inhibit *lats* function or activity, and can be used in the treatment or prevention of disorders characterized by an aberrantly low *cdc2* level or activity.

The *lats* antisense nucleic acids can be directly administered to a cell, or can be produced intracellularly by transcription of exogenous, introduced sequences. Alternatively, *lats* antisense nucleic acids are produced intracellularly by transcription from an exogenous sequence. For example, a vector can be introduced *in vivo* such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a *lats* gene, preferably a human *lats* gene. However, absolute complementarity, although preferred, is not required.

Pharmaceutical compositions of the invention, comprising an effective amount of a *lats* antisense nucleic acid in a pharmaceutically acceptable carrier can be administered to a patient having a disease or disorder which is characterized by aberrantly low *cdc2* activity.

The amount of *lats* antisense nucleic acid that will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the antisense cytotoxicity *in vitro*, and then in useful animal model systems prior to testing and use in humans.

In a specific embodiment, pharmaceutical compositions comprising *lats* antisense nucleic acids are administered via liposomes, microparticles, or microcapsules. In various embodiments of the invention, it may be useful to use such compositions to achieve sustained release of the *lats* antisense nucleic acids. In a specific embodiment, it may be desirable to utilize liposomes targeted via antibodies to specific identifiable central nervous system cell types (Leonetti et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87: 2448-2451; Renneisen et al., 1990, J. Biol. Chem. 265: 16337-16342).

#### **Lats Proteins, Derivatives, Fragments and Lats-cdc2 Complexes**

The *lats* proteins and nucleic acids, and *lats* derivatives and fragments can be produced by any method known in the art.

For recombinant expression of *lats* proteins, and *lats* derivatives and fragments, the nucleic acid containing all or a portion of the nucleotide sequence encoding the protein can

be inserted into an appropriate expression vector, *i.e.*, a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence. In a preferred embodiment, the regulatory elements (*e.g.*, promoter) are heterologous (*i.e.*, not the native gene promoter). Promoters which may be used include the SV40 early promoter (Bernoist and Chambon, 1981, Nature 290: 304-310), and the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22: 787-797), among others.

A variety of host-vector systems may be utilized to express the protein coding sequence. These include mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.

Once a lats protein, or derivative or fragment, has been recombinantly expressed, it may be isolated and purified by standard methods including chromatography (*e.g.*, ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. A lats protein may also be purified by any standard purification method from natural sources.

Alternatively, a lats protein, analog or derivative can be synthesized by standard chemical methods known in the art (*e.g.*, see Hunkapiller et al., 1984, Nature 310:105-111).

The Therapeutics of the invention also include derivatives and fragments related to lats. In particular embodiments, the derivative or fragment is functionally active, *i.e.*, capable of exhibiting one or more functional activities associated with a full-length, wild-type lats protein, *e.g.*, able to inhibit cell proliferation in *in vitro* and/or *in vivo* assays. Additionally, derivatives or fragments that inhibit lats activity, *e.g.*, promote cell proliferation, may also have a use in the methods of the invention. Derivatives or analogs of lats can be tested for the desired activity by procedures known in the art.

In specific embodiments of the invention, the Therapeutic is a lats protein that is phosphorylated, preferably that is phosphorylated on a serine or threonine residue within 20 amino acids upstream of an Ala-Pro-Glu consensus sequence in subdomain eight of a lats kinase domain, more preferably that is phosphorylated on a serine residue corresponding to serine 909 of human lats, as depicted in Figure 12 (SEQ ID NO:2). In another specific embodiment, the therapeutic is a lats derivative in which a serine or threonine residue within 20 residues upstream of an Ala-Pro-Glu consensus in subdomain eight of a lats kinase domain is substituted with a glutamate or aspartate residue, preferably, in which a serine residue corresponding to serine 909 of human lats is replaced with a glutamate residue. In another specific embodiment, the therapeutic is a fragment of a lats protein comprising or consisting of the amino acid sequence corresponding to amino acids 15 to 585 of human lats, as depicted in Figure 12 (SEQ ID NO:2).

In particular, lats derivatives can be made by altering lats sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due



to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a *lats* gene may be used in the practice of the present invention. These include nucleotide sequences comprising all or portions of *lats* genes which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change.

5 Likewise, the *lats* derivatives of the invention include those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a *lats* protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity  
10 which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and  
15 histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

In a specific embodiment of the invention, proteins consisting of or comprising a fragment of a *lats* protein consisting of at least 10 (continuous) amino acids of the *lats* protein is provided. In other embodiments, the fragment consists of at least 20 or 50 amino  
20 acids of the *lats* protein. In specific embodiments, such fragments are not larger than 35, 100 or 200 amino acids. In a specific embodiment, the fragment of a *lats* protein is from the N-terminal portion of the protein, preferably including all or a portion of the amino acids corresponding to amino acids 15-585 of human *lats*. Derivatives or fragments of *lats* include but are not limited to those molecules comprising regions that are substantially  
25 homologous to *lats* or fragments thereof (*e.g.*, in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid sequence of identical size with no insertions or deletions considered, or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, *e.g.*, the blastp program) or whose encoding nucleic acid is capable of hybridizing to the inverse complement (the inverse complement of a nucleic acid strand has the complementary  
30 sequence running in reverse orientation to the strand so that the inverse complement would hybridize without mismatches to the nucleic acid strand; thus, for example, where the coding strand is hybridizable to a nucleic acid with no mismatches between the coding strand and the hybridizable strand, then the inverse complement of the hybridizable strand is identical to the coding strand) of a coding *lats* sequence, under high stringency, moderately stringency, or low stringency conditions, as discussed *infra*.

35 The *lats* derivatives and fragments of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at

the gene or protein level. For example, the cloned *lats* gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

5        Additionally, the *lats*-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including chemical mutagenesis, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem 253:6551), use of TAB® linkers  
10 (Pharmacia), etc.

      Manipulations of the *lats* sequence may also be made at the protein level. Included within the scope of the invention are *lats* protein fragments or other derivatives which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, etc. Any of numerous chemical modifications may be carried out by  
15 known techniques, including specific chemical cleavage by cyanogen bromide, trypsin, oxidation, reduction; etc.

      In addition, analogs and fragments of *lats* can be chemically synthesized. For example, a peptide corresponding to a portion of a *lats* protein which comprises the desired domain, or which mediates the desired activity *in vitro*, can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino  
20 acid analogs can be introduced as a substitution or addition into the *lats* sequence.

      In a specific embodiment, the *lats* derivative is a chimeric, or fusion, protein comprising a *lats* protein or fragment thereof (preferably consisting of at least a domain or motif of the *lats* protein, or at least 15, preferably 20, amino acids of the *lats* protein) joined at its amino- or carboxy-terminus via a peptide bond to an amino acid sequence of a  
25 different protein. In one embodiment, such a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (comprising a *lats*-coding sequence joined in-frame to a coding sequence for a different protein). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively,  
30 such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. Chimeric genes comprising portions of *lats* fused to any heterologous protein-encoding sequences may be constructed. A specific embodiment relates to a chimeric protein comprising a fragment of *lats* of at least six amino acids. In another specific embodiment, the *lats* derivative is a chimeric protein comprising a fragment of *lats* corresponding to amino acids 15-585 of human *lats*.  
35

      In another specific embodiment, the *lats* derivative is a molecule comprising a region of homology with a *lats* protein. By way of example, in various embodiments, a first

protein region can be considered "homologous" to a second protein region when the amino acid sequence of the first region is at least 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 95% identical, when compared to any sequence in the second region of an equal number of amino acids as the number contained in the first region with no insertions or deletions considered, or when compared to an aligned sequence of the second region that has been aligned by a computer homology program known in the art. For example, a molecule can comprise one or more regions homologous to a lats domain or a portion thereof.

### Derivatives of Lats Containing One or More Domains of the Protein

In specific embodiments, the methods of the invention use lats derivatives and fragments that comprise, or alternatively consist of, one or more domains of a lats protein, including but not limited to a lats C-terminal domain 3 (LCD3), lats C-terminal domain 2 (LCD2), lats C-terminal domain 1 (LCD1), kinase domain, kinase subdomains, lats flanking domain (LFD) (amino-terminal to the kinase domain), lats split domain 1 (LSD1), lats split domain 2 (LSD2), SH3-binding domain, and opa repeat domain, functional (*e.g.*, binding) fragments of any of the foregoing, or any combination of the foregoing.

In human lats (h-lats), m-lats, m-lats2, and *Drosophila* lats, the LCD3 domain is the last three amino acids of the protein, which are Val-Tyr-Val in all four proteins. For human lats and *Drosophila* lats, the LCD2 domain is amino acid residues 1077-1086 and 1075-1084, respectively (all amino acid residues provided in this paragraph are for the human and *Drosophila* lats amino acid sequences depicted in Figures 12 and 14, respectively (SEQ ID NOS:2 and 8, respectively)); the LCD1 domain is amino acid residues 1032-1043 and 1035-1047, respectively; the kinase domain is amino acid residues 703-1014 and 711-1018, respectively; the LFD domain is amino acid residues 607-702 and 612-710 respectively; and the putative SH3-binding domain is amino acids 247-268 and 196-217, respectively. For the lats split domains in *Drosophila*, the LSD1 is amino acid residues 365-392 and the LSD2 is amino acids 536-544. In human lats, the LSD1 and LSD2 domains are split into anterior and posterior portions such that the LSD1 is amino acid residues 328-334 and 498-518 and LSD2 is amino acid residues 28-31 and 555-559.

In particular, the Therapeutics of the invention include molecules comprising specific fragments of lats that are those fragments in the respective lats protein most homologous to specific fragments of a human or mouse lats protein.

In a specific embodiment, a lats protein, derivative or fragment is provided that has a kinase domain and has a phosphorylated or dephosphorylated serine situated within 20 residues upstream of an Ala-Pro-Glu consensus in subdomain eight of its kinase domain, or in which the serine situated within 20 residues upstream of that consensus has been deleted or substituted by another amino acid. In various specific embodiments, the invention provides various phosphorylated and dephosphorylated forms of the lats protein, derivative, or fragment that are active or inactive kinase forms. Both phosphorylation and dephosphorylation of lats at different residues could potentially activate or inactivate lats.

Phosphorylation can be carried out by any methods known in the art, *e.g.*, by use of a kinase. Dephosphorylation can be carried out by use of any methods known in the art, *e.g.*, by use of a phosphatase.

Another specific embodiment relates to a derivative or fragment of a lats protein that is a dominant-active protein kinase. Such a derivative or analog comprises a lats kinase domain that has been mutated so as to be dominantly active (exhibit constitutively active kinase activity). It is known that acidic residues such as Glu and Asp sometimes mimic a phosphorylated residue, and changing the phosphorylatable Ser or Thr residue in subdomain eight into a Glu or Asp residue has been previously used to produce constitutively active kinases (Mansour et al., 1994, Science 265:966-970). Thus, changing a serine or threonine residue situated within 20 residues upstream of an Ala-Pro-Glu consensus in subdomain eight of a lats kinase domain into another residue (*e.g.*, Glu, Asp) may be used to make a dominant-active lats protein kinase. For example, changing Ser914 in *Drosophila* lats, or changing Ser909 in human lats, into a Glu residue could produce a dominant active lats kinase.

Another specific embodiment relates to a derivative or fragment of lats that is a dominant-negative protein kinase. Protein kinases can be mutated into dominant negative forms. Expression of a dominant negative protein kinase can suppress the activity of the wild-type form of the same kinase. Dominant negative forms of protein kinases are often obtained by expressing an inactive form of a kinase (Milarski and Saltiel, 1994, J. Biol. Chem. 269(33):21239-21243) or by expressing a noncatalytic domain of a kinase (Lu and Means, 1994, EMBO J. 12:2103-2113; Yarden et al., 1992, EMBO J. 11:2159-2166). Thus, a lats dominant-negative kinase can be obtained by mutating the kinase domain so as to be inactive (*e.g.*, by deletion and/or point mutation). For example, a lats derivative that is a dominant-negative kinase is a lats protein that lacks a kinase domain but comprises one or more of the other domains of the lats protein; *e.g.*, a lats protein derivative truncated at about the beginning of the kinase domain (*i.e.*, a lats fragment containing only sequences amino-terminal to the kinase domain). As another example, a lats derivative that is a dominant-negative kinase is a lats protein in which one of the residues conserved among serine/threonine kinases (see Hanks et al., 1988, Science 241:42-52) is mutated (deleted or substituted by a different residue).

In another specific embodiment, a molecule is provided that comprises one or more domains (or functional portion thereof) of a lats protein but that also lacks one or more domains (or functional portion thereof) of a lats protein. For example, such a protein may lack all or a portion of the kinase domain, but retain at least the SH3-binding domain of a lats protein. In another embodiment, a molecule is provided that comprises one or more domains (or functional portion thereof) of a lats protein, and that has one or more mutant (*e.g.*, due to deletion or point mutation(s)) domains of a lats protein (*e.g.*, such that the mutant domain has decreased function). The kinase domain may be mutant so as to have reduced, absent, or increased kinase activity.

### Lats-cdc2 Complexes

The invention provides lats-cdc2 complexes. In a preferred embodiment, the lats-cdc2 complexes are complexes of human proteins. As used herein, fragment or derivative of a lats-cdc2 complex includes complexes where one or both members of the complex are fragments or derivatives of the wild-type lats or cdc2 protein. Such derivatives and fragments can be generated as described for lats derivatives and fragments above. Preferably, the lats-cdc2 complexes in which one or both members of the complex are a fragment or derivative of the wild type protein are functionally active lats-cdc2 complexes.

In particular aspects, the native proteins, derivatives or analogs of lats and/or cdc2 are of animals, *e.g.* mouse, rat, pig, cow, dog, monkey, human, fly, frog, or of plants.

“Functionally active lats-cdc2 complex” as used herein refers to that material displaying one or more known functional attributes of a complex of full length lats with a full length cdc2, including but not exclusive to control of cell cycle progression, cell proliferation, etc.

In specific embodiments, the lats-cdc2 complex contains a lats protein that is phosphorylated, preferably that is phosphorylated on a serine or threonine residue within 20 amino acids upstream of an Ala-Pro-Glu consensus subdomain eight of a lats kinase domain, more preferably that is phosphorylated on a serine residue corresponding to serine 909 of human lats, as depicted in Figure 12 (SEQ ID NO:2). In another specific embodiment, the lats-cdc2 complex contains a lats derivative in which a serine or threonine residue within 20 residues upstream of an Ala-Pro-Glu consensus subdomain eight of a lats kinase domain is substituted with a glutamate or aspartate residue, preferably, in which a serine residue corresponding to serine 909 of human lats is replaced with a glutamate residue. In another specific embodiment, the therapeutic is a fragment of a lats protein comprising or consisting of the amino acid sequence corresponding to amino acids 15 to 585 of human lats, as depicted in Figure 12 (SEQ ID NO:2).

Methods are presented for screening lats-cdc2 complexes, as well as derivatives and fragments of the lats-cdc2 complexes for the ability to alter lats and/or cdc2 activity, *e.g.*, to alter cell proliferation. For example, such derivatives or fragments which have the desired immunogenicity or antigenicity can be used in immunoassays, for immunization, for inhibition of lats-cdc2 complex activity, etc. Derivatives or fragments that retain, or alternatively lack or inhibit, a property of interest (*e.g.*, participation in a lats-cdc2 complex) can be used as inducers, or inhibitors, respectively, of such a property and its physiological correlates. A specific embodiment relates to a lats-cdc2 complex of a fragment of lats and/or a fragment of cdc2 that can be bound by an anti-lats and/or anti-cdc2 antibody or antibody specific for a lats-cdc2 complex when such a fragment is included within a lats-cdc2 complex.

The lats-cdc2 complexes can be obtained by any method known in the art. The cdc2 nucleotide and amino acid sequence is available from GenBank, accession no. Y00272 (see also, Lee and Nurse, 1987, Nature 327:31-35). The lats-cdc2 complexes can be obtained, for example, by expressing an entire lats coding sequence and a cdc2 coding sequence in the

same cell, either under the control of the same promoter or two separate promoters. In yet another embodiment, a derivative, fragment or homolog of lats and/or a derivative, fragment or homolog of cdc2 are recombinantly expressed. Preferably, the derivative, fragment or homolog of lats and/or the cdc2 protein form a complex with a binding partner identified by a binding assay, such as co-immunoprecipitation with an anti-lats or anti-cdc2 antibody, or interaction in a yeast two-hybrid assay (Fields and Song, 1989, Nature 340:245-246; and Finley and Brent, in DNA Cloning 2, Rickwood and Hames, eds (Oxford University Press, Oxford, 1995)).

In a specific embodiment, fusion or chimeric proteins are provided that contain the domains of a lats protein, or, in a specific embodiment, the amino acid sequence corresponding to amino acids 15 to 585 of human lats, and a cdc2 protein that directly form a lats-cdc2 complex and, optionally, a heterofunctional reagent, such as a peptide linker, linking the two domains, where such a heterofunctional reagent, such as a reagent or linker promotes the interaction of the lats and cdc2 binding domains. These fusion proteins may be particularly useful where the stability of the interaction is desirable (due to the formation of the complex as an intramolecular reaction), for example in production of antibodies specific to the lats-cdc2 complex.

#### **Generation of Antibodies to Lats Proteins and Lats-cdc2 Complexes and Derivatives**

LATS proteins, including functional derivatives and fragments thereof (*e.g.* a LATS protein encoded by a sequence of any one of SEQ ID NOs:2, 4, 6, or 8, or a subsequence thereof) may be used as an immunogen to generate monoclonal or polyclonal antibodies and antibody fragments or derivatives (*e.g.*, chimeric, single chain, Fab fragments, etc.). For example, antibodies to a particular domain of a lats protein may be desired. In a specific embodiment, fragments of a lats protein identified as hydrophilic are used as immunogens for antibody production using art-known methods. Various known methods for antibody production can be used including cell culture of hybridomas; production of monoclonal antibodies in germ-free animals (PCT/US90/02545); the use of human hybridomas (Cole *et al.*, Proc. Natl. Acad. Sci. U.S.A. (1983) 80:2026-2030; Cole *et al.*, in Monoclonal Antibodies and Cancer Therapy (1985) Alan R. Liss, pp. 77-96), and production of humanized antibodies (Jones *et al.*, Nature (1986) 321:522-525; US Pat. No. 5,530,101).

#### **Diagnostic, Prognostic, and Screening Uses of Lats-cdc2 Complexes**

Lats-cdc2 complexes may be markers of specific disease states involving disruption of physiological processes, such as cell cycle progression and cell proliferation, and pathological processes, such as hyperproliferative disorders, including tumorigenesis and tumor progression, and hypoproliferative disorders, and thus have diagnostic utility.

Detecting levels of lats-cdc2 complexes, or individual lats and cdc2 proteins or the mRNA encoding lats and cdc2 may be used in diagnosis or prognosis, to follow the course of disease states, or to follow therapeutic response, etc.

5 Lats-cdc2 complexes, lats and cdc2 proteins, and derivatives, and sub-sequences thereof, *lats* and/or *cdc2* nucleic acids (and sequences complementary thereto), and anti-lats-cdc2 complex antibodies and combinations of antibodies directed against lats and cdc2 have uses in diagnostics. Such molecules can be used in assays, such as immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders characterized by aberrant levels of lats-cdc2 complexes or monitor the treatment thereof.

10 In particular, such an immunoassay is carried out by a method comprising contacting a sample derived from a patient with an anti-lats-cdc2 complex antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody. In a specific aspect, such binding of antibody, in tissue sections, can be used to detect aberrant lats-cdc2 complex localization or aberrant (e.g., high, low or absent) levels of lats-cdc2 complex. In a specific  
15 embodiment, an antibody to a lats-cdc2 complex can be used to assay in a patient tissue or serum sample for the presence of a lats-cdc2 complex where an aberrant level of lats-cdc2 complex is an indication of a diseased condition. By "aberrant levels" is meant an increased or decreased level relative to that present, or a standard level representing that present, in an analogous sample from a portion of the body or from a subject not having the disorder.

The immunoassays which can be used include competitive and non-competitive  
20 assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, etc.

Nucleic acids encoding lats and cdc2 proteins and related nucleotide sequences and sub-sequences, including complementary sequences, can also be used in hybridization  
25 assays. The *lats* and *cdc2* nucleotide sequences, or sub-sequences thereof comprising about at least 8 nucleotides, can be used as hybridization probes. Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant levels of the mRNAs encoding the components of a lats-cdc2 complex. In particular, such a hybridization assay is carried out by a method comprising  
30 contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing to *lats* and *cdc2* DNAs or RNAs, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization.

By way of example, levels of lats-cdc2 complexes and lats and cdc2 proteins can be detected by immunoassay, levels of lats and cdc2 mRNA can be detected by hybridization  
35 assays (e.g., Northern blots, dot blots), binding of lats to cdc2 can be done by binding assays commonly known in the art, translocations and point mutations in *lats* and/or *cdc2* can be detected by Southern blotting, RFLP analysis, PCR using primers that preferably

generate a fragment spanning at least most of the *lats* and/or *cdc2* gene, sequencing of the *lats* and/or *cdc2* genomic DNA or cDNA obtained from the patient, etc.

Also embodied are methods to detect a *lats*-*cdc2* complex in cell culture models that express a *lats*-*cdc2* complex, or derivatives thereof, for the purpose of characterizing or preparing the *lats*-*cdc2* complex for harvest. This embodiment includes cell sorting of prokaryotes such as but not restricted to, bacteria (Davey and Kell, 1996, Microbiol. Rev. 60:641-696), primary cultures and tissue specimens from eukaryotes, including mammalian species such as human (Steele et al., 1996, Clin. Obstet. Gynecol 39:801-813), and continuous cell cultures (Orfao and Ruiz-Arguelles, 1996, Clin. Biochem. 29:5-9).

Kits for diagnostic use are also provided, that comprise in one or more containers an anti-*lats*-*cdc2* complex antibody and, optionally, a labeled binding partner to the antibody. Alternatively, the anti-*lats*-*cdc2* complex antibody can be labeled (with a detectable marker, e.g., a chemiluminescent, enzymatic, fluorescent, or radioactive moiety). A kit is also provided that comprises in one or more containers a nucleic acid probe or probes capable of hybridizing to *lats* and *cdc2* mRNAs. In a specific embodiment, a kit can comprise in one or more containers a pair of primers (e.g., each in the size range of 6-30 nucleotides) that are capable of priming amplification [e.g., by polymerase chain reaction (see e.g., Innis et al., 1990, PCR Protocols, Academic Press, Inc., San Diego, CA), ligase chain reaction (see EP 320,308) use of  $\beta$ -replicase, cyclic probe reaction, or other methods known in the art], under appropriate reaction conditions of at least a portion of a *lats* nucleic acid and a *cdc2* nucleic acid. A kit can optionally further comprise in a container a predetermined amount of a purified *lats*-*cdc2* complex, *lats* and *cdc2* proteins or nucleic acids thereof, e.g., for use as a standard or control.

### Demonstration of Therapeutic Utility

The Therapeutics of the invention are preferably tested *in vitro*, and then *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays which can be used to determine whether administration of a specific Therapeutic is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a Therapeutic, and the effect of such Therapeutic upon the tissue sample is observed. A lower level of proliferation or survival of the contacted cells indicates that the Therapeutic is effective to treat the condition in the patient. Alternatively, instead of culturing cells from a patient, Therapeutics may be screened using cells of a tumor or malignant cell line. Many assays standard in the art can be used to assess such survival and/or growth; for example, cell proliferation can be assayed by measuring  $^3\text{H}$ -thymidine incorporation, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (e.g., *fos*, *myc*) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, etc.



In another embodiment of the invention, a Therapeutic of the invention is screened for activity to modulate (*e.g.*, promote, inhibit or antagonize) *cdc2* levels and/or activity. The levels of *cdc2* protein and mRNA and *cdc2* activity can be determined by any method well known in the art. For example, *cdc2* protein can be quantitated by known immunodiagnostic methods such as western blotting immunoprecipitation using any antibody against *cdc2* (for example, anti-*cdc2* antibodies are commercially available from Santa Cruz Inc.) *Cdc2* mRNA can be quantitated by methods that are well known and routine in the art, for example by northern analysis, RNase protection, the polymerase chain reaction in connection with the reverse transcription, etc. *Cdc2* activity can also be assayed by any method known in the art, for example, by the histone-H1 kinase assay.

Compounds for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to in rats, mice, chicken, cows, monkeys, rabbits, etc.

In a preferred embodiment, *lats* knock-out mice, *e.g.*, as described in the Examples, are used to test therapeutics of the invention for activity to treat or prevent cancers, or to modulate *cdc2* activity.

#### ***Lats* Knock-out Animals**

The invention provides recombinant non-human animals in which one or more *lats* genes have been inactivated, *e.g.*, "knock-out animals". The recombinant non-human animal can be any animal, *e.g.*, mouse, rats, rodents, hamster, sheep, pig, cow, *Drosophila*, *C. elegans*, insects, worms, primates, dogs, etc., and is preferably a mouse. Such an animal can be generated by any method known in the art for disrupting a gene on the chromosome of an animal. *Lats* knock-out animals do not include animals in which one or more *lats* genes have been inactivated by naturally occurring mutations. In a preferred aspect, a *lats* knock-out animal can be produced by promoting homologous recombination between a *lats* gene in its chromosome and an exogenous *lats* gene that has been rendered biologically inactive (preferably by insertion of a heterologous sequence, *e.g.*, an antibiotic resistance gene). Homologous recombination methods for disrupting genes in the mouse genome are described, for example, in Capecchi (1989, Science 244:1288-1292) and Mansour et al. (1988, Nature 336:348-352). A *lats* knock-out mouse may be produced by the method described in the Examples section.

Briefly, all or a portion of a *lats* genomic clone is isolated from genomic DNA from the same species as the knock-out animal. The *lats* genomic clone can be isolated by any method known in the art for isolation of genomic clones (*e.g.*, by probing a genomic library with a probe derived from a *lats* sequence, such as those sequences provided in Figures 12-15, *i.e.*, SEQ ID NOS:1, 3, 5, or 7). Once the genomic clone is isolated, all or a portion of the clone is introduced into a recombinant vector. Preferably, the portion of the clone introduced into the vector that contains at least a portion of an exon of the *lats* gene, *i.e.*, contains a *lats* protein coding sequence. A sequence not homologous to the *lats* sequence,

preferably a positive selectable marker, such as a gene encoding an antibiotic resistance gene, is then introduced into the *lats* gene exon. The selectable marker is preferably operably linked to a promoter, more preferably a constitutive promoter. The non-homologous sequence is introduced anywhere in the *lats* coding sequence that will disrupt *lats* activity, *e.g.*, at a position where point mutations or other mutations have been demonstrated to inactivate *lats* protein function. For example, the non-homologous sequence can be inserted for the coding sequence for the portion of the *lats* protein containing all or a portion of the kinase domain (*e.g.*, the nucleotide sequence coding for at least 50, 100, 150, 200 or 250 amino acids of the kinase domain), the *Lats* C-terminal domain 1, the *Lats* C-terminal domain 2, and the *Lats* C-terminal domain 3, or, more preferably, for the sequence coding for the amino acids corresponding to 756 to 1130 of human *lats* (as depicted in Figure 12 (SEQ ID NO:2) and as indicated in the alignment of human and mouse *lats* in Figure 6A).

The positive selectable marker is preferably a neomycin resistance gene (*neo* gene) or a hygromycin resistance gene (*hygro* gene). The promoter may be any promoter known in the art; by way of example the promoter may be the phosphoglycerate kinase (PKG) promoter (Adra et al., 1987, *Gene* 60:65-74), the *PolIII* promoter (Soriano et al., 1991, *Cell* 64:693-701), or the MC1 promoter, which is a synthetic promoter designed for expression in embryo-derived stem cells (Thomas & Capecchi, 1987, *Cell* 51:503-512). Use of a selectable marker, such as an antibiotic resistance gene, allows for the selection of cells that have incorporated the targeting vector (for example, the expression of the *neo* gene product confers resistance to G418, and expression of the *hygro* gene product confers resistance to hygromycin).

In a preferred embodiment, a negative selectable marker for a counterselection step for homologous, as opposed to non-homologous, recombination of the vector is inserted outside of the *lats* genomic clone insert, *e.g.*, as shown in Figure 6B. For example, such a negative selectable marker is the HSV thymidine kinase gene (HSV-tk), the expression of which makes cells sensitive to ganciclovir. The negative selectable marker is preferably under the control of a promoter such as the PGK promoter, the *PolIII* promoter or the MC1 promoter.

When homologous recombination occurs, the portions of the vector that are homologous to the *lats* gene, as well as the non-homologous insert within the *lats* gene sequences, are incorporated into the *lats* gene in the chromosome, and the remainder of the vector is lost. Thus, since the negative selectable marker is outside the region of homology with the *lats* gene, cells in which homologous recombination has occurred (or their progeny), will not contain the negative selectable marker. For example, if the negative selectable marker is the HSV-tk gene, the cells in which homologous recombination has occurred will not express thymidine kinase and will survive exposure to ganciclovir. This procedure permits the selection of cells in which homologous recombination has occurred, as compared to non-homologous recombination in which it is likely that the negative

selectable marker is also incorporated into the genome along with the *lats* sequences and the positive selectable marker. Thus, cells in which non-homologous recombination has occurred would most likely express thymidine kinase and be sensitive to ganciclovir.

Once the targeting vector is prepared, it is linearized with a restriction enzyme for which there is a unique site in the targeting vector, and the linearized vector is introduced into embryo-derived stem (ES) cells (Gossler et al., 1986, Proc. Natl. Acad. Sci. USA 83:9065-9069) by any method known in the art, for example by electroporation. If the targeting vector includes a positive selectable marker and a negative, counterselectable marker, the ES cells in which homologous recombination has occurred can be selected by incubation in selective media. For example, if the selectable markers are the neo resistance gene and the HSV-tk gene, the cells are exposed to G418 (e.g., approximately 300 µg/ml) and ganciclovir (e.g., approximately 2 µM).

Any technique known in the art for genotyping, for example Southern blot analysis or the polymerase chain reaction, can be used to confirm that the disrupted *lats* sequences have homologously recombined into the *lats* gene in the genome of the ES cells. Because the restriction map of the *lats* genomic clone is known (see Figure 6b) and the sequence of the *lats* coding sequence is known (see Figure 13), the size of a particular restriction fragment or a PCR amplification product generated from DNA from both the disrupted and non-disrupted alleles can be determined. Thus, by assaying for a restriction fragment or PCR product, the size of which differs between the disrupted and non-disrupted *lats* gene, one can determine whether homologous recombination has occurred to disrupt the *lats* gene.

The ES cells with the disrupted *lats* locus can then be introduced into mouse blastocysts by microinjection and then the blastocysts can be implanted into the uteri of pseudopregnant mice using routine techniques. The mice that develop from the implanted blastocysts are chimeric for the disrupted allele. The chimeric male mice can be crossed to female mice, and this cross can be designed such that germline transmission of the allele is linked to transmission of a certain coat color. The germline transmission of the allele can be confirmed by Southern blotting or PCR analysis, as described above, of genomic DNA isolated from tail samples.

### Isolating *Lats* Genes

Clones comprising *lats* nucleotide sequences, particularly *lats* genomic clones, can be isolated by any method known in the art. The nucleotide sequences encoding, and the corresponding amino acid sequences of, human *lats*, mouse *lats*, mouse *lats2* and *Drosophila* *lats* are provided in Figures 12-15, respectively (SEQ ID NOS:1-8, respectively) and bacterial cells containing the plasmid pBS(KS)-h-*lats*, which contains the gene encoding human *lats*, were deposited on March 24, 1995 with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2201, and assigned Accession No. 69769. *Lats* nucleic acids, either *lats* genomic clones or *lats* specific probes to identify *lats* genomic clones, can be obtained by any method known in the art, e.g., from

the deposited plasmid, by the polymerase chain reaction (PCR) using synthetic primers hybridizable to the 3' and 5' ends of a *lats* nucleotide sequence and/or by cloning from a cDNA or genomic library using an oligonucleotide probe specific for the gene sequence, such as a probe from the *lats* gene insert in plasmid pBS(KS)-h-*lats*. Genomic clones can be identified by probing a genomic DNA library under appropriate hybridization conditions, e.g., high stringency conditions, low stringency conditions or moderate stringency conditions, depending on the relatedness of the probe to the genomic DNA being probed. For example, if the *lats* probe and the genomic DNA are from the same species, then high stringency hybridization conditions may be used; however, if the *lats* probe and the genomic DNA are from different species, then low stringency hybridization conditions may be used. High, low and moderate stringency conditions are all well known in the art.

Procedures for low stringency hybridization are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film.

Procedures for high stringency hybridizations are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1 X SSC at 50°C for 45 minutes before autoradiography.

Moderate stringency conditions for hybridization are as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhardt's solution, 0.5% SDS, and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in the hybridization mixture for 18-20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1 X SSC and 0.1% SDS.

Any eukaryotic cell potentially can serve as the nucleic acid source for the molecular cloning of the *lats* gene. The nucleic acid sequences encoding *lats* can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as

additional primate sources, insects, etc. The DNA may be obtained by standard procedures known in the art, preferably from cloned genomic DNA (*e.g.*, a DNA "library") from the desired cell (see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.). The gene should be molecularly cloned into a suitable vector for propagation of the gene.

In preferred embodiments, the genomic clone used to generate a recombinant, non-human animal by homologous recombination contains at least a portion of the *lats* coding sequence of SEQ ID NO:3; alternatively, the genomic clone contains at least a portion of the *lats* coding sequence of SEQ ID NO:5.

#### Methods of Screening Therapeutics Using *Lats* Knock-out Mice

The invention provides methods for screening for compounds useful in the treatment or prevention of cancer or in the treatment and prevention of pituitary diseases and disorders by administration or application of the compound to be tested to a *lats* knock-out animal, preferably a *lats* knock-out mouse.

In a preferred embodiment, the invention provides a method for screening a potential therapeutic compound for activity in treating or preventing cancer. The potential therapeutic compound is administered to a recombinant non-human animal having at least one inactivated *lats* gene (*i.e.*, a *lats* knock-out animal, preferably a *lats* knock-out mouse), preferably two inactivated *lats* genes (*i.e.*, is homozygous for the inactivated *lats* allele). The size or progression of the cancer is then compared to that before the compound was added, or to a comparable recombinant animal without the administration of the compound, or to a normal, non-recombinant animal. A decrease in the size or progression of the cancer in the recombinant non-human animal after the administration of the compound as compared to the same animal prior to the administration or to another recombinant non-human animal not so administered or the standard size or progression of the cancer indicates that the compound has activity in treating or preventing cancer.

The screening method of the invention can be used to screen for potential therapeutic compounds for the treatment or prevention of any cancer, preferably a cancer or neoplastic disease that is caused by the *lats* knock-out mutation. As described in the Examples section, *infra*, *lats* knock-out mice are susceptible to ovarian stromal tumors and soft tissue sarcomas that metastasize to vital organs. Accordingly, in preferred embodiments, the invention provides methods for screening compounds useful in treating or preventing ovarian tumors and soft tissue sarcomas. *Lats* knock-out mutations in other animals or in other *lats* homologs may make the resulting knock-out animal susceptible to other types of neoplastic disease. The invention also contemplates use of these other *lats* knock-out animals to screen compounds for efficacy in treating or preventing the types of neoplastic diseases found in these *lats* knock-out animals. Additionally, compounds

effective to treat or prevent ovarian tumors and/or soft tissue sarcomas in *lats* knock-out animals may also be effective to treat or prevent other types of cancers and neoplastic disease. Thus, *lats* knock-out animals may be used to screen for compounds that have activity to treat or prevent these other types of cancers and neoplastic disease.

5 The invention also provides methods of screening compounds for efficacy in treating or preventing skin cancer. As demonstrated in Examples section, *infra*, exposure to carcinogens induced, at a high frequency, skin tumors in the *lats* knock-out mice. Many methods are known in the art for inducing skin carcinogenesis in animals (for review see DiGiovanni, 1992, Pharmac. Ther. 54:63-128). Generally, mouse skin tumors can be elicited by application of a carcinogenic dose of tumor initiator, *e.g.*, 600 to 800 nmole of a  
10 pure polycyclic aromatic hydrocarbon such as 9,10-dimethyl-1,2-benzanthracene (DMBA). Other tumor initiators include, but are not limited to, arylamines, carbamates, haloalkylethers, haloaromatics, lactones, nitro-aromatics, nitrosamides and ureas. Alternatively, and preferably, mouse skin tumors can be induced by an initial application of a single sub-carcinogenic dose of a tumor initiator, *e.g.*, DMBA, and then repeated doses or  
15 exposures to a tumor promoter, such as phorbol esters (*e.g.*, TPA), teleocidins, polyacetates, okadaic acid, calyculin A, palytoxin, and thapsigargin. Ultraviolet B (UVB) radiation, skin abrasion and skin wounding are also strong tumor promoters.

In a preferred embodiment, such skin tumors are induced by a two-step process comprising a single treatment with DMBA, preferably 50  $\mu$ l of a 0.5% DMBA solution in acetone, to the dorsal surface of the mouse 1 to 5 days after birth followed by repeated  
20 exposure to UVB irradiation, *e.g.*, exposures of approximately three times per week with an initial exposure of approximately 100 mJ/cm<sup>2</sup> per session, increasing the dosage by 10% per treatment (unless erythema or scaling occurs) to a maximum of 700 mJ/cm<sup>2</sup>, with an average of about 27 treatment sessions per mouse (Serrano et al., 1996, Cell 85:27-37).

Accordingly, in a preferred embodiment, the invention provides a method for  
25 screening a potential therapeutic compound for activity in treating or preventing skin cancer comprising administering the compound to a recombinant non-human animal in which one, preferably two, *lats* genes have been inactivated (*i.e.*, a *lats* knock-out animal) and in which recombinant non-human animal tumors have been induced by exposure to at least one carcinogen. The size or progression of the skin tumors are then compared before and after the administration of the compound. A reduction in the size or progression of the skin  
30 tumors in the recombinant non-human animal administered the compound as compared to same animal prior to administration of the compound or to the animal not so administered or to the standard size or progression of the skin tumors, indicates that the compound has activity in treating or preventing skin cancer. In another embodiment, the compound to be screened is administered by recombinantly expressing the compound in the recombinant  
35 non-human animal inactivated for the *lats* gene.

The administration of the compound to be tested can be carried out by any method known in the art, *e.g.*, orally, intravenously, intramuscularly, intraperitoneally,

subcutaneously, rectally, topically, etc. For the screening of compounds for efficacy in treating or preventing skin cancer, the compound is preferably applied topically.

After administration of the compound to be tested, the tumors, sarcomas, and other cancers can be evaluated by any diagnostic or histopathological method for detecting and evaluating tumors and cancers, for example, by visual inspection of the tumors (particularly for skin tumors), manual palpitation of tumors, biopsy or surgical removal of the tumor tissue and subsequent inspection, and sacrifice and dissection of the recombinant non-human animal. Morphological evaluation of tissue, either removed by biopsy or dissected from a sacrificed mouse, may be performed by fixing the tissue by any method known in the art, for example, in 10% neutral buffered formalin at 4°C, and subsequent dehydration, e.g., in ethanol. The fixed and dehydrated tissue may be embedded in paraffin and then sectioned, for example into 4-5 mm sections by any method known in the art. Sections can be stained, for example, with a standard stain, such as hematoxylin and eosin, for microscopic inspection.

Another aspect of the invention provides methods for screening potential therapeutic compounds for efficacy in treating or preventing diseases or disorders associated with pituitary dysfunction. *Lats* knock-out mice display a number of consequences of pituitary dysfunction, as described in the Examples section, *infra*. The methods of the invention can be used to screen compounds for efficacy in treating or preventing such pituitary dysfunctions as pituitary hyperplasia, fertility defects, such as defective ovulation, lack of breast development, abnormal reproductive cycles in females, LH hypogonadotropic hypogonadism, reduced levels of pituitary hormones, specifically LH, GH and PRL, and reduced growth and metabolic abnormalities caused by reduced GH levels. Therapeutics that are effective to treat one or more of these conditions associated with pituitary dysfunction may also be effective to treat or prevent other conditions, diseases or disorders associated with pituitary dysfunction.

In a preferred embodiment, potential therapeutic compounds to be screened for activity in treating or preventing diseases and disorders associated with pituitary dysfunction are administered to a recombinant non-human animal in which one or more chromosomal copies of the *lats* gene have been inactivated (*i.e.*, a *lats* knock-out animal, preferably a *lats* knock-out mouse). Levels of an indicator of pituitary function or dysfunction are then compared in the recombinant non-human animal before and after the compound was administered. In one embodiment, the compound to be screened is administered by recombinantly expressing the compound in the recombinant non-human animal having an inactivated *lats* gene.

Indicators of pituitary function that may be assayed include fertility, ovulation, the female reproductive cycle (*e.g.*, the estrus cycle), breast tissue development, growth or size of the animal, including weight, skeletal size, *e.g.*, of the skull and/or longitudinal bones, and organ weight, and serum levels of LH, GH and PRL. These indicators may be measured by any means known in the art for evaluating these indicators. For example,

fertility may be evaluated by attempting to mate an animal and determining whether conception occurred, measuring sperm count in male animals or detecting ovulation in female animals. The reproductive organ tissue may also be examined histopathologically (e.g., by fixing, sectioning and staining the tissue for inspection) for morphological defects, particularly in the testis, ovaries, and breast tissue. Whether the animal goes through an estrus cycle may be determined by observation of the animal. Hormone levels may be determined by any method known in the art, for example in serum samples by radio immunoassay using antibodies specific for the particular hormone. Lack of normal growth can be determined by measuring the animal e.g., the weight, size of the skull and/or longitudinal bones, or organ weight, during maturation.

### Candidate Therapeutics

Candidate therapeutics may come from any source of therapeutics known in the art. For example, these therapeutics can be proteins, nucleic acids (including anti-sense nucleic acids), antibodies, peptides, organic molecules, etc. In some instances, compounds may be screened first in *in vitro* assays to determine their potential as anti-cancer or anti-pituitary dysfunction therapeutics.

For example, chemical libraries may be screened for useful therapeutics. Exemplary libraries are commercially available from several sources (ArQule, Tripos/PanLabs, ChemDesign, Pharmacopoeia). Many diversity libraries suitable for use are known in the art and can be used to provide compounds to be tested according to the present invention. Alternatively, libraries can be constructed using standard methods. Chemical (synthetic) libraries (Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251), recombinant expression libraries, or polysome-based libraries are exemplary types of libraries that can be used. Other examples include combinatorial libraries (Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712), organic diversity (e.g., nonpeptide) libraries (Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) may be used. Libraries of non-peptides, e.g., peptide derivatives (for example, that contain one or more non-naturally occurring amino acids) can also be used. One example of these are peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371). Peptoids are polymers of non-natural amino acids that have naturally occurring side chains attached not to the alpha carbon but to the backbone amino nitrogen. Since peptoids are not easily degraded by human digestive enzymes, they are advantageously more easily adaptable to drug use.



### Therapeutic/Prophylactic Administration and Compositions

The invention provides methods of treatment (and prophylaxis) by administration to a subject of an effective amount of a Therapeutic of the invention. In a preferred aspect, the Therapeutic is substantially purified. The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human. In a specific embodiment, a non-human mammal is the subject.

Various delivery systems are known and can be used to administer a Therapeutic of the invention, e.g., encapsulation in liposomes (Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989)), microparticles, microcapsules, recombinant cells capable of expressing the Therapeutic, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a Therapeutic nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.

In a specific embodiment where the Therapeutic is a nucleic acid encoding a protein Therapeutic, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), etc. Alternatively, a nucleic acid Therapeutic can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a Therapeutic, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the Therapeutic is administered. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to

provide the form for proper administration to the patient. The formulation should suit the mode of administration.

5 In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.

10 The amount of the Therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

20 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.

### Screening for Lats Agonists and Antagonists

Lats nucleic acids, proteins, and derivatives may be used in screening assays to detect molecules that specifically bind to lats nucleic acids, proteins, or derivatives and thus have potential use as agonists or antagonists of lats, in particular, molecules that thus affect cell proliferation and/or cdc2 activity, or molecules that promote or inhibit formation of lats-cdc2 complexes. In a preferred embodiment, such assays are performed to screen for molecules with potential utility as lead compounds for drug development, particularly as anti-cancer drugs. The invention thus provides assays to detect molecules that specifically bind to lats nucleic acids, proteins, or derivatives or bind to or interfere with the formation of lats-cdc2 complexes. For example, recombinant cells expressing *lats* nucleic acids can be used to recombinantly produce lats proteins in these assays, to screen for molecules that bind to a lats protein, and recombinant cells expressing *lats* and *cdc2* nucleic acids can be used to recombinant produce both lats and cdc2 proteins in these assays, to screen for molecules that bind to or inhibit formation of a lats-cdc2 complex. Molecules (*e.g.*, putative binding partners of lats) are contacted with the lats protein (or fragment thereof) under conditions conducive to binding, and then molecules that specifically bind to the lats protein or bind to or interfere with the formation of lats-cdc2 complexes are identified.

Similar methods can be used to screen for molecules that bind to lats derivatives or nucleic acids. Methods that can be used to carry out the foregoing are commonly known in the art.

By way of example, diversity libraries, such as random or combinatorial peptide or nonpeptide libraries can be screened for molecules that specifically bind to lats. Many libraries are known in the art that can be used, *e.g.*, chemically synthesized libraries, recombinant (*e.g.*, phage display libraries), and *in vitro* translation-based libraries.

Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R.B., et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

*In vitro* translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see *e.g.*, Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992, BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

In a specific embodiment, screening can be carried out by contacting the library members with a lats protein (or nucleic acid or derivative) immobilized on a solid phase and

harvesting those library members that bind to the protein (or nucleic acid or derivative). Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited hereinabove.

5 In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a lats protein or derivative or that interfere with the formation of lats-cdc2 complexes. Additionally, the two hybrid system or co-immunoprecipitation of lats and cdc2 can be used as assays to  
10 screen for compounds that promote or inhibit formation of lats-cdc2 complexes.

In a preferred embodiment, the invention provides a method of screening for a molecule that modulates (*i.e.*, inhibits, antagonizes or promotes) directly or indirectly, the formation of a complex of lats and cdc2 proteins comprising measuring the levels of said complex formed from lats and cdc2 proteins in the presence of said molecule (optionally, purified) under conditions conducive to formation of the complex; and comparing the levels  
15 of said complex with the levels of said complex that are formed in the absence of said molecule, lower or higher level of said complex in the presence of said molecule indicates that the molecule modulates formation of said complex.

20

## EXAMPLES

### EXAMPLE 1: Human Lats Modulates Cdc2/Cyclin A Activity

Using mammalian cell culture assays, we have found that lats is phosphorylated in a cell cycle-dependent manner and that it complexes with cdc2 in early mitosis. Lats associated cdc2 has no mitotic cyclin partner and no kinase activity for histone H1.  
25 Furthermore, we have found that *lats* mutant cells in *Drosophila* abnormally accumulate cyclin A. These biochemical observations indicate that lats is a negative regulator of cdc2/cyclin A, a finding supported by *in vivo* genetic data demonstrating that lats specifically interacts with cdc2 and cyclin A in *Drosophila*.

### 30 **Materials and Methods**

For yeast two-hybrid experiments, DNA encoding N-terminal h-lats (amino acid numbers 15 to 585 of the human lats protein sequence as depicted in Figure 12 (SEQ ID NO:2)), C-terminal h-lats (amino acid number 589 to 1130 of the human lats protein sequence as depicted in Figure 12 (SEQ ID NO:2)), and h-lats (amino acid numbers 15 to 1130 of the human lats protein sequence as depicted in Figure 12 (SEQ ID NO:2)) were  
35 cloned into pBTM116 (Bartel et al., Cellular Interactions in Development: A Practical Approach, ed. D. Hartley (Oxford University Press, Oxford, England (1993)). DNA

encoding human cdc2, CDK2, CDK4 and C-terminal h-lats were cloned in pACT (Durfee et al., 1993, Genes & Devel. 8:440-452). The constructs were transformed into yeast strain L40 (Vojtek et al., 1993, Cell 74:205-214). The transformants were tested for growth on SD his-ura-trp-leu medium (Bio101, California) and for  $\beta$ -galactosidase activities (Vojtek et al., 1993, Cell 74:205-214).

For baculovirus experiments, full-length *h-lats* cDNA was cloned into the vector pBacPAK8 and baculovirus were produced according to the protocols provided by Clontech. IPLB-Sf21 cells were co-infected with equal amounts of h-lats and human cdc2-baculoviruses and were harvested 62 hours after infection for immunoprecipitation and immunoblot assay.

### Fly Genetics

The full-length *h-lats* cDNA was cloned into the vector pCaSpeR-hs (Tummel and Pirrott, 1992, *Drosophila* Information Service 71:150). Multiple transformant lines were obtained and used in rescue experiments with *lats*<sup>es32</sup>, *lats*<sup>e26-1</sup>, *lats*<sup>al</sup>, and *lats*<sup>XI</sup> alleles. Expression of *hs-h-lats* was induced as described in Xu et al. (1995, Development 121:1053-1063) -- incubation at 37°C for one hour every day until eclosure. Since the induction of *h-lats* requires heat-shock treatments, X-ray irradiation was used to induce mitotic clones in *y w P[hs-h-lats]/y w; P[FRT]82B lats<sup>XI</sup>/P[y+]96E* animals. The rest of the *lats* mutant mitotic clones were induced and labeled according to Xu and Rubin (1993, Development 117:1223-1237). The *Drosophila lats* and *h-lats* cDNAs were cloned into the pGMR vector to generate multiple transformant lines (Hay et al., 1994, Development 120:2121-2129). Besides the mutations mentioned above, *cdc2c*<sup>E136E</sup> (a gift of Helena Richardson), *cycA*<sup>ncol14</sup>, *Df(2R)59A-B* were used for *cdc2c*, *cyclin A* and *cyclin B*, respectively.

### Tissue Culture

HeLa cells were synchronized at different cell cycle stages by various treatments as described by Knehr et al. (1995, Exp. Cell. Res. 217:546-553). Briefly, cells were arrested at G1 by thymidine and hydroxyurea treatment; at S phase by thymidine double block (incubation in the presence of 2 mM thymidine for 24 hours, followed by recovery in the absence of thymidine for 12 hours, followed by another incubation in 2 mM thymidine for 14 hours) plus a 4 hour incubation in medium without thymidine; and at G2 by thymidine double block plus an 8 hour incubation in medium without thymidine. To arrest cells in M phase, cells were treated with 0.1  $\mu$ g/ml nocodazole (Sigma) for 12 hours and mitotic cells were shaken off of the flask and washed twice with cold DMEM without serum. These mitotic cells were then resuspended in fresh warm medium without nocodazole and incubated in suspension at 37°C. Cells were harvested at various time points after removal of nocodazole (herein "ARN") for further analysis. CHO cells were grown in  $\alpha$ -MEM medium plus 7% FBS and IPLB-Sf21 cells were grown in sf-900 II SFM plus 10% FBS.

### Antibodies and Immunochemistry

Anti-human *lats* rat monoclonal and rabbit polyclonal antibodies were raised against a GST-N-h-Lats (GST fused to the N-terminal portion of *lats*, *i.e.*, consisting of amino acids 15-585 of the human *lats* amino acid sequence as depicted in Figure 12 (SEQ ID NO:2) fusion protein. Anti-human *cdc2* (#sc 054), anti-human cyclin B (#sc 245), anti-human cyclin A (#sc 239) monoclonal antibodies were purchased from Santa Cruz Inc. Rabbit polyclonal anti-*Drosophila* Cyclin A and B antibodies were gifts of David Glover. Monoclonal mouse anti-BrdU antibodies (#347580) were purchased from Becton Dickinson and monoclonal mouse anti-c-myc antibodies (#OP 10) were purchased from Oncogene Sciences. Propidium iodide (Sigma) was used as a DNA marker.

HeLa, CHO, or IPLB Sf21 cells were lysed in TG buffer (1% Triton, 10% glycerol) (Sun et al., 1996, Genes & Devel. 10:395-406) plus freshly added proteinase inhibitors (1 mM PMSF, 10 µg/ml leupeptin, 1 µg/ml pepstatin, and 2 µg/ml aprotinin). The lysates were centrifuged at 50 K, 4°C for 12 minutes. Supernatants were pre-cleaned by incubating with protein G-agarose. Immunoprecipitation and western blots were performed by the procedures described by Sun et al. (1996, Genes & Devel. 10:395-406). Western blots were visualized by enhanced chemiluminescence (Amersham). Whenever necessary the blots were stripped following the procedure described by Edgar et al. (1994, Genes & Devel. 8:440-452). Calf Intestinal Phosphatase (CIP) treatments were carried out as described in Sun et al. (1996, Genes & Devel. 10:395-406).

### H1 Kinase Assay

HeLa cell lysates (50 minutes ARN) were pre-cleaned by incubation in protein G-agarose. Immunoprecipitates were washed three times with TG buffer and twice with 1X kinase buffer (50 mM Tris-HCl 7.5, 10 mM MgCl<sub>2</sub>, 5 mM EGTA, 2 mM DTT) without DDT. The kinase assay was carried out on ice for 10 minutes in 35 µl of 1X kinase buffer containing 15 µCi of γ-<sup>32</sup>P ATP, 1.6 µg of histone H1, and 1.5 µM ATP. The kinase activities were measured by quantifying the intensities of histone-H1 phosphorylation using a PhosphorImager (Molecular Dynamics). The amounts of *cdc2* in the immunoprecipitates were determined by anti-*cdc2* immunoblotting and densitometer scanning (Molecular Dynamics). The kinase assay experiments were repeated three times.

## Results

### Human Lats Can Functionally Replace its Fly Counterpart

Sequence conservation suggested that human *lats* could be a functional homolog of *Drosophila* *lats*. To test this, the human *lats* cDNA was introduced into the *Drosophila* genome under the control of the heat shock-inducible promoter (*hs-h-lats*) (Lis et al., 1983, Cell 35:403-410) and expressed the transgene was expressed under the conditions previously established for rescue using the fly *lats* gene (Xu et al., 1995, Development 121:1053-1064; and PCT Publication WO 96/30402, published October 3, 1996). In

mosaic flies, clones of cells mutant for *lats* undergo extensive overproliferation and develop into large tumors in various tissues (Figure 1A and Xu et al., 1995, Development 121:1053-1064). Expression of human *lats* completely suppressed tumor formation in *lats* mosaic flies (Figures 1B-D). Instead, the *lats* mutant cells (genetically marked as *yellow-* cells) in these human *lats*-expressing mosaic animals developed into normal adult structures (Figures 1C and D). The ability of the human gene to support normal fly development was further examined. Expression of the human *lats* transgene in homozygous *lats* mutant *Drosophila* rescued all developmental defects including embryonic lethality found in homozygous *lats* mutants. Furthermore, the extent of phenotypic rescue correlated with the level of human *lats* expression. Complete phenotypic rescue required daily induction of human *lats*, and leaky expression of *lats* controlled by the heat shock promoter at 25°C resulted in partial suppression of the *lats* mutant overproliferation phenotype (Figures 1E and F). These data demonstrate that human *lats* is an authentic homolog of the *Drosophila* *lats* tumor suppressor.

#### **Lats is phosphorylated in a cell cycle-dependent manner**

To further explore the function of *lats*, the biochemical properties of the human *lats* protein were examined. *Lats* immunoprecipitated from HeLa cells had two major migrating forms (Figure 2A, lane 6). The slow-migrating form of *lats* was converted into the fast-migrating form after the proteins were incubated with calf intestine alkaline phosphatase (CIP) (Figure 2A). Addition of a phosphatase specific inhibitor,  $\beta$ -glycerophosphate, to the phosphatase reaction blocked this conversion (Figure 2A, lanes 5 and 10). These results indicate that the slow-migrating form is phosphorylated *lats*, while the fast-migrating form is dephosphorylated *lats*.

*Lats* immunoprecipitated from cells at different mitotic stages displayed varying amounts of the two forms (compare lanes 1 and 6 of Figure 2A), suggesting that the phosphorylation state of *lats* may oscillate with the cell-cycle. To verify this possibility, *lats* proteins were immunoprecipitated from extracts of HeLa cells at G0, G1, S, and G2 phases, and different time points during mitosis (minutes after removal of nocodazole (ARN) block) (Knehr, et al., 1995, Exp. Cell Res. 217:546-553). DAPI staining was used to verify the cell cycle progression. All *lats* protein was phosphorylated at late prophase (0 minutes ARN; Figure 2B), and remained phosphorylated through metaphase (50 minutes ARN; Figures 2B and C). Dephosphorylated *lats* could be detected when cells in the culture begin to enter anaphase (75 minutes ARN; Figures 2B and C), and by the start of telophase (100 minutes ARN) most of the *lats* protein was dephosphorylated (Figures 2B and C). In late mitosis, G1, S, G2 or G0 phase, *lats* molecules were in the dephosphorylated form (Figure 2B). These observations strongly suggest that the *lats* protein undergoes two major phosphorylation changes during the cell cycle. At the G2/M boundary or in early prophase, *lats* is phosphorylated, and *lats* becomes dephosphorylated at the metaphase/anaphase boundary or in early anaphase.

### Lats complexes with cdc2 during mitosis

*Lats* mutant cells in *Drosophila* mosaic for the *lats* mutation do differentiate, indicating that mutations in *lats* do not block cellular differentiation in general (Figures 1G and H). The *lats* mutant overproliferation phenotype and cell cycle-dependent phosphorylation of lats suggest that the protein could be directly involved in the regulation of the cell cycle.

Immunoprecipitation experiments were carried out to examine whether lats proteins complex with known cell cycle regulators. Interestingly, cdc2 was found to co-immunoprecipitate with lats in mitotic cells (Figures 3A and B). The co-precipitation of lats and cdc2 was confirmed in both murine and human cells using several polyclonal and monoclonal anti-human lats antibodies (as described above in the Materials and Methods section, *supra*). Although similar amounts of lats were immunoprecipitated from HeLa cells during different stages of mitosis (Figure 3B, upper panel), the amount of co-precipitated cdc2 varied (Figure 3B, lower panel). Co-precipitated cdc2 was most abundant at early mitosis (0 and 50 minutes ARN; Figure 3B; also see Figures 2B and C for cell cycle progression). The amount of co-precipitated cdc2 then progressively decreased as the cell cycle progressed (Figure 3B--lanes 100', 150', and 200'). No cdc2 co-immunoprecipitation could be detected in quiescent cells in G0 (Figure 3A and Figure 2B). The difference in the amount of co-precipitated cdc2 cannot be attributed to changes of cdc2 levels during the cell cycle, since it has previously been shown that the cdc2 protein is maintained at a nearly constant level in cycling cells (Dalton, 1992, EMBO J. 11:1797-1804; McGowan et al., 1990, Mol. Cell. Biol. 10:3847-3851). Indeed, equal amounts of cdc2 protein were precipitated from the 50 minutes and 200 minutes ARN extracts when anti-cdc2 antibodies were used.

The interaction of lats and cdc2 proteins was studied by expressing human lats and cdc2 proteins in the baculovirus expression system. The baculovirus-expressed cdc2 and lats proteins could be co-immunoprecipitated using either anti-human lats or anti-cdc2 antibodies (Figure 3C). This result suggests that the *in vivo* lats/cdc2 complex may result from direct binding of the two proteins.

The interaction between lats and cdc2 was also examined using the yeast two-hybrid assay (Fields and Song, 1989, Nature 340:245-245; Finley and Brent, in DNA Cloning 2, Rickwood and Hames, eds (Oxford University Press (Oxford, 1995))). Consistent with the co-immunoprecipitation results, full length lats and the N-terminal region of lats interacted with cdc2 in the assay (Figure 3E). Since the C-terminal kinase domain of lats did not interact with cdc2, these results indicate that lats associates with cdc2 through its N-terminal domain. Furthermore, neither full length lats nor the N-terminal region of lats showed any interaction with two G1 cell cycle kinases, CDK2 and CDK4 (Figure 3E), indicating that the association between lats and cdc2 is specific.



### The lats/cdc2 complex is inactive for H1 kinase activity

We examined whether the lats/cdc2 complex has any kinase activity on the substrate histone H1. Lats/cdc2 and cdc2/cyclin B complexes were immunoprecipitated separately from 50 minute ARN HeLa cell extracts using either anti-human lats or anti-cyclin B monoclonal antibodies and assayed for histone H1 kinase activities. In contrast to the cdc2/cyclin B complex, the lats/cdc2 complex showed no detectable kinase activity for histone H1 (Figure 3D). Densitometer readings indicated that the H1 kinase activity of the lats/cdc2 complex does not differ from the background control and is at least 25 fold lower than the kinase activity of the cdc2/cyclin B complex. These results indicate that cdc2 molecules associated with lats are inactive or have dramatically reduced mitotic kinase activity.

The lack of H1 kinase activity in the lats-associated cdc2 could be due to the inhibition of the kinase activity of the cdc2/cyclin complex by lats. Alternatively, the lats/cdc2 complex may lack cyclin A and B which are the indispensable subunits for cdc2 kinase activity (Draetta et al., 1989, Cell 56:829-838; Solomon et al., 1990, Cell 63:1013-1024). Neither cyclin A nor cyclin B proteins could be detected in the lats/cdc2 immunocomplex when probed with anti-cyclin A and B antibodies (Figure 3B), indicating that lats modulates cdc2 activity in a way different from that of the known cyclin dependent kinase inhibitors (CDIs) (Sherr, 1996, Science 274:1672-1677; Harper, 1997, Cancer Surveys 29:91-107).

### Lats genetically interacts with cdc2 and cyclin A during *Drosophila* development

In *Drosophila*, cdc2 also complexes with cyclin A or B (Knoblich et al., 1994, Cell 77:107-120). We examined the potential genetic interactions between lats, cdc2, cyclin A and cyclin B in *Drosophila*. Animals heterozygous for the strong *cdc2* allele, *cdc2<sup>B47</sup>*, or homozygous for the temperature sensitive *cdc2<sup>ts</sup>* mutation at permissive temperature are viable and morphologically normal (Clegg et al., 1993, Genome 36:676-685). The *lats<sup>P8</sup>* mutation causes late pupal lethality in homozygous mutants (Figure 4A), and reducing cdc2 activity in *lats<sup>P8</sup>* homozygotes by introducing one copy of a *cdc2* mutant allele (*cdc2<sup>B47</sup>* or *cdc2<sup>ts</sup>/+*; *lats<sup>P8</sup>/lats<sup>P8</sup>*) was sufficient to rescue the lats-associated lethality (Figure 4B). Furthermore, the overproliferation phenotype of *lats<sup>P8</sup>* adult appendages were also suppressed. Rescued animals had near-wild type eyes in comparison to the overproliferated, large, rough eyes of the *lats<sup>P8</sup>* mutants (Figures 4C and D). Reducing cdc2 activity also suppressed the giant larvae/pupae and disc overproliferation phenotypes of the *lats<sup>E26-1</sup>* animals (Figures 4E and F). The *Drosophila* CDK2 homolog, cdc2c complexes with Cyclin E (Lehner and O'Farrell, 1990, Cell 61:535-547; Knoblich et al., 1994, Cell 77:107-120). Consistent with the result of the yeast two-hybrid assay for human lats and CDK2 (Figure 3C), inactivation of one copy of the *cdc2* gene did not modify the phenotypes of the *lats<sup>P8</sup>* mutant animals. We further examined the potential genetic

interaction between *lats*, *cyclin A* and *cyclin B* in *Drosophila* as described above. Interestingly, while cyclin B did not interact with *lats*, cyclin A behaved similarly to *cdc2*. Inactivation of one copy of the cyclin A gene resulted in almost identical phenotypic suppression of the *lats*<sup>P8</sup> and *lats*<sup>E26-1</sup> mutants as did the *cdc2* mutants (data not shown). Thus, the specific genetic interactions between *lats*, *cdc2*, and cyclin A confirms the biochemical data indicating that *lats* regulates cell proliferation by negatively modulating *cdc2*/cyclin A activity.

While *cdc2* protein remains at a constant level during the cell cycle (Dalton, 1992, EMBO J. 11:1797-1804; McGowan et al., 1990, Mol. Cell. Biol. 10:3847-3851), cyclin A and B are degraded when the *cdc2*/cyclin complexes are inactivated (Draetta et al., 1989, Cell 56:829-828; Murray et al., 1989, Nature 339:280-286; King et al., 1994, Cell 79:563-571).

Accordingly, whether *lats* inactivation leads to accumulation of cyclin A and B was also determined. In the *Drosophila* eye imaginal disc, cyclin A and B are detected in cells anterior to the morphogenetic furrow (MF) as well as in a stripe of cells posterior to the MF which are undergoing the last round of cell division (the second mitotic wave) (Thomas et al., 1994, Cell 77:1003-1014). In clones of *lats* cells located anterior to the MF, anti-cyclin A or B antibody staining did not detect any obvious changes in levels of the two proteins (Figures 5A-N; Whitfield et al., 1990, EMBO J. 9:2563-2572), which might be due to the fact that cells in this region already accumulate high levels of both cyclin A and B. Cells in the MF are synchronized in G1 and so are the cells posterior to the MF which are differentiating into neurons. Both populations of the G1 cells have no detectable cyclin A or B (Thomas et al., 1994, Cell 77:1003-1014; Figures 5B and H). However, in clones of *lats*<sup>+</sup> cells in the MF and in the region posterior to the MF, a high level of cyclin A was detected (Figures 5A-E). Interestingly, in *lats*<sup>-/-</sup> cells, cyclin A was still degraded in cells at late mitosis (Figure 5F), indicating that *lats* affects limited aspects of the cell cycle. Finally, consistent with the genetic interaction results, *lats*<sup>-/-</sup> clones did not cause obvious changes in the staining pattern of cyclin B (Figures 5G and H). These results provide direct evidence indicating that inactivation of *lats* causes overproliferation by deregulating *cdc2*/cyclin A activity.

The role of *lats* in cell cycle regulation was examined by overexpressing *lats* in the developing eye imaginal disc. When *Drosophila* and human *lats* cDNAs were expressed in cells in and posterior to the MF under the direction of the GMR promoter (Hay et al., 1994, Development 120:2121-2129), they exhibited similar phenotypes. Adult eyes from these animals were smaller than wild type and had irregular architecture with missing bristles, a phenotype reminiscent to that of overexpressing *p21* under the same promoter (*GMR-p21*; de Nooij and Hariharan, 1995, Science 270:983-985) (Figures 5I and J). Sections of GMR-*lats* adult retinas also revealed a phenotype identical to that observed in retinas from flies transformed with *GMR-p21*. While almost all of the ommatidia contained the full complement of photoreceptor cells, many pigment cells were missing (Figure 5K). This

phenotype suggested that, like overexpression of p21, overexpression of lats blocked the last round of cell division in the developing eye disc. Further examination of the GMR-lats eye discs revealed that in the region of second mitotic wave there was an accumulation of cells with intense propidium-iodide staining, indicating that the cells were tetraploid, which was followed immediately posteriorly by apoptotic cells with fragmented nuclei (Figure 5L). In contrast to the overexpression of p21 which blocked entry into S phase, overexpressing lats arrested cells at G2/M or M phase. Consistent with this conclusion, BrdU labeling experiments revealed that the S phase of the cells in the second mitotic wave did occur in GMR-lats eye discs (Figures 5M and N).

## 10 Discussion

### The lats molecules are a novel family of conserved proteins

Expression of human lats under the same conditions used for rescue by the fly gene completely suppressed tumor formation in *lats* mosaic flies and rescued all developmental defects in *lats* homozygous mutant *Drosophila*. These experiments provide definitive evidence for functional conservation among the *lats* genes, indicating that human lats can perform all functions that are normally provided by the fly protein.

### A model for lats function

Our biochemical and genetic data support the hypothesis that lats is a negative regulator of cdc2/cyclin A. Cdc2 co-immunoprecipitated with lats using either HeLa and CHO cell extracts or baculovirus-expressed proteins. Cdc2 also interacted with lats in yeast two-hybrid assays. Moreover, lats-associated cdc2 has no cyclin A or B subunit and no histone H1 kinase activity. In *Drosophila*, *lats* mutant cells abnormally accumulated cyclin A. Genetic data in *Drosophila* demonstrate that the overproliferation and lethality phenotypes of *lats* mutants can be suppressed by mutations in *cdc2* and *cyclin A* genes. The genetic interaction between lats, cdc2, and cyclin A is highly specific. While animals heterozygous for cdc2 or cyclin A did not display any defects, removal of one copy of either gene was sufficient to dominantly suppress the *lats* mutant phenotypes. Such a genetic interaction was not observed in hundreds of genes examined, including other positive cell cycle regulators such as *cdc2c*, *cyclin B*, and *dE2F*.

The lats kinase domain contains all 11 subdomains previously found in other protein kinases (Hanks et al., 1988, Science 241:42-45), suggesting that it is an active protein kinase. However, lats alone and lats/cdc2 complex do not appear to have any autophosphorylation activity or phosphorylation activity for cdc2 and histone H1. Yeast two-hybrid experiments showed that the N-terminal region of lats interacted with cdc2 much more strongly than did full-length lats (Figure 3E). This result indicates that the C-terminal kinase domain of lats has a negative effect on the binding between the lats N-terminal region and cdc2.

The association of lats with cdc2 is directly correlated with its state of phosphorylation (compare Figures 2B and 3B). During early mitosis, lats is phosphorylated and associates with cdc2. At G0, lats is dephosphorylated and fails to associate with cdc2. Furthermore, the transition of the lats phosphorylation state during mitosis correlates with a change in its ability to bind to cdc2. Phosphorylation is a common mechanism that regulates protein activities during the cell cycle (Hunter, 1995, Cell 80:225-236).

### Cell-cell communication mechanism regulating cell proliferation

Many tumor suppressors probably evolved to play important regulatory roles during development. The study of the normal developmental functions of a tumor suppressor is essential to our understanding of the mechanisms of tumorigenesis. A growing body of evidence suggests that proliferating cells in a developing *Drosophila* imaginal disc communicate to maintain a constant disc size, and that lats plays an important role in this process. Using mutations such as *Minute* and *dE2F* in *Drosophila*, it has been shown that, from a young mosaic disc containing cells of different genotypes, the number of progeny cells from a given parental cell can vary dramatically in a mature disc, while the overall size of the mature disc is unaffected (Simpson, 1979, Devel. Biol. 69:182-193; Simpson and Morata, 1981, Devel. Biol. 85:299-308; Brook et al., 1996, EMBO J. 15:3676-3683). Imaginal discs can also undergo regeneration when a small region of a disc is surgically removed, a phenomenon similar to liver regeneration in mammals (French et al., 1976, Science 193:969-981; Meinhardt, 1994, Bioessays 16:627-632; Michalopoulos and DeFrances, 1997, Science 276:60-66). Consistent with the notion that proliferation is regulated by local cell interaction, it has been shown that DNA replication and mitosis in growing discs occur in small, non-clonal clusters of cells throughout the disc (Adler and MacQueen, 1981, Exp. Cell Res. 133:452-456; Milan et al., 1996, Proc. Natl. Acad. Sci. USA 93:11687-11692; Milan et al., 1996, Proc. Natl. Acad. Sci. USA 93:640-645). Furthermore, young discs transplanted into adult hosts grow until the disc reaches its normal size, indicating that such a size control mechanism is an intrinsic property of the cells in each disc (Bryant in The Genetics and Biology of *Drosophila*, Vol. 2c, Ashburner and Novitski, eds. (Academic Press, New York, 1978). Transplantation experiments in mice revealed a similar size control phenomenon with anlagen of some vertebrate organs (Leitina et al., 1971, Transplantation 11:499-502).

*Lats* mutations dramatically disrupt the size and shape of discs in *Drosophila*. Clones of *lats* mutant cells in mosaic discs overproliferate to form massive outgrowths that are sometimes larger than the mature discs themselves, and animals homozygous for many *lats* alleles also have dramatically overgrown discs (Figures 1A and F; Xu et al., 1995, Development 121:1053-1063). These *lats* phenotypes indicate that an inhibitory cell-cell communication mechanism has been disrupted and suggest that the lats protein could be a component of this mechanism regulating cell proliferation. The overproliferation phenotype of lats behaves in a cell autonomous fashion: inactivating lats causes mutant cells

to overproliferate (Xu et al., 1995, Development 121:1053-1063). Furthermore, in mosaic discs containing *lats* mutant clones, there is an overproliferation of *lats* mutant cells as well as a reduction in the number of wild type cell. These observations are consistent with a regulatory mechanism where *lats* mutant cells are able to send signals inhibiting cell proliferation but are defective in receiving such signals.

While the mammalian cdc2/cyclin A complex is involved in G2/M regulation (Hamaguchi et al., 1992, J. Cell Biol. 117:1041-1053; Hunter and Pines, 1994, Cell 79:573-582), *Drosophila* cdc2/cyclin A functions at the G1/S phase transition in addition to the G2/M phase transition. Ectopic activation of cdc2/cyclin A by overexpressing cyclin A in G1 arrested cells can drive the G1/S transition and induce S phase in cells lacking cyclin E (Dong et al., 1997, Genes & Devel. 11:94-105; Sprenger et al., 1997, Curr. Biol. 7:488-499). This G1/S activity is greatly enhanced when both cyclin A and an activated form of cdc2 are overexpressed. In *roughex* (*rux*) mutants, cells accumulate cyclin A in early G1 and progress into S phase precociously (Thomas et al., 1994, Cell 77:1003-1014; Thomas et al., 1997, Genes & Devel. 11:1289-1298). Loss of fizzy-related (*fzr*), a cdc2-related fly gene, results in accumulation of mitotic cyclins in G1 cells and causes progression through an extra division cycle in the embryonic epidermis (Sigrist and Lehner, 1997, Cell 90:671-681). These observations have shown that in *Drosophila* extra cdc2/Cyclin A activity can cause overproliferation. Consistent with these observations, we find that Cyclin A is abnormally accumulated in *lats* mutant cells (Figures 5A-N) and *lats* phenotypes can be suppressed by *cdc2* and *cyclin A* mutations. Several aspects of the *lats* phenotype are unique. First, *lats* mutants deregulate cdc2/cyclin A activities which affects both the G1/S and G2/M transitions. Second, while mutants such as *rux*, *fizzy* (*fzy*), and *fzr* accumulate multiple mitotic cyclins and thus affect activities of several cdc2/cyclin complexes (Thomas et al., 1994, Cell 77:1003-1014; Dawson et al., 1995, J. Cell Biol. 129:725-737; Sigrist and Lehner, 1997, Cell 90:671-681), *lats* mutants appear to only affect cdc2/cyclin A. Finally, in *lats* mutant cells, cyclin A is degraded at late mitosis (Figure 5F), further indicating that many aspects of the cell cycle are normal in *lats* mutants. These properties distinguish *lats* mutants from genetic alterations that affect multiple CDK/cyclin complexes or that abnormally activate CDK/cyclin at a single cell-cycle stage or throughout the entire cell cycle, and provide an explanation for the extensive overproliferation phenotype of the *Drosophila lats* mutants.

The data provided herein indicate that cdc2/cyclin A activity is negatively regulated by the *lats* protein. Yeast two-hybrid assays show that *lats* specifically interacts with *cdc2* but not other CDKs. Genetic data in *Drosophila* also show that *lats* interacts with *cdc2* but not the fly CDK2 homolog, *cdc2c*. Given that p16- and p21-like CDK inhibitors have not been found for *cdc2*, it is possible that *cdc2* and the rest of the CDKs are negatively regulated by different families of proteins. Alternatively, the activity of each CDK could be modulated by both types of negative regulators. In both flies and mammals, cdc2/cyclin A is inactivated during early mitosis by degradation of cyclin A, while degradation of cyclin B

occurs later at the metaphase/anaphase transition (Minshull et al., 1990, EMBO J. 9:2865-2875; Whitfield et al., 1990, EMBO J. 9:2563-2572). The mechanism of such differential inactivation of cdc2/cyclin is unknown. Our data indicate that lats specifically modulates cdc2/cyclin A activity but not cdc2/cyclin B activity: cyclin A but not cyclin B mutants interact with lats genetically; *lats* mutant cells abnormally accumulate cyclin A but not cyclin B (Figures 5A-N).

Finally, overexpression of cdc2 and cyclin A has been reported in multiple types of human tumors (Wang et al., 1990, Nature 343:555-557; Keyomarsi and Pardee, 1993, Proc. Natl. Acad. Sci. USA 90:1112-1116; Arany et al., 1994, Surg. Onc. 3:153-159). Negative regulators of CDK/Cyclins (e.g., p16) have been shown to function as tumor suppressors in mammals (Serrano et al., 1996, Cell 85:27-37). The biochemical and genetic data for lats provided herein suggest that lats would behave as a tumor suppressor in mammals.

## **EXAMPLE 2: Mice Deficient for Lats Develop Soft Tissue Sarcomas, Ovarian Tumors and Pituitary Dysfunction**

### **Materials and Methods**

#### **Generation of *lats*<sup>-/-</sup> mice**

Mouse *lats* genomic DNA was isolated by screening a 129 library (Stratagene) using a mouse *lats* cDNA as a probe. A SalI fragment from the cDNA was subcloned into a pBS vector. We cleaved this construct at the EcoRV site (Figure 6B), and inserted a 1.8 kb fragment encoding PGK-neo. We subsequently digested with BamHI and XhoI and inserted a 3 kb PGK-TK gene cassette.

D3 embryonic stem (ES) cells were electroporated with the SfiI linearized vector, and selected in 0.3 mg/ml G418 and 2  $\mu$ M ganciclovir media for incorporation of the vector. The ES cell clones analyzed underwent homologous recombination at the *lats* locus (Figure 6B). For genotyping, genomic DNA from the ES cells was digested with BamHI and EcoRV and analyzed by Southern blotting using the BamHI-EcoRI probe from the vector (Figure 6C). The double digest of the wild type allele generates a 3.5 kb fragment that hybridizes to the probe, while double digest of the disrupted allele generates a 5.8 kb fragment that hybridizes to the probe. *Lats* heterozygous ES cells were microinjected into CS7BL/6 blastocysts which were transplanted into uteri of pseudopregnant ICR mice. Chimeric male progeny were crossed to CS7BL/6 females. Germline transmission of the disrupted allele was detected in agouti progeny by Southern blotting.

#### **Cell culture and protein analysis**

Proteins were extracted from whole-cell lysates of *lats*<sup>-/-</sup> mouse embryonic fibroblasts (MEFs) derived from 13-days post-coitum mouse embryos, separated using SDS-PAGE, transferred and probed with rabbit polyclonal anti-lats antibody, followed by enhanced chemiluminescence detection (Amersham).

### Histopathological examinations

For morphological evaluation, tissues were fixed in 10% neutral buffered formalin at 4°C overnight, dehydrated with ethanol, embedded in paraffin, and sectioned into 4 to 5 mm sections. Paraffin sections were prepared by standard procedures and stained with hematoxylin and eosin.

### Gonadotropin treatment

Mice were injected intraperitoneally with FSH administered in the form of 5 IU of pregnant mare serum gonadotropin (Sigma). 44-46 hours later, mice were injected intraperitoneally with LH in the form of 5 IU of human chorionic gonadotropin (Sigma).

### Pituitary hormone measurements

We used 20 *lats*<sup>-/-</sup> and 20 *lats*<sup>+/-</sup> age, sex, and estrus cycle matched females and males for these analyses. Mouse serum levels of PRL, LH, GH, FSH, and TSH were determined in pooled serum samples by double antibody radioimmunoassays (RIAs). These sensitive, specific mouse pituitary hormone RIAs were developed by A. F. Parlow, and are distributed to the scientific research community via the National Hormone & Pituitary Program of NIDDK, NIH (see <http://www.humc.edu/hormones>).

### UVB and DMBA tumorigenic treatments

UVB and DMBA treatments were performed as described by Serrano et al. (1996, Cell 85:27-37). Briefly, skin tumors were induced by first applying a single dose of 9,10-dimethyl-1,2-benzathralene (DMBA; 50 µl of an 0.5% solution in acetone) to the dorsal surface of the mouse 1 to 5 days after birth. This treatment was followed by exposure to ultraviolet B (UVB) irradiation approximately three times per week for, on average, 27 treatments, with an initial exposure of approximately 100 mJ/cm<sup>2</sup>, increasing the dosage by 10% per treatment to a maximum of 700 mJ/cm<sup>2</sup>.

## Results and Discussion

### Targeted Disruption of the mouse *lats* gene

A 17.5 kilobase *lats* genomic clone obtained from a mouse 1295V library was used to construct a targeting vector for homologous recombination by positive-negative selection (Mansour et al., 1988, Nature 336:348-352; Capecchi, 1989, Science 244:1288-1292) as shown in Figure 6B. A PGK-neo cassette was inserted in inverse orientation into an exon of the *lats* clone resulting in the removal of amino acid sequence corresponding to amino acids 756-1130 of human *lats* (Figure 6A). We electroporated D3 embryonic stem cells (Gossler et al., 1986, Proc. Natl. Acad. Sci USA 83:9065-9069) with the *lats*-neo construct; single clones resistant to G418 and ganciclovir were screened by Southern blot hybridization using a mouse *lats* probe 5' to the portion of the *lats* gene contained in the targeting vector (Figure 6B). Restriction enzyme digestion of the wild-type *lats* locus with

BamHI and EcoRV generated a 3.5 kb fragment, while the correctly targeted, disrupted locus generated a 5.8 kb fragment (Figures 6B and C). A targeting frequency of approximately 1 in 100 was observed. Male chimeras transmitted the targeted *lats* allele through the germline, as demonstrated by Southern blot analysis of tail DNA.

- 5 Immunoprecipitation and western blotting of *lats*<sup>-/-</sup> mouse embryonic fibroblast lysates (derived from 13.5 days post-coitum embryos (dpc)) with polyclonal anti-human *lats* antibody confirmed the absence of *lats* protein in homozygous null embryos (Figure 6D).

#### Growth and viability of *lats*<sup>-/-</sup> mice

- When assessed at 3 weeks of age, the number of *lats* mutant animals was drastically  
10 lower than expected; 8% of pups genotyped from double heterozygote matings were *lats*<sup>-/-</sup>, significantly lower than the expected frequency of 25%. Just before birth at embryonic day 18.5 (dpc), however, live homozygous embryos were found at the frequency predicted by Mendelian law (25%). The majority of homozygotes died within the first day of life, and their death was associated with internal hemorrhage into vital organs. The reason that some  
15 *lats*<sup>-/-</sup> mice survived while most did not is uncertain, but the mixed genetic background (strains 129 and C57BL/6) of the mice could be contributory. The weight of homozygous embryos at birth was approximately 70% of that of wild-type embryos (*lats*<sup>+/+</sup>, 1.5 ± 0.3 g; *lats*<sup>-/-</sup>, 1.3 ± 0.3 g; *lats*<sup>+/-</sup>, 1.1 ± 0.1 g). All of these *lats*<sup>-/-</sup> mice were growth retarded. Most of the surviving *lats* homozygous mutant animals gained weight slowly, attaining only 60-70% of normal weight as adults (Figures 7A and B). A representative growth curve for *lats*  
20 deficient mice is shown in Figure 7B. To determine if there was a correlation between weight and growth, skeletal growth and organ weight was examined. By radiography, we observed differences in the skull and longitudinal bones that corresponded to the decrease in the size of the mouse. The decreased body weight was not due to the animals being leaner than their wild-type siblings, because the weight of most organs tested had decreased in proportion to the whole body weight. Exceptions were seen in a few particularly reduced  
25 organs, including the testis and the ovary.

#### Pituitary dysfunction

- Male *lats*<sup>-/-</sup> mice displayed decreased fertility although histopathological examination of the testis did not reveal obvious structural abnormalities. *Lats*<sup>-/-</sup> females all  
30 displayed severe fertility defects, and approximately 60% of the females were completely sterile. Ovaries from all *lats* deficient females examined contained far fewer follicles than age and parity matched ovaries from *lats*<sup>+/+</sup> females (Figures 8A-D). The majority of follicles observed were primary and secondary follicles. Formation of the antrum was much less prominent than in normal mice. The follicles also contained fewer degenerative  
35 granulosa cells, which are common in atretic follicles in normal mice. Moreover, the formation of a corpus luteum was not detected (Figures 8A-D). These histological findings suggest an impairment of ovulation in *lats*<sup>-/-</sup> ovaries, and potential endocrine dysfunction.



The amount of breast epithelial tissue was markedly decreased in *lats*<sup>-/-</sup> females, with some females displaying a complete lack of macroscopic nipple-formation (Figures 9D and E). Histologically, the mammary glands of *lats*<sup>-/-</sup> mice were frequently reduced to a “fat pad” devoid of a ductular component (Figure 9F). This too suggested an endocrine component to the phenotype, as loss of *lats* may alter the levels of hormones that affect breast development.

Estrus is another indicator of endocrine function. Vaginal smears taken from control (*+/+*) mice showed that they cycled through proestrus, estrus, metestrus, and diestrus in 4 days as described previously for normal mice (Nelson et al., 1982, Biol. Reprod. 27:327-339). In contrast, infertile *lats*<sup>-/-</sup> females did not cycle, and remained in continuous metestrus, an observation that further characterizes their infertility. The abnormal estrus cycle might reflect an underlying problem in signaling between the pituitary and the ovary. To determine if *lats*<sup>-/-</sup> ovaries could respond to appropriate gonadotropin stimulation, young adult mice (7 *lats*<sup>-/-</sup> females; 2 control females) were injected with a Follicle-Stimulating Hormone (FSH) analog (pregnant mare serum), and 46 hours later with a Luteinizing Hormone (LH) preparation (human chorionic gonadotropin). This treatment allowed *lats*<sup>-/-</sup> females to cycle into a prolonged period of estrus, confirming that the temporal synchronization of the levels of endogenous FSH and/or LH in *lats*<sup>-/-</sup> females is deficient.

In all *lats* knock-out mouse pituitaries examined (n=20), hyperplastic changes were readily apparent. There were multiple foci of atypical cells showing irregularly shaped nuclei with an increased content of chromatin and variability in size (Figures 10A and B). This histological atypia was accompanied by a pathological dysfunction of the pituitary. For example, hormone measurements in sera from *lats*<sup>-/-</sup> females revealed: the levels of LH were 3-fold lower than controls (Figure 10C); the PRL levels were less than half of controls (Figure 10D); and Growth Hormone (GH) levels were reduced by 25%. These deficiencies may have resulted from an unbalanced increase in the number of certain types of cells in this normally highly organized tissue. The reduced serum GH level may contribute to the reduced size of *lats*<sup>-/-</sup> mice. The diminished levels of serum LH could account for the lack of proper follicular maturation and differentiation, as well as the infertility observed in female *lats*<sup>-/-</sup> animals, with greater atypia in the pituitary leading to the more severe phenotype. The PRL and LH defects, together, account for both the lack of mammary gland development and the corpus luteum insufficiency syndrome which these animals display.

Interestingly, serum levels of pituitary Follicle Stimulating Hormone (FSH) (Figure 10E) and Thyroid Stimulating Hormone (TSH) are normal. The observation that *lats*<sup>-/-</sup> mice display a selective LH deficiency while sustaining normal FSH production supports a model of differential regulation of the two gonadotropins. This is in accordance with data from Lee and coworkers demonstrating that the transcription factor NGFI-A specifically regulates LH- $\beta$  (Lee et al., 1996, Science 273:1219-1221). *Lats*<sup>-/-</sup> mice thereby provide a model for the human reproductive dysfunction of isolated LH hypogonadotropic hypogonadism.

It is interesting to note that the pituitary deficiencies of *lats*<sup>-/-</sup> mice resembles those of other cell cycle regulator knock-out mice, such as the *Rb*<sup>+/-</sup>, *p53*<sup>-/-</sup>, and *p27*<sup>-/-</sup> mice. In these examples, pituitary cells and other endocrine organs appear to be crucially dependent on cell cycle regulation for their proper development. Indeed, tumor suppressors may play such a key role in the pituitary because critical function in this tissue allows for a link between control of single cell proliferation and total organismal growth and survival.

#### Tumor development in *lats*<sup>-/-</sup> mice

Another cause for the infertility of *lats*-deficient females is that they developed ovarian stromal cell tumors by the age of 3 months. The body of the normal ovary consists of spindle-shaped cells, reticular fibers and ground substance which together constitute the ovarian stroma, in which numerous follicles are embedded (Wheater et al., 1987, Functional Histology; Figure 8A). Stromal cell tumors in *lats*<sup>-/-</sup> mice obliterated the normal structure of the ovary, eliminating follicles progressively (Figures 8B and D). These stromal cell tumors are probably not resultant from pituitary dysfunction, as stromal cell tumors are most often local events (Clement, "Histology of the Ovary" in Histology For Pathologists, Second Ed., Sternberg, ed. (Lippincott-Raven, 1997) pp 934-935). Some *lats*<sup>-/-</sup> females were able to give birth to one litter, then became infertile as the stromal cell tumors expanded into the remaining functional ovary. To date, these stromal cell tumors have not yet displayed signs of malignancy. Stromal cell tumors were observed in all *lats* deficient mice examined (n=22), and extended throughout the entire ovary as determined by serial sectioning.

Additional evidence supporting the role of *lats* in mammalian tumorigenesis is that thus far, approximately 15% of all *lats*<sup>-/-</sup> females (n=28) between 4 to 10 months of age have developed large soft tissue sarcomas with metastases to vital organs (e.g. the lungs) (Figures 11A-C). Taking genetic backgrounds into consideration and using litter mates as controls, approximately 57% of all *lats*<sup>-/-</sup> animals developed soft tissue sarcomas. Histology revealed that these sarcomas consist of pleiomorphic, spindle-shaped cells with mitotic figures (Figure 11C), and they displayed immunohistochemical features of fibrosarcomas. No tumors were detected in control mice (n=80). It is possible that the spontaneous rate of tumor formation is even higher in *lats*<sup>-/-</sup> mice as some tumors may be occult, and therefore not readily identifiable. *Lats*<sup>+/-</sup> mice remained tumor free up to 8 months of age. This phenotype is consistent with that observed in heterozygotes for the CDK inhibitors, p27 and p16 (Fero et al., 1996, Cell 85:733-744; Kiyokawa et al., 1996, Cell 85:721-732; Nakayama et al., 1996, Cell 85:707-720; and Serrano et al., 1996, Cell 85:27-37).

The susceptibility of *lats*<sup>-/-</sup> mice to tumor induction by carcinogens was assessed using a standard two-stage protocol consisting of a single application of 9,10-dimethyl-1,2-benzanthracene (DMBA) followed by repeated exposure to ultraviolet B rays (Serrano et al., 1996, Cell 85:27-37). By 7 weeks of age, over 71% of *lats*<sup>-/-</sup> animals developed soft tissue sarcomas, whereas all of the control animals remained free of obvious tumors. The

frequency of tumor development in these *lats*<sup>-/-</sup> animals is particularly impressive, given the fact that C57BL/6 mice are poorly susceptible to the development of skin tumors (as reviewed by DiGiovanni, 1991, Pharm. & Ther. 54:63-128). The spontaneous and induced tumors observed in *lats*<sup>-/-</sup> animals provide clear evidence of the role of *lats* in mammalian tumorigenesis, and attest to the functional conservation of *lats*.

Although both *Drosophila* and mice develop tumors when *lats* is inactivated, the correlation between genotype and phenotype differs between the two organisms. While every *lats*<sup>-/-</sup> cell overproliferates in mosaic flies (Xu et al. 1995, Development 121:1053-1063), only certain tissues in *lats*<sup>-/-</sup> mice develop tumors. This phenotypic difference could be due to the increased complexity in cell cycle control in mammals. For example, in *Drosophila*, *cdc2*/Cyclin A functions at both the G1/S and G2/M transitions in the cell cycle (Whitfield et al., 1990, EMBO J. 9:2563-2573; Knoblich and Lehner, 1993, EMBO J. 12:65-74; Knoblich et al., 1994, Cell 77:117-120; Sauer et al., 1995, Genes & Devel. 9:1237-1239; Sigrist and Lehner, 1997, Cell 90:671-681; Sprenger et al., 1997, Curr. Biol. 7:488-499; Thomas et al., 1997, Genes & Dev. 11:1289-1298). In mammals, however, a different CDK, CDK2, complexes with cyclin A to regulate the G1/S transition, while *cdc2*/cyclin A functions in the G2/M transition (Girard et al., 1991, Cell 67:1169-1179; Tsai et al., 1991, Nature 353:174-177; Hamaguchi et al., 1992, J. Cell. Biol. 117:1041-1053; Pagano et al., 1992, EMBO J. 11:961-967; Rosenblatt et al., 1992, Proc. Natl. Acad. Sci. USA 89:2824-2828; Hunter and Pines, 1994, Cell 79:573-582; Resnitzky et al., 1995, Mol. Cell Biol. 15:4347-4352). We have shown that *lats* negatively regulates *cdc2*/cyclin A, but does not appear to interact with CDK2. Thus, while inactivation of *lats* in *Drosophila* affects regulation of both the G1/S and G2/M transitions of the cell cycle, the removal of *lats* function in mammalian cells only affects control of the G2/M transition. This result is consistent with the fact that human cancers are often caused by mutations in multiple, non-homologous cell cycle control pathways (Kinzler and Vogelstein, 1996, Cell 87:159-170; Weinberg, 1996, Sci. Am. 275:62-70). The higher degree of redundancy in mammalian genomes could also contribute to the phenotypic difference between fly and mouse *lats* mutants.

Although most human tumor suppressors that have been characterized function in the regulation of G1/S (Brown, 1997, Adv. Genet. 36:45-135), there are indications that deregulation of G2/M and M controls may also contribute to tumorigenesis in mammals. For example, p53 is involved in the regulation of both G1/S and G2/M (and M) (Cross et al., 1995, Science 267:1353-1356; Hermeking et al., 1997, Mol. Cell 1:3-11). Inactivation of p53 in mice leads to impressive tumor development, while the disruption of p21, the p53-downstream effector for G1/S, has no tumorigenic effect (Deng et al., 1995, Cell 82:675-684). Recent data also suggests that Rb plays a role in G2/M in addition to its G1/S involvement (Niculescu et al., 1998, Mol. Cell Biol. 18:629-643). Furthermore, overexpression of *cdc2* and mitotic cyclins has been reported in multiple types of human tumors (Arany et al., 1994, Surg. Oncol. 3:153-159; Keyomarsi and Pardee, 1993, Proc.

Natl. Acad. Sci USA 90:1112-1116; Wang et al., 1990, Nature 343:555-557). Signaling through the RHAMM receptor affects cell proliferation by down-regulation of cdc2 and cyclin B transcripts and proteins and results in reversal of tumorigenesis (Mohapatra et al., 1996, J. Exper. Med. 183:1663-1668). The tumorigenic phenotype of *lats*<sup>-/-</sup> mice further supports the notion that the regulation of G2/M or M also plays a role in mammalian tumor development.

A comparison between *lats*<sup>-/-</sup> and *p16*-knock-out mice is interesting in several respects. Both *lats* and *p16* are negative regulators of CDKs. In addition, *lats*-knock-out mice resemble *p16*-knock-out animals (Serrano et al., 1996, Cell 85:27-37) in that homozygotes develop tumors at an early age while heterozygotes do not. Although different types of tumors are observed in these two mutants (e.g., ovarian tumors in *lats*<sup>-/-</sup> mice and lymphomas in *p16*<sup>-/-</sup> mice), both types of knock-out mice develop soft tissue sarcomas. The frequencies of spontaneous soft tissue sarcomas between these two knock-out mutants cannot be directly compared due to protocol differences, however, induced tumors in these animals were obtained using the same induction protocol (Serrano et al., 1996, Cell 85:27-37). Interestingly, the frequency of induced tumor formation in *lats*<sup>-/-</sup> knock-out mice is even higher than that observed for *p16*<sup>-/-</sup> mice. Over 71% of *lats*<sup>-/-</sup> animals developed soft tissue sarcomas by 7 weeks of age. Only 10% of the *p16*<sup>-/-</sup> mice developed tumors by 7 weeks of age, and 60% of them displayed tumors between the ages of 6-12 weeks (Serrano et al., 1996, Cell 85:27-37).

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

## WHAT IS CLAIMED IS:

1. A recombinant non-human animal in which a *lats* gene has been inactivated by a method comprising introducing a nucleic acid into the animal, or an ancestor thereof, which nucleic acid comprises a non-*lats* sequence flanked by *lats* genomic sequences that promote homologous recombination, such that said non-*lats* sequence replaces the nucleotide sequence encoding the Lats C-terminal domain 1, the Lats C-terminal domain 2, the Lats C-terminal domain 3, and a portion of the kinase domain of the *lats* protein encoded by the *lats* gene.
2. The recombinant non-human animal of claim 1 in which the non-*lats* sequence replaces the nucleotide sequence encoding the amino acids that correspond to amino acids 756-1130 of human *lats*, as depicted in Figure 12 (SEQ ID NO:2).
3. The recombinant non-human animal of claim 1 which is a mouse.
4. The recombinant non-human animal of claim 3 in which the *lats* gene contains a *lats* coding sequence of SEQ ID NO:3.
5. The recombinant non-human animal of claim 1 in which both alleles of the *lats* gene have been inactivated.
6. A method for screening a potential therapeutic compound for activity in treating or preventing cancer comprising administering the compound to the recombinant non-human animal of claim 1; and comparing the size or progression of the cancer in the recombinant non-human animal to which the compound was administered with the size or progression of the cancer in the same recombinant non-human animal prior to administration of the compound or in a recombinant non-human animal that was not so administered or to a standard size or progression of the cancer for such same or a recombinant non-human animal that was not so administered, wherein a decrease in the size or progression of the cancer in the recombinant non-human animal administered the compound as compared to the same animal prior to the administration or to the recombinant non-human animal not so administered or to the standard size or progression of the cancer, indicates that the compound has activity in treating or preventing cancer.
7. The method of claim 6 in which the non-*lats* sequence replaces the nucleotide sequence encoding the amino acids that correspond to amino acids 756-1130 of human *lats*, as depicted in Figure 12 (SEQ ID NO:2).

8. The method of claim 6 in which the recombinant non-human animal is a mouse.

9. The method of claim 8 in which the *lats* gene contains the *lats* coding sequence of SEQ ID NO:3.

10. The method of claim 6 in which both alleles of the *lats* gene have been inactivated.

11. The method of claim 6 in which the compound is screened for activity in treating or preventing soft tissue sarcomas.

12. The method of claim 6 in which the compound is screened for activity in treating or preventing ovarian tumors.

13. A method for screening a potential therapeutic compound for activity in treating or preventing cancer comprising recombinantly expressing the compound in the recombinant non-human animal of claim 1; and comparing the size or progression of the cancer in the recombinant non-human animal in which the compound was expressed with the size or progression of the cancer in the same recombinant non-human animal prior to expression of the compound or in a recombinant non-human animal in which the compound was not so expressed or to a standard size or progression of the cancer for such same or a recombinant non-human animal in which the compound was not so expressed, wherein a decrease in the size or progression of the cancer in the recombinant non-human animal in which the compound was expressed as compared to the same animal prior to the expression of the compound or to the recombinant non-human animal in which said compound was not so expressed or to the standard size or progression of the cancer, indicates that the compound has activity in treating or preventing cancer.

14. A method for screening a potential therapeutic compound for activity in treating or preventing skin cancer comprising administering the compound to a *lats* knock-out animal having skin tumors induced by exposure to at least one carcinogen; and comparing the size or progression of the skin tumors on the *lats* knock-out animal to which the compound was administered with the size or progression of skin cancers on the same *lats* knock-out animal prior to administration of the compound or on a *lats* knock-out animal in which skin tumors have also been induced by exposure to said at least one carcinogen but which has not been administered the compound or to a standard size or progression of the skin tumors for such same or a *lats* knock-out animal that was not so administered, wherein a reduction in the size or progression of the skin tumors in the *lats* knock-out animal administered the compound as compared to the same animal prior to

administration of the compound or to the animal not so administered or to the standard size or progression of the skin tumors, indicates that the compound has activity in treating or preventing skin cancer.

5        15.     The method of claim 14 in which the *lats* knock-out animal has at least one *lats* gene which was inactivated by promoting homologous recombination between *lats* genomic sequences and a nucleic acid having non-*lats* sequences flanked by genomic sequences.

10       16.     The method of claim 15 in which the non-*lats* sequence replaces the nucleotide sequence encoding the Lats C-terminal domain 1, the Lats C-terminal domain 2, the Lats C-terminal domain 3, and a portion of the kinase domain of the *lats* protein encoded by the *lats* gene.

15       17.     The method of claim 15 in which the non-*lats* sequence replaces the nucleotide sequence encoding the amino acids that correspond to amino acids 756-1130 of human *lats*, as depicted in Figure 12 (SEQ ID NO:2).

18.     The method of claim 14 in which the *lats* knock-out animal is a mouse.

20       19.     The method of claim 18 in which the *lats* gene contains the *lats* coding sequence of SEQ ID NO:3.

20.     The method of claim 14 in which both alleles of the *lats* gene have been inactivated.

25       21.     The method of claim 14 in which the skin tumors were induced by 9,10-dimethyl-1,2-benzanthracene and repeated exposure to ultraviolet B radiation.

22.     The method of claim 14 in which the potential therapeutic compound is administered topically.

30       23.     A method for screening a potential therapeutic compound for activity in treating or preventing skin cancer comprising recombinantly expressing the compound in a *lats* knock-out animal having skin tumors induced by exposure to at least one carcinogen; and comparing the size or progression of the skin tumors on the *lats* knock-out animal in which the compound was expressed with the size or progression of skin cancers on the same *lats* knock-out animal prior to expression of the compound or on a *lats* knock-out animal in  
35       which skin tumors have also been induced by exposure to said at least one carcinogen but in which the compound has not been expressed or to a standard size or progression of the skin

tumors for such same or a *lats* knock-out animal in which the compound was not so expressed, wherein a reduction in the size or progression of the skin tumors in the *lats* knock-out animal in which the compound was expressed as compared to the same animal prior to expression of the compound or to the animal in which the compound was not so expressed or to the standard size or progression of the skin tumors, indicates that the compound has activity in treating or preventing skin cancer.

24. A method for screening a potential therapeutic compound for activity in treating or preventing a disease or disorder associated with pituitary dysfunction comprising administering the compound to a *lats* knock-out animal; and comparing the level of an indicator of pituitary dysfunction in the *lats* knock-out animal to which the compound has been administered to the level of the indicator in the same *lats* knock-out animal prior to administration of the compound or to a *lats* knock-out animal that has not been administered the compound or to a standard level of the indicator for such same or a *lats* knock-out animal that was not so administered, wherein a change in the indicator toward the level of the indicator in a wild type animal not afflicted with a pituitary dysfunction as compared to the same animal prior to administration of the compound or to the animal not so administered or to the standard level of the indicator, indicates that the compound is active to treat or prevent a disease or disorder associated with pituitary dysfunction.

25. The method of claim 24 in which the *lats* knock-out animal has at least one *lats* gene which was inactivated by promoting homologous recombination between *lats* genomic sequences and a nucleic acid having non-*lats* sequences flanked by genomic sequences.

26. The method of claim 25 in which the non-*lats* sequence replaces the nucleotide sequence encoding the Lats C-terminal domain 1, the Lats C-terminal domain 2, the Lats C-terminal domain 3, and a portion of the kinase domain of the *lats* protein encoded by the *lats* gene.

27. The method of claim 25 in which the non-*lats* sequence replaces the nucleotide sequence encoding the amino acids that correspond to amino acids 756-1130 of human *lats*, as depicted in Figure 12 (SEQ ID NO:2).

28. The method of claim 24 in which the *lats* knock-out animal is a mouse.

29. The method of claim 28 in which the *lats* gene contains a *lats* coding sequence of SEQ ID NO:3.



30. The method of claim 24 in which both alleles of the *lats* gene have been inactivated.
31. The method of claim 24 in which the indicator is fertility.
- 5 32. The method of claim 24 in which the indicator is ovulation.
33. The method of claim 24 in which the indicator is linear growth.
34. The method of claim 24 in which the indicator is serum levels of luteinizing  
10 hormone, growth hormone or prolactin.
35. The method of claim 24 in which the disease or disorder is LH hypogonadotropic hypogonadism.
- 15 36. A method for screening a potential therapeutic compound for activity in treating or preventing a disease or disorder associated with pituitary dysfunction comprising recombinantly expressing the compound in a *lats* knock-out animal; and comparing the level of an indicator of pituitary dysfunction in the *lats* knock-out animal in which the compound has been expressed to the level of the indicator either in the same *lats* knock-out animal prior to expression of the compound or to a *lats* knock-out animal in which the  
20 compound has not been expressed or to a standard level of the indicator for such same or a *lats* knock-out animal in which the compound was not so expressed, wherein a change in the indicator toward the level of the indicator in a wild type animal not afflicted with a pituitary dysfunction as compared to the same animal prior to expression of the compound or to the animal in which the compound was not so expressed or to the standard level of the indicator, indicates that the compound is active to treat or prevent a disease or disorder associated with  
25 pituitary dysfunction.
37. The method of claim 6, 14 or 24 in which the compound is purified.
38. A method for treating a cancer that has been shown to be refractory to a  
30 chemotherapy or radiation therapy in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a molecule that promotes *lats* function.
39. The method of claim 38 in which the subject is a human.
- 35 40. The method of claim 38 in which the molecule is a *lats* protein.

41. The method of claim 38 in which the molecule is a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

5 42. The method of claim 38 in which the molecule is a protein having the amino acid sequence of SEQ ID NO:2.

43. The method of claim 38 in which the molecule is a lats analog or derivative that has activity to promote lats function.

10 44. The method of claim 38 in which the molecule is a protein encoded by a first nucleic acid that is hybridizable under conditions of low stringency to a second nucleic acid having a nucleotide sequence that is the reverse complement of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7, said protein having activity to inhibit cell overproliferation.

15 45. The method of claim 38 in which the molecule is a protein consisting of at least 20 contiguous amino acids of a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8, said protein having activity to inhibit cell overproliferation.

20 46. The method of claim 38 in which the molecule is a protein comprising a domain of a lats protein selected from the group consisting of a lats C-terminal domain 3 (LCD3), lats C-terminal domain 2 (LCD2), lats C-terminal domain 1 (LCD1), kinase domain, lats flanking domain (LFD), lats split domain 1 (LSD1), lats split domain 2 (LSD2), and SH3-binding domain, said protein having activity to inhibit cell  
25 overproliferation.

47. The method of claim 40 in which the lats protein is phosphorylated.

48. The method of claim 47 in which the lats protein is phosphorylated on a serine or threonine residue within 20 residues upstream of the amino acid sequence Ala-Pro-  
30 Glu in a subdomain eight of a kinase domain of said lats protein.

49. The method of claim 48 in which the lats protein is phosphorylated at a serine residue corresponding to serine 909 of the human lats amino acid sequence, as depicted in Figure 12 (SEQ ID NO:2).

35 50. The method of claim 43 in which the lats analog or derivative has a threonine or serine residue within 20 residues upstream of the amino acid sequence Ala-Pro-Glu in a

subdomain eight of a kinase domain of said lats analog or derivative substituted with an aspartate or glutamate residue.

5 51. The method of claim 50 in which the lats analog or derivative has a glutamate residue substituted for a serine residue at the residue corresponding to serine 909 of the human lats amino acid sequence, as depicted in Figure 12 (SEQ ID NO:2).

52. The method of claim 38 in which said molecule is a chimeric protein comprising a fragment of a lats protein, said fragment consisting of at least 20 contiguous amino acids of said lats protein, fused via a covalent bond to an amino acid sequence of a  
10 second protein, said second protein not being a lats protein, said chimeric protein having activity to inhibit cell overproliferation.

53. The method of claim 38 in which said cancer has been shown to be refractory to radiation therapy.

15 54. The method of claim 38 in which said cancer has been shown to be refractory to chemotherapy.

55. The method of claim 54 in which said chemotherapy kills cancer cells during S phase of the cell cycle.

20 56. The method of claim 54 in which said chemotherapy kills cancer cells during mitosis.

57. The method of claim 38 which further comprises administering one or more chemotherapeutic agents to the subject.

25 58. The method of claim 57 in which said one or more chemotherapeutic agents are administered concurrently with the administration of said molecule.

59. The method of claim 57 in which said one or more chemotherapeutic agents  
30 are administered subsequent to the administration of said molecule.

60. The method of claim 38 in which said molecule is a nucleic acid comprising a nucleotide sequence encoding a lats protein.

35 61. The method of claim 60 in which said nucleotide sequence is SEQ ID NO:1.

62. The method of claim 60 in which said nucleotide sequence encodes a protein having the amino acid sequence of SEQ ID NO:2.

5 63. The method of claim 38 in which said molecule is a first nucleic acid that hybridizes under low stringency conditions to a second nucleic acid that is the reverse complement of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.

64. A method for treating a cancer that has been shown to be refractory to a chemotherapy or radiation therapy in a subject in need of such treatment comprising  
10 administering to the subject a therapeutically effective amount of a cell that expresses a recombinant nucleic acid that promotes lats function.

65. The method of claim 64 in which said nucleic acid comprises the nucleotide sequence of SEQ ID NO:1.

15 66. The method of claim 64 in which said nucleic acid comprises a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:2.

67. A kit comprising in one or more containers a therapeutically effective amount of a molecule selected from the group consisting of a lats protein, a lats derivative, a  
20 lats analog, a nucleic acid encoding a lats protein, a nucleic acid encoding a lats derivative, and a nucleic acid encoding a lats analog; and at least one chemotherapeutic agent.

68. A purified complex of a lats protein and a cdc2 protein.

25 69. The purified complex of claim 68 in which the proteins are human proteins.

70. The purified complex of claim 68 in which the lats protein is phosphorylated.

71. The purified complex of claim 70 in which the lats protein is phosphorylated on a serine or threonine residue within 20 residues upstream of the amino acid sequence  
30 Ala-Pro-Glu in a subdomain eight of a kinase domain of said lats protein.

72. The purified complex of claim 71 in which the lats protein is phosphorylated at a serine residue corresponding to serine 909 of the human lats amino acid sequence, as depicted in Figure 12 (SEQ ID NO:2).

35 73. A purified complex selected from the group consisting of a complex of a derivative of a lats and a cdc2 protein, a complex of a lats protein and a derivative of a cdc2,

and a complex of a derivative of a lats protein and a derivative of a cdc2 protein, in which the derivative of the lats protein is able to form a complex with a wild-type cdc2 protein and the derivative of the cdc2 is able to form a complex with a wild-type lats protein.

5        74.     The purified complex of claim 73 in which the derivative of the lats protein and/or the cdc2 protein is fluorescently labeled.

      75.     The purified complex of claim 73 in which the lats derivative has a threonine or serine residue within 20 residues upstream of the amino acid sequence Ala-Pro-Glu in a subdomain eight of a kinase domain of said lats derivative substituted with an aspartate or  
10    glutamate residue.

      76.     The purified complex of claim 75 in which the lats derivative has a glutamate residue substituted for a serine residue at the residue corresponding to serine 909 of the human lats amino acid sequence, as depicted in Figure 12 (SEQ ID NO:2).

15       77.     The purified complex of claim 73 in which the lats derivative is a fragment of a lats protein consisting of the amino acid sequence corresponding to amino acids 15-585 of the amino acid sequence of human lats, as depicted in Figure 12 (SEQ ID NO:2).

      78.     A chimeric protein comprising a fragment of a lats protein consisting of at  
20    least 6 amino acids fused via a covalent bond to a fragment of a cdc2 protein consisting of at least 6 amino acids.

      79.     The chimeric protein of claim 78 in which the fragment of the lats protein is a fragment capable of binding the cdc2 protein and in which the fragment of the cdc2  
25    protein is a fragment capable of binding the lats protein.

      80.     The chimeric protein of claim 78 in which the fragment of the lats protein has an amino acid sequence corresponding to amino acids 15 to 585 of the amino acid sequence of human lats, as depicted in Figure 12 (SEQ ID NO:2).

30       81.     The chimeric protein of claim 79 in which the fragment of the lats protein and the fragment of the cdc2 protein form a lats-cdc2 complex.

      82.     An antibody which immunospecifically binds the complex of claim 68 or a fragment or derivative of said antibody containing the binding domain thereof.

35       83.     The antibody of claim 82 which does not immunospecifically bind a lats protein or a cdc2 protein that are not part of a lats-cdc2 complex.

84. An isolated nucleic acid or an isolated combination of nucleic acids comprising a nucleotide sequence encoding a lats protein and a nucleotide sequence encoding a cdc2 protein.

5 85. The isolated nucleic acid or isolated combination of nucleic acids of claim 84 which are nucleic acid vectors.

86. An isolated nucleic acid that comprises a nucleotide sequence encoding the chimeric protein of claim 78.

10 87. A cell containing the nucleic acid of claim 84, which nucleic acid is recombinant.

88. A cell containing the nucleic acid of claim 86, which nucleic acid is recombinant.

15 89. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the complex of claim 68; and a pharmaceutically acceptable carrier.

20 90. The pharmaceutical composition of claim 89 in which the proteins are human proteins.

91. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the complex of claim 73; and a pharmaceutically acceptable carrier.

25 92. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the chimeric protein of claim 79; and a pharmaceutically acceptable carrier.

30 93. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the antibody of claim 83 or a fragment or derivative of said antibody containing the binding domain thereof; and a pharmaceutically acceptable carrier.

35 94. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the nucleic acids or combination of nucleic acids of claim 84; and a pharmaceutically acceptable carrier.

95. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the isolated nucleic acid of claim 86; and a pharmaceutically acceptable carrier.

5 96. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the recombinant cell of claim 87; and a pharmaceutically acceptable carrier.

97. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the recombinant cell of claim 88; and a  
10 pharmaceutically acceptable carrier.

98. A method of producing a complex of a lats protein and a cdc2 protein comprising growing a recombinant cell containing the nucleic acid of claim 84 such that the encoded lats and cdc2 proteins are expressed and bind to each other, and recovering the  
15 expressed complex of the lats protein and the cdc2 protein.

99. A method of diagnosing or screening for the presence of or a predisposition for developing a disease or disorder characterized by an aberrant level of a complex of a lats protein and a cdc2 protein in a subject comprising measuring the level of said complex, RNA encoding the lats and the cdc2 proteins, or functional activity of said complex, in a  
20 sample derived from the subject, in which an increase or decrease in the level of said complex, said RNA encoding lats and cdc2, or functional activity of said complex in the sample, relative to the level of said complex, said RNA encoding lats and cdc2, or functional activity of said complex found in an analogous sample from a subject not having the disease or disorder or a predisposition for developing the disease or disorder, indicates  
25 the presence of the disease or disorder or a predisposition for developing the disease or disorder.

100. A kit comprising in one or more containers a substance selected from the group consisting of a complex of a lats and a cdc2 protein, an antibody against said complex, nucleic acid probes capable of hybridizing to RNA of lats and RNA of cdc2, or  
30 pairs of nucleic acid primers capable of priming amplification of at least a portion of a gene for lats and a gene for cdc2.

101. A method for modulating the activity of cdc2 comprising administering a molecule that promotes, inhibits, or antagonizes lats function.

35 102. A method for inhibiting the activity of cdc2 comprising administering a molecule that promotes lats function.

103. A method for increasing the activity of cdc2 comprising administering a molecule that inhibits or antagonizes lats function.

5 104. A method for treating or preventing a disease or disorder associated with an aberrantly high level of cdc2 in a subject in need of such treatment or prevention comprising administering to the subject a therapeutically effective amount of a molecule that promotes lats function.

105. The method of claim 104 in which said molecule is selected from the group consisting of a lats protein, a lats derivative or analog that promotes lats function, a nucleic acid encoding a lats protein, and nucleic acid encoding a lats derivative or analog that promotes lats function, and a lats agonist.

106. A method for treating or preventing a disease or disorder associated with an aberrantly low level of cdc2 activity in a subject in which such treatment or prevention is desired comprising administering to the subject a therapeutically effective amount of a molecule that inhibits or antagonizes lats function.

107. The method of claim 106 in which said molecule is selected from the group consisting of a lats analog or derivative that inhibits or antagonizes lats function, an anti-lats antibody, and a *lats* antisense nucleic acid.

20 108. A method for screening a molecule for efficacy in treating or preventing a cancer refractory to chemotherapy or radiation therapy, said method comprising contacting cancer cells that are refractory to treatment with chemotherapeutic agents or radiation with the molecule and comparing the proliferation or survival of the contacted cells with the proliferation or survival of cells not so contacted, wherein a lower level of proliferation or survival of the contacted cells indicates that the molecule is effective to treat or prevent the cancer.

109. The method of claim 108 in which said cells are cultured *in vitro* from a tissue sample of a patient.

30 110. A method for screening a molecule for activity to modulate cdc2 levels or activity comprising contacting cells with the molecule, and comparing the level of cdc2 protein, mRNA or activity in cells contacted with the molecule to the amount of cdc2 protein, mRNA, or activity in cells not so contacted, wherein an increase or decrease in the amount of cdc2 protein, mRNA, or activity in the contacted cells relative to the amount of cdc2 protein, mRNA, or activity in the cells not so contacted indicates that the molecule has activity to modulate cdc2 levels or activity.




111. A method for screening a molecule for activity to modulate, directly or indirectly, the formation of a complex of lats and cdc2 proteins comprising measuring the levels of said complex formed from lats and cdc2 proteins in the presence of said molecule under conditions conducive to formation of the complex; and comparing the levels of said complex with the levels of said complex that are formed in the absence of said molecule, wherein a lower or higher level of said complex in the presence of said molecule indicates that the molecule modulates formation of said complex.

112. The method of claim 111 in which the molecule inhibits formation of the complex.

113. The method of claim 111 in which the molecule promotes formation of the complex.


**THIS PAGE BLANK (USPTO)**




FIGS. 1A-H

**THIS PAGE BLANK (USPTO)**

2/25




**THIS PAGE BLANK (USPTO)**



FIGS. 3A-E

**THIS PAGE BLANK (USPTO)**






**FIGS. 4A-F**

**THIS PAGE BLANK (USPTO)**

5/25



FIGS. 5A-N


**THIS PAGE BLANK (USPTO)**

1 MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNL6KPSDAAKAEHNMSKMSTEDPRQVRNPPK h-Lats  
 71 FGTHHKALQEI RNSLLPFANETN6SRSTSEVNPQMLQDLQAAGFDEDMVIAQLQKTNNRSIEAAIEFISK h-Lats  
 141 MSYQDPRREQMAAAAARPI NASMKPGNVDOSVRAUSWAGSKSLVPOKHGHPGESEVATHSESPNSOITJ h-Lats  
 EVOFSLNRKOSWKGSKEFLVPORHGPSIGENVVYRRESPNSOAJ m-Lats  
 211 JGHPLSGSGISAFVJAHPSNGORVNPPPPPOVHSVTPPPPPHGOI PPPPGITPPPPPSWE PINSOTKHYSGR h-Lats  
 JGRPLSGSGIAAFVJAHPSNGORVNPPPPPOVRSVTPPPPPHGOI PPPPGITPPPPPSWE PINSOTKHYSGR m-Lats  
 281 MEYVISHISPVPPGAVLEGYPPIPLNISPMPNPPNJAURGISSVPVGHOPIMMSSEKFNFPSEHPGMJND h-Lats  
 MEYVISHISPVPPGAVLEGYPPIPLNISPMPNPPNJAURGISSVPVGHOPIMMSSEKFNFPSEHPGMJND m-Lats  
 351 TETUJPMIIONVVTAITFNUPPPPYPLTANGUSPSALOTGSAAPSSVTNGSIPOSMMVPPNRNHNME h-Lats  
 GOSDFIVHONV-ITISITROPPPPYPLTPANGOSPSALOTGSAAPSSVTNGSIPOSMMVPPNRNHNME m-Lats  
 421 YNISVPGLOTAMPSSSAPAOSSPSSSHEIPTWOPNIPVRSNSFNPNPLGNASHSANSOPSATTVIATIT h-Lats  
 YNISVPGLOTAMPSSSAPAOSSPSSSHEIPTWOPNIPVRSNSFNPNPLGNASHSANSOPSATTVIATIT m-Lats  
 491 PAPIOOPVKSMRVLKPELOTALAPTHPSWVPOPJIVOPSPFPEGIASNVITMPPVAEAPNYOGPPPPYP h-Lats  
 PAPIOOPVKSMRVLKPELOTALAPTHPSWVPOPJIVOPSPFPEGIASNVITMPPVAEAPNYOGPPPPYP m-Lats  
 561 KLLHONPSVPPYESISKPSKEDJPSLPKEDSEKSYENVDSGDKERKOTITSPILVHKNKKDEEHRRESR h-Lats  
 KLLHONPSVPPYESISKPSKEDJPSLPKEDSEKSYENVDSGDKERKOTITSPILVHKNKKDEEHRRESR m-Lats  
 631 IOSYSPQAFKFFMEOHVENVLKSHOORLHKKOLENEMMRVGLSODAOODMRKMLCOKESSNYIRLKRKRM h-Lats  
 IOSYSPQAFKFFMEOHVENVLKSHOORLHKKOLENEMMRVGLSODAOODMRKMLCOKESSNYIRLKRKRM m-Lats  
 701 JKSMFVKIKTLGIGAFGEVCLAHKVDIKALYATKILHKKDVLLENOVAHVKAERDILAEADNEWVRLVY h-Lats  
 JKSMFVKIKTLGIGAFGEVCLARKVDIKALYATKILHKKDVLLENOVAHVKAERDILAEADNEWVRLVY m-Lats  
 771 SFODKONLYFVMDYIPGGDMMSSLIRMGIFPENLARFYIAELTCAVESVHKMGFIHRDIKPDNIIIDRGG h-Lats  
 SFODKONLYFVMDYIPGGDMMSSLIRMGIFPENLARFYIAELTCAVESVHKMGFIHRDIKPDNIIIDRGG m-Lats  
 841 JIKLIDFGLCTGFHWTHDSKY YOSGDHPRDSMDFSNEWGDPSCHRGDHLKPLEHHAAROHORCLAHSL h-Lats  
 JIKLIDFGLCTGFHWTHDSKY YOSGDHPRDSMDFSNEWGDPSCHRGDHLKPLEHHAAROHORCLAHSL m-Lats  
 911 JGIPNYIAPEVLLRTGYTOLCDWWSVGVIIEMLVGOPPF LAOTPLETOMKVINWOTSLHIPPOAKLSPE h-Lats  
 JGIPNYIAPEVLLRTGYTOLCDWWSVGVIIEMLVGOPPF LAOTPLETOMKVINWOTSLHIPPOAKLSPE m-Lats  
 981 ASDLIKLCRGPEORLGKNGADEIKAHPPFKTIDFSSDLROQSASYIPKITHPTDTSNFDPPVDPDKLWSD h-Lats  
 ASDLIKLCRGPEORLGKNGADEIKAHPPFKTIDFSSDLROQSASYIPKITHPTDTSNFDPPVDPDKLWSD m-Lats  
 1051 DNEENNVNDILNGWYKNGKHPEHAFYEFTFRFDFDNGYPYNYPKPIEVEYINSOGSEQOSDEDDONIGS h-Lats  
 GSEENIGDTLSSWYKNGKHPEHAFYEFTFRFDFDNGYPYNYPKPIEVEYINSOGSEQOSDEDDONIGS m-Lats  
 1121 EIKNHDLVYV h-Lats  
 DGNNRDLVYV m-Lats

FIG. 6A

**THIS PAGE BLANK (USPTO)**



7/25



FIGS. 6B-D

**THIS PAGE BLANK (USPTO)**






FIGS. 7A-B

**THIS PAGE BLANK (USPTO)**


9/25



**FIGS. 8A-D**

**THIS PAGE BLANK (USPTO)**


10/25



FIGS. 9A-F

**THIS PAGE BLANK (USPTO)**


11/25



FIGS. 10A-E

**THIS PAGE BLANK (USPTO)**





**FIGS. 11A-C**

**THIS PAGE BLANK (USPTO)**

13/25

```

      10      20      30      40      50      60      70      80
      *      *      *      *      *      *      *      *
ACCTTTGGGT TGCTGGGACG GACTCTGGCC GCCTCAGCGT CCGCCCTCAG GCCCGTGGCC GCTGTCCAGG AGCTCTGCTC

      90     100     110     120     130     140     150     160
      *      *      *      *      *      *      *      *
TCCCCTCCAG AGTTAATTAT TTATATTGTA AAGAATTTTA ACAGTCCTGG GGAATTCTTT GAAGGATCAT TTTCACTTTT

      170     180     190     200     210     220     230     240
      *      *      *      *      *      *      *      *
GCTCAGAAGA AAGCTCTGGA TCTATCAAAT AAAGAAGTCC TTCGTGTGGG CTACATATAT AGATGTTTTT ATGAAGAGGA
                                     M K R

      250     260     270     280     290     300     310     320
      *      *      *      *      *      *      *      *
GTGAAAAGCC AGAAGGATAT AGACAAATGA GGCCTAAGAC CTTTCTCTGCC AGTAACTATA CTGTCAAGTAG CCGGCAAATG
S E K P   E G Y   R Q M   R P K T   F P A   S N Y   T V S S   R Q M

      330     340     350     360     370     380     390     400
      *      *      *      *      *      *      *      *
TTACAAGAAA TTCGGGAATC CCTTAGGAAT TTATCTAAAC CATCTGATGC TGCTAAGGCT GAGCATAACA TGAGTAAAAT
L Q E   I R E S   L R N   L S K   P S D A   A K A   E H N   M S K M

      410     420     430     440     450     460     470     480
      *      *      *      *      *      *      *      *
GTCAACCGAA GATCCTCGAC AAGTCAGAAA TCCACCCAAA TTTGGGACGC ATCATAAAGC CTTGCAGGAA ATTCGAAACT
S T E   D P R   Q V R N   P P K   F G T   H H K A   L Q E   I R N

      490     500     510     520     530     540     550     560
      *      *      *      *      *      *      *      *
CTCTGCTTCC ATTTGCAAAT GAAACAAATT CTCTCTCGAG TACTTCAGAA GTTAATCCAC AAATGCTTCA AGACTTGCAA
S L L P   F A N   E T N   S S R S   T S E   V N P   Q M L Q   D L Q

      570     580     590     600     610     620     630     640
      *      *      *      *      *      *      *      *
GCTGCTGGAT TTGATGAGGA TATGGTTATA CAAGCTCTTC AGAAAAGTAA CAACAGAAAT ATAGAAGCAG CAATTGAATT
A A G   F D E D   M V I   Q A L   Q K T N   N R S   I E A   A I E F

      650     660     670     680     690     700     710     720
      *      *      *      *      *      *      *      *
CATTAGTAAA ATGAGTTACC AAGATCCTCG ACGAGAGCAG ATGGCTGCAG CAGCTGCCAG ACCTATTAAT GCCAGCATGA
I S K   M S Y   Q D P R   R E Q   M A A   A A A R   P I N   A S M

      730     740     750     760     770     780     790     800
      *      *      *      *      *      *      *      *
AACCAGGGAA TGTGCAGCAA TCAGTTAACC GCAAACAGAG CTGGAAAGGT TCTAAAGAAT CCTTAGTTCC TCAGAGGCAT
K P G N   V Q Q   S V N   R K Q S   W K G   S K E   S L V P   Q R H

      810     820     830     840     850     860     870     880
      *      *      *      *      *      *      *      *
GGCCCGCCAC TAGGAGAAAG TGTGGCCTAT CATTCTGAGA GTCCCAACTC ACAGACAGAT GTAGGAAGAC CTTTGTCTGG
G P P   L G E S   V A Y   H S E   S P N S   Q T D   V G R   P L S G

      890     900     910     920     930     940     950     960
      *      *      *      *      *      *      *      *
ATCTGGTATA TCAGCATTTG TTCAAGCTCA CCCTAGCAAC GGACAGAGAG TGAACCCCCC ACCACCACCT CAAGTAAGGA
S G I   S A F   V Q A H   P S N   G Q R   V N P P   P P P   Q V R

      970     980     990     1000     1010     1020     1030     1040
      *      *      *      *      *      *      *      *
GTGTTACTCC TCCACCACCT CCAAGAGGCC AGACTCCCCC TCCAAGAGGT ACAACTCCAC CTCCCCCTTC ATGGGAACCA
S V T P   P P P   P R G   Q T P P   P R G   T T P   P P P S   W E P

```

FIG. 12

**THIS PAGE BLANK (USPTO)**

1050 1060 1070 1080 1090 1100 1110 1120  
AACTCTCAAA CAAAGCGCTA TTCTGGAAC ATGGAATACG TAATCTCCCG AATCTCTCT GTCCACCTG GGGCATGGCA  
N S Q T K R Y S G N M E Y V I S R I S P V P P G A W Q

1130 1140 1150 1160 1170 1180 1190 1200  
AGAGGGCTAT CCTCCACCAC CTCTCAACAC TTCCCCCATG AATCCTCCTA ATCAAGGACA GAGAGGCATT AGTTCTGTTC  
E G Y P P P P L N T S P M N P P N Q G Q R G I S S V

1210 1220 1230 1240 1250 1260 1270 1280  
CTGTTGGCAG ACAACCAATC ATCATGCAGA GTTCTAGCAA ATTTAACTTT CCATCAGGGA GACCTGGAAT GCAGAATGGT  
P V G R Q P I I M Q S S S K F N F P S G R P G M Q N G

1290 1300 1310 1320 1330 1340 1350 1360  
ACTGGACAAA CTGATTTTCAT GATACACCAA AATGTTGTCC CTGCTGGCAC TGTGAATCGG CAGCCACCAC CTCCATATCC  
T G Q T D F M I H Q N V V P A G T V N R Q P P P P Y P

1370 1380 1390 1400 1410 1420 1430 1440  
TCTGACAGCA GCTAATGGAC AAAGCCCTTC TGCTTTACAA ACAGGGGGAT CTGCTGCTCC TTCGTCATAT ACAAATGGAA  
L T A A N G Q S P S A L Q T G G S A A P S S Y T N G

1450 1460 1470 1480 1490 1500 1510 1520  
GTATTCCTCA GTCTATGATG GTGCCAAACA GAAATAGTCA TAACATGGAA CTATATAACA TTAGTGTACC TGGACTGCAA  
S I P Q S M M V P N R N S H N M E L Y N I S V P G L Q

1530 1540 1550 1560 1570 1580 1590 1600  
ACAAATGGC CTCAGTCATC TTCTGCTCCA GCCCAGTCAT CCCCAGCAG TGGGCATGAA ATCCCTACAT GGCAACCTAA  
T N W P Q S S S A P A Q S S P S S G H E I P T W Q P N

1610 1620 1630 1640 1650 1660 1670 1680  
CATACCAGTG AGGTCAAATT CTTTAAATAA CCCATTAGGA AATAGAGCAA GTCACCTCTGC TAATCTCAG CCTTCTGCTA  
I P V R S N S F N N P L G N R A S H S A N S Q P S A

1690 1700 1710 1720 1730 1740 1750 1760  
CAACAGTCAC TGCAATTACA CCAGCTCCTA TTCAACAGCC TGTGAAAAGT ATGCGTGTAT TAAAACCAGA GCTACAGACT  
T T V T A I T P A P I Q Q P V K S M R V L K P E L Q T

1770 1780 1790 1800 1810 1820 1830 1840  
GCTTTAGCAC CTACACACCC TTCTTGATA CCACAGCCAA TTCAAACCTGT TCAACCCAGT CCTTTTCTCTG AGGGAACCGC  
A L A P T H P S W I P Q P I Q T V Q P S P F P E G T A

1850 1860 1870 1880 1890 1900 1910 1920  
TTCAAATGTG ACTGTGATGC CACCTGTTGC TGAAGCTCCA AACTATCAAG GACCACCACC ACCCTACCCA AAACATCTGC  
S N V T V M P P V A E A P N Y Q G P P P P Y P K H L

1930 1940 1950 1960 1970 1980 1990 2000  
TGCACCAAAA CCCATCTGTT CCTCCATACG AGTCAATCAG TAAGCCTAGC AAAGAGGATC AGCCAAGCTT GCCCAAGGAA  
L H Q N P S V P P Y E S I S K P S K E D Q P S L P K E

2010 2020 2030 2040 2050 2060 2070 2080  
GATGAGAGTG AAAAGAGTTA TGAAAATGTT GATAGTGGGG ATAAAGAAAA GAAACAGATT ACAACTTCAC CTATTACTGT  
D E S E K S Y E N V D S G D K E K K Q I T T S P I T V

FIG. 12 (cont.)

**THIS PAGE BLANK (USPTO)**

This page is not part of  
the pamphlet!

**WO 00-10602**  
**2/2**

Date: 02 mar 2000

Destination: Agent

Address:

**THIS PAGE BLANK (USPTO)**



15/25

2090 2100 2110 2120 2130 2140 2150 2160  
TAGGAAAAAC AAGAAAGATG AAGAGCGAAG GGAATCTCGT ATTCAAAGTT ATTCTCCTCA AGCATTAAAA TTCTTTATGG  
R K N K K D E E R R E S R I Q S Y S P Q A F K F F M

2170 2180 2190 2200 2210 2220 2230 2240  
AGCAACATGT AGAAAATGTA CTCAAATCTC ATCAGCAGCG TCTACATCGT AAAAAACAAT TAGAGAATGA AATGATGCGG  
E Q H V E N V L K S H Q Q R L H R K K Q L E N E M M R

2250 2260 2270 2280 2290 2300 2310 2320  
GTTGGATTAT CTCAAGATGC CCAGGATCAA ATGAGAAAGA TGCTTTGCCA AAAAGAATCT AATTACATCC GTCTTAAAG  
V G L S Q D A Q D Q M R K M L C Q K E S N Y I R L K R

2330 2340 2350 2360 2370 2380 2390 2400  
GGCTAAATG GACAAGTCTA TGTTTGTGAA GATAAAGACA CTAGGAATAG GAGCATTGGG TGAAGTCTGT CTAGCAAGAA  
A K M D K S M F V K I K T L G I G A F G E V C L A R

2410 2420 2430 2440 2450 2460 2470 2480  
AAGTAGATAC TAAGGCTTTG TATGCAACAA AAATCTCTCG AAAGAAAGAT GTTCTTCTTC GAAATCAAGT CGCTCATGTT  
K V D T K A L Y A T K T L R K K D V L L R N Q V A H V

2490 2500 2510 2520 2530 2540 2550 2560  
AAGGCTGAGA GAGATATCCT GGCTGAAGCT GACAATGAAT GGGTAGTTCTG TCTATATTAT TCATTCCAAG ATAAGGACAA  
K A E R D I L A E A D N E W V V R L Y Y S F Q D K D N

2570 2580 2590 2600 2610 2620 2630 2640  
TTTATACTTT GTAATGGACT ACATTCCTGG GGGTGATATG ATGAGCCTAT TAATTAGAAT GGGCATCTTT CCAGAAAGTC  
L Y F V M D Y I P G G D M M S L L I R M G I F P E S

2650 2660 2670 2680 2690 2700 2710 2720  
TGGCAGGATT CTACATAGCA GAACTTACCT GTGCAGTTGA AAGTGTTCAT AAAATGGGTT TTATTCATAG AGATATTAAA  
L A R F Y I A E L T C A V E S V H K M G F I H R D I K

2730 2740 2750 2760 2770 2780 2790 2800  
CCTGATAATA TTTTGATGTA TCGTGATGGT CATATTAAAT TGAATGACTT TGGCCTCTGC ACTGGCTTCA GATGGACACA  
P D N I L I D R D G H I K L T D F G L C T G F R W T H

2810 2820 2830 2840 2850 2860 2870 2880  
CGATTCTAAG TACTATCAGA GTGGTGACCA TCCACGGCAA GATAGCATGG ATTTCAGTAA TGAATGGGGG GATCCCTCAA  
D S K Y Y Q S G D H P R Q D S M D F S N E W G D P S

2890 2900 2910 2920 2930 2940 2950 2960  
GCTGTGATG TGGAGACAGA CTGAAGCCAT TAGAGCGGAG AGCTGCAAGC CAGCACCAGC GATGTCTAGC ACATTCCTTG  
S C R C G D R L K P L E R R A A R Q H Q R C L A H S L

2970 2980 2990 3000 3010 3020 3030 3040  
GTTGGGACTC CCAATTATAT TGCACTGAA GTGTTGCTAC GAACAGGATA CACACAGTTG TGTGATTGGT GGAGTGTGG  
V G T P N Y I A P E V L L R T G Y T Q L C D W W S V G

3050 3060 3070 3080 3090 3100 3110 3120  
TGTTATTCTT TTTGAAATGT TGGTGGGACA ACCTCCTTTC TTGGCAGAAA CACCATTAGA AACACAAATG AAGGTTATCA  
V I L F E M L V G Q P P F L A Q T P L E T Q M K V I

FIG. 12 (cont.)

**THIS PAGE BLANK (USPTO)**

3130 3140 3150 3160 3170 3180 3190 3200  
\* \* \* \* \*  
ACTGGCAAAC ATCTCTTCAC ATTCCACCAC AAGCTAAACT CAGTCCTGAA GCTTCTGATC TTATTATTAA ACTTTGCCGA  
N W Q T S L H I P P Q A K L S P E A S D L I I K L C R  
3210 3220 3230 3240 3250 3260 3270 3280  
\* \* \* \* \*  
GGACCCGAAG ATCGCTTAGG CAAGAATGGT GCTGATGAAA TAAAGCTCA TCCATTTTTT AAAACAATTG ACTTCTCCAG  
G P E D R L G K N G A D E I K A H P F F K T I D F S S  
3290 3300 3310 3320 3330 3340 3350 3360  
\* \* \* \* \*  
TGACCTGAGA CAGCAGTCTG CTTCATACAT TCCTAAAATC ACACACCCAA CAGATACATC AAATTTTGAT CCTGTTGATC  
D L R Q Q S A S Y I P K I T H P T D T S N F D P V D  
3370 3380 3390 3400 3410 3420 3430 3440  
\* \* \* \* \*  
CTGATAAATT ATGGAGTGAT GATAACGAGG AAGAAAATGT AAATGACACT CTCAATGGAT GGTATAAAAA TGGAAAGCAT  
P D K L W S D D N E E E N V N D T L N G W Y K N G K H  
3450 3460 3470 3480 3490 3500 3510 3520  
\* \* \* \* \*  
CCTGAACATG CATTCTATGA ATTTACCTTC CGAAGGTTTT TTGATGACAA TGGCTACCCA TATAATTATC CGAAGCCTAT  
P E H A F Y E F T F R R F F D D N G Y P Y N Y P K P I  
3530 3540 3550 3560 3570 3580 3590 3600  
\* \* \* \* \*  
TGAATATGAA TACATTAATT CACAAGGCTC AGAGCAGCAG TCGGATGAAG ATGATCAAAA CACAGGCTCA GAGATTAAAA  
E Y E Y I N S Q G S E Q Q S D E D D Q N T G S E I K  
3610 3620 3630 3640 3650 3660 3670 3680  
\* \* \* \* \*  
ATCGCGATCT AGTATATGTT TAACACACTA GTAAATAAAT GTAATGAGGA TTGTAAAAG GGCTGAAAT GCGAGGTGTT  
N R D L V Y V \*  
3690 3700 3710 3720 3730 3740 3750 3760  
\* \* \* \* \*  
TTGAGGTTCT GAGAGTAAAA TTATGCAAAT ATGACAGAGC TATATATGTG TGCTCTGTGT ACAATATTTT ATTTTCCTAA  
3770 3780 3790 3800 3810 3820 3830 3840  
\* \* \* \* \*  
ATTATGGGAA ATCCTTTTAA AATGTAAATT TATTCCAGCC GTTTAAATCA GTATTTAGAA AAAAATTGTT ATAAGGAAAG  
3850 3860 3870 3880 3890 3900 3910 3920  
\* \* \* \* \*  
TAAATTATGA ACTGAATATT ATAGTCAGTT CTTGGTACTT AAAGTACTTA AAATAAGTAG TGCTTTGTTT AAAAGGAGAA  
3930 3940 3950 3960 3970 3980  
\* \* \* \* \*  
ACCTGGTATC TATTTGTATA TATGCTAAAT AATTTTAAAA TACAAGAGTT TTTGAAATTT TTTT

FIG. 12 (cont.)

**THIS PAGE BLANK (USPTO)**

17/25

10 20 30 40 50 60 70 80  
\* \* \* \* \*  
GTGCAACATT CAATTAACCG AAAACAAAGC TGGAAAGGTT CTAAGAGATC TCTAGTTCCT CAGAGACACG GCCCATCTCT  
V Q H S I N R K Q S W K G S K E S L V P Q R H G P S L  
90 100 110 120 130 140 150 160  
\* \* \* \* \*  
AGGAGAAAAT GTGGTTTATC GTTCTGAAAG CCCCAACTCA CAGGCGGATG TAGGAAGACC TCTGTCTGGA TCCGGCATTG  
G E N V V Y R S E S P N S Q A D V G R P L S G S G I  
170 180 190 200 210 220 230 240  
\* \* \* \* \*  
CAGCATTTGC TCAAGCTCAC CCAAGCAATG GACAGAGAGT GAACCCCCCA CCACCACCTC AAGTTAGGAG TGTTACTCCT  
A A F A Q A H P S N G Q R V N P P P P P Q V R S V T P  
250 260 270 280 290 300 310 320  
\* \* \* \* \*  
CCACCACCTC CGAGAGGCCA GACCCACCT CCCCAGGCA CCACTCCCCC TCCCCCTCA TGGGAACCAA GCTCTCAGAC  
P P P P R G Q T P P P R G T T P P P P S W E P S S Q T  
330 340 350 360 370 380 390 400  
\* \* \* \* \*  
AAAGCGCTAC TCTGGAACA TGGAGTACGT AATCTCCCGA ATCTCCCCTG TTCCACCTGG GGCGTGGCAG GAGGGGTACC  
K R Y S G N M E Y V I S R I S P V P P G A W Q E G Y  
410 420 430 440 450 460 470 480  
\* \* \* \* \*  
CTCCACCACC TCTTACCACT TCTCCCATGA ATCCCCCTAG CCAGGCTCAG AGGGCCATTA GTTCTGTTCC AGTTGGTAGA  
P P P P L T T S P M N P P S Q A Q R A I S S V P V G R  
490 500 510 520 530 540 550 560  
\* \* \* \* \*  
CAACCCATCA TCATGCAGAG TACTAGCAAA TTAACTTTA CACCAGGGCG ACCTGGAGTT CAGAATGGTG GTGGTCAGTC  
Q P I I M Q S T S K F N F T P G R P G V Q N G G G Q S  
570 580 590 600 610 620 630 640  
\* \* \* \* \*  
TGATTTATC GTGCACCAAA ATGTCCCCAC TGGTTCTGTG ACTCGGCAGC CACCACCTCC ATATCCTCTG ACCCCAGCTA  
D F I V H Q N V P T G S V T R Q P P P P Y P L T P A  
650 660 670 680 690 700 710 720  
\* \* \* \* \*  
ATGGACAAAG CCCCTCTGCT TTACAAACAG GGGCTTCTGC TGCTCCACCA TCATTCGCCA ATGGAACCGT TCCTCAGTCG  
N G Q S P S A L Q T G A S A A P P S F A N G N V P Q S  
730 740 750 760 770 780 790 800  
\* \* \* \* \*  
ATGATGGTGC CCAACAGGAA CAGTCATAAC ATGGAGCTTT ATAATATTAA TGTCCCTGGA CTGCAAACAG CCTGGCCCCA  
M H V P N R N S H N M E L Y N I N V P G L Q T A W P Q  
810 820 830 840 850 860 870 880  
\* \* \* \* \*  
GTCGTCTTCT GCTCTGCGC AGTCATCCCC AAGCGGTGGG CATGAAATTC CTACATGGCA ACCTAACATA CCAGTGAGGT  
S S S A P A Q S S P S G G H E I P T W Q P N I P V R  
890 900 910 920 930 940 950 960  
\* \* \* \* \*  
CAAATTCTTT TAATAACCCA TTAGGAAGTA GAGCAAGTCA CTCTGCTAAT TCTCAGCCTT CTGCCACTAC AGTCACTGCC  
S N S F N N P L G S R A S H S A N S Q P S A T T V T A

FIG. 13

**THIS PAGE BLANK (USPTO)**

970 980 990 1000 1010 1020 1030 1040  
\* \* \* \* \*  
ATCACACCCG CTCCTATTCA ACAGCCCGTG AAAAGCATGC GCGTCTTGAA ACCAGAGCTG CAGACTGCTT TAGCCCCAAC  
I T P A P I Q Q P V K S M R V L K P E L Q T A L A P T

1050 1060 1070 1080 1090 1100 1110 1120  
\* \* \* \* \*  
CCATCCTTCT TGGATGCCAC AGCCAGTTCA GACTGTTTCAG CCTACCCCTT TTTCTGAGGG TACAGCTTCA AGTGTGCCTG  
H P S W M P Q P V Q T V Q P T P F S E G T A S S V P

1130 1140 1150 1160 1170 1180 1190 1200  
\* \* \* \* \*  
TCATCCCACC TGTGCTGAA GCTCCAAGCT ATCAAGGTCC ACCACCGCCT TATCCAAAAC ATCTGCTACA CCAAAACCCA  
V I P P V A E A P S Y Q G P P P P Y P K H L L H Q N P

1210 1220 1230 1240 1250 1260 1270 1280  
\* \* \* \* \*  
TCTGTCCCTC CATATGAGTC AGTAAGTAAG CCCTGCAAG ATGAACAGCC TAGCTTACCC AAGGAAGATG ATAGTGAGAA  
S V P P Y E S V S K P C K D E Q P S L P K E D D S E K

1290 1300 1310 1320 1330 1340 1350 1360  
\* \* \* \* \*  
GAGTGGCGAC AGTGGTGACT CTGGGGATAA AGAAAAGAAA CAGATTACAA CTTACCTAT CACTGTTTCGG AAAAACAAGA  
S A D S G D S G D K E K K Q I T T S P I T V R K N K

1370 1380 1390 1400 1410 1420 1430 1440  
\* \* \* \* \*  
AAGATGAAGA ACGAAGAGAG TCTCGGATTC AGAGTTACTC CCCACAGGCC TTAAAGTTCT TCATGGAGCA GCACGTAGAG  
K D E E R R E S R I Q S Y S P Q A F K F F M E Q H V E

1450 1460 1470 1480 1490 1500 1510 1520  
\* \* \* \* \*  
AACGTCTCTGA AGTCTCATCA GCAGCGTCTG CATCGGAAGA AGCAGCTAGA AAATGAAATG ATGCGGGTTG GATTATCTCA  
N V L K S H Q Q R L H R K K Q L E N E M M R V G L S Q

1530 1540 1550 1560 1570 1580 1590 1600  
\* \* \* \* \*  
AGATGCCCCAG GATCAAATGA GAAAGATGCT TTGCCAGAAA GAGTCTAACT ATATTGCTCT TAAAAGGGCT AAAATGGACA  
D A Q D Q M R K M L C Q K E S N Y I R L K R A K M D

1610 1620 1630 1640 1650 1660 1670 1680  
\* \* \* \* \*  
AGTCTATGTT TGTAAGATA AAGACATTAG GAATAGGAGC GTTTGGTGAA GTCTGTCTAG CAAGAAAAGT CGATACTAAA  
K S M F V K I K T L G I G A F G E V C L A R K V D T K

1690 1700 1710 1720 1730 1740 1750 1760  
\* \* \* \* \*  
GCTTTGTATG CAACAAAGAC TCTTCGAAAG AAAGACGTTT TGCTCCGAAA TCAGGTGGCT CATGTGAAAG CGGAGAGGGA  
A L Y A T K T L R K K D V L L R N Q V A H V K A E R D

1770 1780 1790 1800 1810 1820 1830 1840  
\* \* \* \* \*  
TATCCTAGCA GAAGCCGACA ATGAGTGGGT GGTCCGCCTG TACTACTCTT TCCAGGACAA GGACAACTTG TACTTTGTGA  
I L A E A D N E W V V R L Y Y S F Q D K D N L Y F V

1850 1860 1870 1880 1890 1900 1910 1920  
\* \* \* \* \*  
TGGACTACAT TCCTGGGGGG GATATGATGA GCGTATTAAT TAGAATGGGC ATCTTTCTCTG AAAATCTGGC ACGATTCTAC  
M D Y I P G G D M M S L L I R M G I F P E N L A R F Y

1930 1940 1950 1960 1970 1980 1990 2000  
\* \* \* \* \*  
\* \* \* \* \*

FIG. 13 (cont.)

**THIS PAGE BLANK (USPTO)**



ATAGCAGAAC	TTACCTGTGC	AGTTGAAAGT	GTTCATAAAA	TGGGTTTTAT	TCATAGAGAT	ATTAAACCTG	ATAACATTTT
I A E	L T C A	V E S	V H K	M G F I	H R D	I K P	D N I L
2010	2020	2030	2040	2050	2060	2070	2080
*	*	*	*	*	*	*	*
GATTGACCGT	GATGGCCATA	TTAAATTGAC	TGACTTTGGC	TTGTGCACTG	GCTTCAGATG	GACACATGAC	TCCAAGTACT
I D R	D G H	I K L T	D F G	L C T	G F R W	T H D	S K Y
2090	2100	2110	2120	2130	2140	2150	2160
*	*	*	*	*	*	*	*
ACCAGAGTGG	GGATCACCCA	CGGCAAGATA	GCATGGATTT	CAGTAACGAA	TGGGGAGATC	CTTCCAATTG	TCGGTGTGGG
Y Q S G	D H P	R Q D	S M D F	S N E	W G D	P S N C	R C G
2170	2180	2190	2200	2210	2220	2230	2240
*	*	*	*	*	*	*	*
GACAGACTGA	AGCCACTGGA	GCGGAGAGCT	GCTCGCCAGC	ACCAGCGATG	TCTAGCCCAT	TCTCTGGTTG	GGACTCCCAA
D R L	K P L E	R R A	A R Q	H Q R C	L A H	S L V	G T P N
2250	2260	2270	2280	2290	2300	2310	2320
*	*	*	*	*	*	*	*
TTATATTGCA	CCTGAAGTGC	TACTGCGAAC	AGGATATACA	CAGCTGTGTG	ACTGGTGGAG	TGTTGGTGTG	ATTCTTTGTG
Y I A	P E V	L L R T	G Y T	Q L C	D W W S	V G V	I L C
2330	2340	2350	2360	2370	2380	2390	2400
*	*	*	*	*	*	*	*
AAATGTTGGT	GGGACAACCT	CCTTTCTTGG	CACAAACCCC	ATTAGAAACA	CAAATGAAGG	TTATCATCTG	GCAAACCTCT
E M L V	G Q P	P F L	A Q T P	L E T	Q M K	V I I W	Q T S
2410	2420	2430	2440	2450	2460	2470	2480
*	*	*	*	*	*	*	*
CTACACATCC	CTCCTCAAGC	TAAGCTGAGT	CCTGAAGCCT	CTGACCTCAT	TATCAAACCTG	TGTCGAGGAC	CAGAAGACCG
L H I	P P Q A	K L S	P E A	S D L I	I K L	C R G	P E D R
2490	2500	2510	2520	2530	2540	2550	2560
*	*	*	*	*	*	*	*
CCTCGGCAAG	AACGGTGCTG	ATGAGATAAA	GGCTCATCCA	TTTTTTAAGA	CCATCGATTT	CTCTAGTGAT	CTGAGACAGC
L G K	N G A	D E I K	A H P	F F K	T I D F	S S D	L R Q
2570	2580	2590	2600	2610	2620	2630	2640
*	*	*	*	*	*	*	*
AGTCTGCTTC	ATACATCCCT	AAAATCACGC	ATCCAACAGA	TACATCCAAT	TTCGACCCTG	TTGATCCTGA	TAAATTGTGG
Q S A S	Y I P	K I T	H P T D	T S N	F D P	V D P D	K L W
2650	2660	2670	2680	2690	2700	2710	2720
*	*	*	*	*	*	*	*
AGCGATGGCA	GCGAGGAGGA	AAATATCAGT	GACACTCTGA	GCGGATGGTA	TAAAAATGGG	AAGCACCCCG	AGCACGCTTT
S D G	S E E E	N I S	D T L	S G W Y	K N G	K H P	E H A F
2730	2740	2750	2760	2770	2780	2790	2800
*	*	*	*	*	*	*	*
CTATGAGTTC	ACCTTTCGGA	GGTTTTTTGA	TGACAATGGC	TACCCATATA	ATTATCCAAA	GCCTATTGAG	TATGAATACA
Y E F	T F R	R F F D	D N G	Y P Y	N Y P K	P I E	Y E Y
2810	2820	2830	2840	2850	2860	2870	2880
*	*	*	*	*	*	*	*
TTCATTACAA	GGGCTCAGAA	CAACAGTCTG	ATGAAGATGA	TCAACACACA	AGCTCCGATG	GAAACAACCG	AGATCTAGTG
I H S Q	G S E	Q Q S	D E D D	Q H T	S S D	G N N R	D L V
2890	2900	2910	2920	2930	2940	2950	2960
*	*	*	*	*	*	*	*
TATGTTTAAT	AAACTAGGAG	ATCATGTGAA	GAATTGCAA	GAGGCCTGAA	GTGCAGGGGT	TTTTGAAGTT	TTGAGAAAAAT
Y V	*						

FIG. 13 (cont.)

**THIS PAGE BLANK (USPTO)**

```
      2970      2980      2990      3000      3010      3020      3030      3040
      *          *          *          *          *          *          *          *
TATGCAAATG TGACAGAGTT TGTGTGCTCT GTGTACAATA TTTTATTTTC CTAAGTTATG GGAAATTGTT TTAAATGTT
      3050      3060      3070      3080      3090      3100      3110      3120
      *          *          *          *          *          *          *          *
AATTTATTCC ACCCTTTTAA TTCAGTAATT TAGAAAAAAT TGTTATAAGG AAAGTAAATT ATGAACTGAG TATTATAGTC
      3130      3140      3150      3160      3170      3180      3190      3200
      *          *          *          *          *          *          *          *
AATTCTTGGT ACTTAAAGTA CTTAAAAAGA GAAGCCTGGT ATCTTTTGTA TATATAATAA ATAATTTTAA AATCCCAAAA
      3210
      *
AAAAAAAAAA AAA
```

FIG. 13 (cont.)

**THIS PAGE BLANK (USPTO)**

10 20 30 40 50 60 70 80  
\* \* \* \* \*  
ATGAGAGCCA CCCCAGAGTT TGGACCTTAT CAAAAAGCTC TCAGGGAAAT CCGATATTCC CTCTGCCTT TTGCCAACGA  
M R A T P K F G P Y Q K A L R E I R Y S L L P F A N E  
90 100 110 120 130 140 150 160  
\* \* \* \* \*  
GTCAGGCACT TCGGCAGCTG CAGAGGTGAA CCGGCAGATG CTTCAGGAGT TGGTGAATGC GGCATGTGAC CAGGAGATGG  
S G T S A A A E V N R Q M L Q E L V N A A C D Q E M  
170 180 190 200 210 220 230 240  
\* \* \* \* \*  
CTGGCAGAGC GCTCACGCAG ACGGGCAGTA GGAGTATCGA AGCTGCCTTG GAGTACATCA GTAAGATGGG CTACCTGGAC  
A G R A L T Q T G S R S I E A A L E Y I S K M G Y L D  
250 260 270 280 290 300 310 320  
\* \* \* \* \*  
CCCAGGAATG AGCAGATTGT GCGAGTCATC AAGCAGACCT CCCCAGGAAA GGGCCTGGCG TCCACCCCGG TGA CTGGCG  
P R N E Q I V R V I K Q T S P G K G L A S T P V T R R  
330 340 350 360 370 380 390 400  
\* \* \* \* \*  
GCCAGTTTC GAGGGCACAG GGAAGCACT CCCATCCTAC CACCAGCTGG GTGGTGCAA CTACGAGGGC CCCGCCGCAC  
P S F E G T G E A L P S Y H Q L G G A N Y E G P A A  
410 420 430 440 450 460 470 480  
\* \* \* \* \*  
TGGAGGAGAT GCCGCGGCAA TATTTAGACT TTCTCTTCCC TGGAGCCGGA GCCGGCACCC ACGGTGCCCA GGCTCACCAG  
L E E M P R Q Y L D F L F P G A G A G T H G A Q A H Q  
490 500 510 520 530 540 550 560  
\* \* \* \* \*  
CATCTCCCA AAGGGTACAG CACAGCAGTA GAGCCAAGTG CGCACTTTC GGGCACACAC TATGGTCTGT GTCATCTACT  
H P P K G Y S T A V E P S A H F P G T H Y G R G H L L  
570 580 590 600 610 620 630 640  
\* \* \* \* \*  
ATCGGAGCAG TCTGGGTATG GGGTGCAGCG CAGTTCTCTC TTCCAGAACA AGACGCCACC AGATGCCTAT TCCAGCATGG  
S E Q S G Y G V Q R S S S F Q N K T P P D A Y S S M  
650 660 670 680 690 700 710 720  
\* \* \* \* \*  
CCAAGGCCCA GGGTGGCCCT CCCGCCAGCC TCACCTTTC TGCCCATGCT GGGCTGTACA CTGCCTCGCA CCACAAGCCG  
A K A Q G G P P A S L T F P A H A G L Y T A S H H K P  
730 740 750 760 770 780 790 800  
\* \* \* \* \*  
GGGCTACCC CACCTGGGGC CCACCCATTA CATGTGTTGG GCACCGGGG TCCCACGTTT ACTGGCGAAA GCTCTGCACA  
A A T P P G A H P L H V L G T R G P T F T G E S S A Q  
810 820 830 840 850 860 870 880  
\* \* \* \* \*  
GGCTGTGCTG GCACCGTCCA GGAACAGCCT CAATGCTGAC TTGTACGAGC TGGGCTCCAC GGTGCCCTGG TCTGCAGCTC  
A V L A P S R N S L N A D L Y E L G S T V P W S A A  
890 900 910 920 930 940 950 960  
\* \* \* \* \*  
CACTGGCAGC CCGCGACTCG CTGCAGAAGC AGGGTCTAGA AGCCTCGCGG CCGCATGTGG CTTTTCGGGC TGGCCCCAGC  
P L A R R D S L Q K Q G L E A S R P H V A F R A G P S

FIG. 14

**THIS PAGE BLANK (USPTO)**

22/25

970	980	990	1000	1010	1020	1030	1040
AGGACCAACT	CCTTCAACAA	CCCACAACCT	GAGCCCTCAC	TGCCCCGCCC	CAACACGGTC	ACCGCCGTGA	CGGCCGCACA
R T N	S F N N	P Q P	E P S	L P A P	N T V	T A V	T A A H
1050	1060	1070	1080	1090	1100	1110	1120
CATCCTTCAC	CCTGTGAAGA	GCGTGCGTGT	GCTGCGGCCC	GAGCCCCAGA	CAGCCGTGGG	GCCCTCGCAC	CCCGCCTGGG
I L H	P V K	S V R V	L R P	E P Q	T A V G	P S H	P A W
1130	1140	1150	1160	1170	1180	1190	1200
TGGCTGCGCC	CACAGCACCT	GCCACTGAGA	GCCTGGAGAC	GAAGGAGGGC	AGCGCAGGCC	CACACCCGCT	GGATGTGGAC
V A A P	T A P	A T E	S L E T	K E G	S A G	P H P L	D V D
1210	1220	1230	1240	1250	1260	1270	1280
TATGGCGGCT	CCGAGCGCAG	GTGCCCACCG	CCTCCGTATC	CAAAGCACTT	GCTGCTGCCC	AGTAAGTCTG	AGCAGTACAG
Y G G	S E R R	C P P	P P Y	P K H L	L L P	S K S	E Q Y S
1290	1300	1310	1320	1330	1340	1350	1360
CGTGGACCTG	GACAGCCTGT	GCACCAGTGT	GCAGCAGAGT	CTGCGAGGGG	GCACTGATCT	AGACGGGAGT	GACAAGAGCC
V D L	D S L	C T S V	Q Q S	L R G	G T D L	D G S	D K S
1370	1380	1390	1400	1410	1420	1430	1440
ACAAAGGTGC	GAAGGGAGAC	AAAGCTGGCA	GAGACAAAAA	GCAGATTCAG	ACCTCCCCGG	TGCCTGTCCG	CAAGAATAGC
H K G A	K G D	K A G	R D K K	Q I Q	T S P	V P V R	K N S
1450	1460	1470	1480	1490	1500	1510	1520
AGAGATGAAG	AGAAGAGAGA	GTCTCGCATC	AAGAGTTACT	CCCCTTATGC	CTTCAAATTC	TTCATGGAGC	AACACGTGGA
R D E	E K R E	S R I	K S Y	S P Y A	F K F	F M E	Q H V E
1530	1540	1550	1560	1570	1580	1590	1600
GAATGTCATC	AAAACCTACC	AGCAGAAGGT	CAGCCGGAGG	CTACAGCTGG	AGCAGGAAAT	GGCCAAAGCT	GGGCTCTGTG
N V I	K T Y	Q Q K V	S R R	L Q L	E Q E M	A K A	G L C
1610	1620	1630	1640	1650	1660	1670	1680
AGGCCGAGCA	GGAGCAGATG	AGGAAGATCC	TCTACCAGAA	GGAGTCTAAC	TACAACCGGC	TGAAGAGGGC	CAAGATGGAC
E A E Q	E Q M	R K I	L Y Q K	E S N	Y N R	L K R A	K M D
1690	1700	1710	1720	1730	1740	1750	1760
AAGTCCATGT	TTGTGAAAAT	CAAGACTCTA	GGCATCGGTG	CCTTTGGGGA	AGTGTGCCTC	GCTTGTAAGC	TGGACACTCA
K S M	F V K I	K T L	G I G	A F G E	V C L	A C K	L D T H
1770	1780	1790	1800	1810	1820	1830	1840
CGCTCTGTAC	GCCATGAAGA	CTCTCAGGAA	GAAGGATGTC	CTGAACCGGA	ATCAAGTGGC	CCATGTCAAG	GCTGAGAGGG
A L Y	A M K	T L R K	K D V	L N R	N Q V A	H V K	A E R
1850	1860	1870	1880	1890	1900	1910	1920
ACATCCTGGC	TGAAGCAGAC	AATGAGTGGG	TGGTCAAACCT	CTACTACTCC	TTCCAGGACA	AGGACAGCCT	GTACTTTGTG
D I L A	E A D	N E W	V V K L	Y Y S	F Q D	K D S L	Y F V
1930	1940	1950	1960	1970	1980	1990	2000

FIG. 14 (cont.)

**THIS PAGE BLANK (USPTO)**



970 980 990 1000 1010 1020 1030 1040  
\* \* \* \* \*  
AGGACCAACT CCTTCAACAA CCCACAACCT GAGCCCTCAC TGCCCGCCCC CAACACGGTC ACCGCCGTGA CGGCCGCACA  
R T N S F N N P Q P E P S L P A P N T V T A V T A A H

1050 1060 1070 1080 1090 1100 1110 1120  
\* \* \* \* \*  
CATCCTTCAC CCTGTGAAGA GCGTGCCTGT GCTGCGGCCC GAGCCCCAGA CAGCCGTGGG GCCCTCGCAC CCCGCCTGGG  
I L H P V K S V R V L R P E P Q T A V G P S H P A W

1130 1140 1150 1160 1170 1180 1190 1200  
\* \* \* \* \*  
TGGCTGCGCC CACAGCACCT GCCACTGAGA GCCTGGAGAC GAAGGAGGGC AGCGCAGGCC CACACCCGCT GGATGTGGAC  
V A A P T A P A T E S L E T K E G S A G P H P L D V D

1210 1220 1230 1240 1250 1260 1270 1280  
\* \* \* \* \*  
TATGGCGGCT CCGAGCGCAG GTGCCACCG CCTCCGTATC CAAAGCACCT GCTGCTGCCC AGTAAGTCTG AGCAGTACAG  
Y G G S E R R C P P P P Y P K H L L L P S K S E Q Y S

1290 1300 1310 1320 1330 1340 1350 1360  
\* \* \* \* \*  
CGTGGACCTG GACAGCCTGT GCACCACTGT GCAGCAGAGT CTGCGAGGGG GCACTGATCT AGACGGGAGT GACAAGAGCC  
V D L D S L C T S V Q Q S L R G G T D L D G S D K S

1370 1380 1390 1400 1410 1420 1430 1440  
\* \* \* \* \*  
ACAAAGGTGC GAAGGGAGAC AAAGCTGGCA GAGACAAAA GCAGATTTCAG ACCTCCCCGG TGCTGTCCG CAAGAATAGC  
H K G A K G D K A G R D K K Q I Q T S P V P V R K N S

1450 1460 1470 1480 1490 1500 1510 1520  
\* \* \* \* \*  
AGAGATGAAG AGAAGAGAGA GTCTCGCATC AAGAGTTACT CCCCTTATGC CTTCAAATTC TTCTAGGAGC AACACGTGGA  
R D E E K R E S R I K S Y S P Y A F K F F M E Q H V E

1530 1540 1550 1560 1570 1580 1590 1600  
\* \* \* \* \*  
GAATGTCATC AAAACCTACC AGCAGAAGGT CAGCCGAGG CTACAGCTGG AGCAGGAAAT GGCCAAAGCT GGGCTCTGTG  
N V I K T Y Q Q K V S R R L Q L E Q E M A K A G L C

1610 1620 1630 1640 1650 1660 1670 1680  
\* \* \* \* \*  
AGGCCGAGCA GGAGCAGATG AGGAAGATCC TCTACCAGAA GGAGTCTAAC TACAACCGGC TGAAGAGGGC CAAGATGGAC  
E A E Q E Q M R K I L Y Q K E S N Y N R L K R A K M D

1690 1700 1710 1720 1730 1740 1750 1760  
\* \* \* \* \*  
AAGTCCATGT TTGTGAAAAT CAAGACTCTA GGCATCGGTG CCTTTGGGGA AGTGTGCCTC GCTTGTAAAGC TGGACACTCA  
K S M F V K I K T L G I G A F G E V C L A C K L D T H

1770 1780 1790 1800 1810 1820 1830 1840  
\* \* \* \* \*  
CGCTCTGTAC GCCATGAAGA CTCTCAGGAA GAAGGATGTC CTGAACCGGA ATCAAGTGGC CCATGTCAAG GCTGAGAGGG  
A L Y A M K T L R K K D V L N R N Q V A H V K A E R

1850 1860 1870 1880 1890 1900 1910 1920  
\* \* \* \* \*  
ACATCCTGGC TGAAGCAGAC AATGAGTGGG TGGTCAAACCT CTACTACTCC TTCCAGGACA AGGACAGCCT GTACTTTGTG  
D I L A E A D N E W V V K L Y Y S F Q D K D S L Y F V

1930 1940 1950 1960 1970 1980 1990 2000  
\* \* \* \* \*  
\* \* \* \* \*

FIG. 14 (cont.)

**THIS PAGE BLANK (USPTO)**

2970	2980	2990	3000	3010	3020	3030	3040
CTCGAGGAAA	CCCAAAATGA	GATTTCTTTT	CAGAAGACAA	ACTCAAGCTT	AGGAATCCTT	CATTTT TAGT	TCTGGTAAAT
3050	3060	3070	3080	3090	3100	3110	3120
GGGCAACAGG	AAGAGTCAAC	ATGATTTCAA	ATTAGCCCTC	TGAGGACCTT	CACTGCATTA	AAACAGTATT	TTTTAAAAAA
3130	3140	3150					
TTAGTACAGT	ATGGAAGAG	CAC TTATTTT	GGGGG				

FIG. 14 (cont.)

**THIS PAGE BLANK (USPTO)**




FIG. 15

**THIS PAGE BLANK (USPTO)**

## SEQUENCE LISTING

&lt;110&gt; Yale University

<120> TREATMENT AND PREVENTION OF CANCER AND PITUITARY  
DISORDERS WITH LATS PROTEINS, DERIVATIVES AND  
FRAGMENTS, AND LATS KNOCK-OUT ANIMAL MODELS

&lt;130&gt; 6523-020-228

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 8

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 3984

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (231) .. (3620)

&lt;400&gt; 1

```

acctttgggt tgctgggacg gactctggcc gcctcagcgt ccgcccctcag gcccgtggcc 60
gctgtccagg agctctgctc tcccctccag agttaattat ttatattgta aagaatttta 120
acagtcctgg ggacttcctt gaaggatcat tttcactttt gctcagaaga aagctctgga 180
tctatcaaat aaagaagtcc ttcgtgtggg ctacatatat agatgttttc atg aag      236
                                   Met Lys
                                   1

agg agt gaa aag cca gaa gga tat aga caa atg agg cct aag acc ttt      284
Arg Ser Glu Lys Pro Glu Gly Tyr Arg Gln Met Arg Pro Lys Thr Phe
      5              10              15

cct gcc agt aac tat act gtc agt agc cgg caa atg tta caa gaa att      332
Pro Ala Ser Asn Tyr Thr Val Ser Ser Arg Gln Met Leu Gln Glu Ile
      20              25              30

cgg gaa tcc ctt agg aat tta tct aaa cca tct gat gct gct aag gct      380
Arg Glu Ser Leu Arg Asn Leu Ser Lys Pro Ser Asp Ala Ala Lys Ala
      35              40              45              50

gag cat aac atg agt aaa atg tca acc gaa gat cct cga caa gtc aga      428
Glu His Asn Met Ser Lys Met Ser Thr Glu Asp Pro Arg Gln Val Arg
              55              60              65

aat cca ccc aaa ttt ggg acg cat cat aaa gcc ttg cag gaa att cga      476
Asn Pro Pro Lys Phe Gly Thr His His Lys Ala Leu Gln Glu Ile Arg
      70              75              80

```

**THIS PAGE BLANK (USPTO)**



aac tct ctg ctt cca ttt gca aat gaa aca aat tct tct cgg agt act	524
Asn Ser Leu Leu Pro Phe Ala Asn Glu Thr Asn Ser Ser Arg Ser Thr	
85 90 95	
tca gaa gtt aat cca caa atg ctt caa gac ttg caa gct gct gga ttt	572
Ser Glu Val Asn Pro Gln Met Leu Gln Asp Leu Gln Ala Ala Gly Phe	
100 105 110	
gat gag gat atg gtt ata caa gct ctt cag aaa act aac aac aga agt	620
Asp Glu Asp Met Val Ile Gln Ala Leu Gln Lys Thr Asn Asn Arg Ser	
115 120 125 130	
ata gaa gca gca att gaa ttc att agt aaa atg agt tac caa gat cct	668
Ile Glu Ala Ala Ile Glu Phe Ile Ser Lys Met Ser Tyr Gln Asp Pro	
135 140 145	
cga cga gag cag atg gct gca gca gct gcc aga cct att aat gcc agc	716
Arg Arg Glu Gln Met Ala Ala Ala Ala Ala Arg Pro Ile Asn Ala Ser	
150 155 160	
atg aaa cca ggg aat gtg cag caa tca gtt aac cgc aaa cag agc tgg	764
Met Lys Pro Gly Asn Val Gln Gln Ser Val Asn Arg Lys Gln Ser Trp	
165 170 175	
aaa ggt tct aaa gaa tcc tta gtt cct cag agg cat ggc ccg cca cta	812
Lys Gly Ser Lys Glu Ser Leu Val Pro Gln Arg His Gly Pro Pro Leu	
180 185 190	
gga gaa agt gtg gcc tat cat tct gag agt ccc aac tca cag aca gat	860
Gly Glu Ser Val Ala Tyr His Ser Glu Ser Pro Asn Ser Gln Thr Asp	
195 200 205 210	
gta gga aga cct ttg tct gga tct ggt ata tca gca ttt gtt caa gct	908
Val Gly Arg Pro Leu Ser Gly Ser Gly Ile Ser Ala Phe Val Gln Ala	
215 220 225	
cac cct agc aac gga cag aga gtg aac ccc cca cca cca cct caa gta	956
His Pro Ser Asn Gly Gln Arg Val Asn Pro Pro Pro Pro Pro Gln Val	
230 235 240	
agg agt gtt act cct cca cca cct cca aga ggc cag act ccc cct cca	1004
Arg Ser Val Thr Pro Pro Pro Pro Pro Arg Gly Gln Thr Pro Pro Pro	
245 250 255	
aga ggt aca act cca cct ccc cct tca tgg gaa cca aac tct caa aca	1052
Arg Gly Thr Thr Pro Pro Pro Pro Ser Trp Glu Pro Asn Ser Gln Thr	
260 265 270	
aag cgc tat tct gga aac atg gaa tac gta atc tcc cga atc tct cct	1100
Lys Arg Tyr Ser Gly Asn Met Glu Tyr Val Ile Ser Arg Ile Ser Pro	
275 280 285 290	
gtc cca cct ggg gca tgg caa gag ggc tat cct cca cca cct ctc aac	1148
Val Pro Pro Gly Ala Trp Gln Glu Gly Tyr Pro Pro Pro Pro Leu Asn	
295 300 305	

**THIS PAGE BLANK (USPTO)**

act tcc ccc atg aat cct cct aat caa gga cag aga ggc att agt tct	1196
Thr Ser Pro Met Asn Pro Pro Asn Gln Gly Gln Arg Gly Ile Ser Ser	
310 315 320	
gtt cct gtt ggc aga caa cca atc atc atg cag agt tct agc aaa ttt	1244
Val Pro Val Gly Arg Gln Pro Ile Ile Met Gln Ser Ser Ser Lys Phe	
325 330 335	
aac ttt cca tca ggg aga cct gga atg cag aat ggt act gga caa act	1292
Asn Phe Pro Ser Gly Arg Pro Gly Met Gln Asn Gly Thr Gly Gln Thr	
340 345 350	
gat ttc atg ata cac caa aat gtt gtc cct gct ggc act gtg aat cgg	1340
Asp Phe Met Ile His Gln Asn Val Val Pro Ala Gly Thr Val Asn Arg	
355 360 365 370	
cag cca cca cct cca tat cct ctg aca gca gct aat gga caa agc cct	1388
Gln Pro Pro Pro Pro Tyr Pro Leu Thr Ala Ala Asn Gly Gln Ser Pro	
375 380 385	
tct gct tta caa aca ggg gga tct gct gct cct tcg tca tat aca aat	1436
Ser Ala Leu Gln Thr Gly Gly Ser Ala Ala Pro Ser Ser Tyr Thr Asn	
390 395 400	
gga agt att cct cag tct atg atg gtg cca aac aga aat agt cat aac	1484
Gly Ser Ile Pro Gln Ser Met Met Val Pro Asn Arg Asn Ser His Asn	
405 410 415	
atg gaa cta tat aac att agt gta cct gga ctg caa aca aat tgg cct	1532
Met Glu Leu Tyr Asn Ile Ser Val Pro Gly Leu Gln Thr Asn Trp Pro	
420 425 430	
cag tca tct tct gct cca gcc cag tca tcc ccg agc agt ggg cat gaa	1580
Gln Ser Ser Ser Ala Pro Ala Gln Ser Ser Pro Ser Ser Gly His Glu	
435 440 445 450	
atc cct aca tgg caa cct aac ata cca gtg agg tca aat tct ttt aat	1628
Ile Pro Thr Trp Gln Pro Asn Ile Pro Val Arg Ser Asn Ser Phe Asn	
455 460 465	
aac cca tta gga aat aga gca agt cac tct gct aat tct cag cct tct	1676
Asn Pro Leu Gly Asn Arg Ala Ser His Ser Ala Asn Ser Gln Pro Ser	
470 475 480	
gct aca aca gtc act gca att aca cca gct cct att caa cag cct gtg	1724
Ala Thr Thr Val Thr Ala Ile Thr Pro Ala Pro Ile Gln Gln Pro Val	
485 490 495	
aaa agt atg cgt gta tta aaa cca gag cta cag act gct tta gca cct	1772
Lys Ser Met Arg Val Leu Lys Pro Glu Leu Gln Thr Ala Leu Ala Pro	
500 505 510	
aca cac cct tct tgg ata cca cag cca att caa act gtt caa ccc agt	1820
Thr His Pro Ser Trp Ile Pro Gln Pro Ile Gln Thr Val Gln Pro Ser	
515 520 525 530	

**THIS PAGE BLANK (USPTO)**

cct ttt cct gag gga acc gct tca aat gtg act gtg atg cca cct gtt	1868
Pro Phe Pro Glu Gly Thr Ala Ser Asn Val Thr Val Met Pro Pro Val	
535 540 545	
gct gaa gct cca aac tat caa gga cca cca cca ccc tac cca aaa cat	1916
Ala Glu Ala Pro Asn Tyr Gln Gly Pro Pro Pro Pro Tyr Pro Lys His	
550 555 560	
ctg ctg cac caa aac cca tct gtt cct cca tac gag tca atc agt aag	1964
Leu Leu His Gln Asn Pro Ser Val Pro Pro Tyr Glu Ser Ile Ser Lys	
565 570 575	
cct agc aaa gag gat cag cca agc ttg ccc aag gaa gat gag agt gaa	2012
Pro Ser Lys Glu Asp Gln Pro Ser Leu Pro Lys Glu Asp Glu Ser Glu	
580 585 590	
aag agt tat gaa aat gtt gat agt ggg gat aaa gaa aag aaa cag att	2060
Lys Ser Tyr Glu Asn Val Asp Ser Gly Asp Lys Glu Lys Lys Gln Ile	
595 600 605 610	
aca act tca cct att act gtt agg aaa aac aag aaa gat gaa gag cga	2108
Thr Thr Ser Pro Ile Thr Val Arg Lys Asn Lys Lys Asp Glu Glu Arg	
615 620 625	
agg gaa tct cgt att caa agt tat tct cct caa gca ttt aaa ttc ttt	2156
Arg Glu Ser Arg Ile Gln Ser Tyr Ser Pro Gln Ala Phe Lys Phe Phe	
630 635 640	
atg gag caa cat gta gaa aat gta ctc aaa tct cat cag cag cgt cta	2204
Met Glu Gln His Val Glu Asn Val Leu Lys Ser His Gln Gln Arg Leu	
645 650 655	
cat cgt aaa aaa caa tta gag aat gaa atg atg cgg gtt gga tta tct	2252
His Arg Lys Lys Gln Leu Glu Asn Glu Met Met Arg Val Gly Leu Ser	
660 665 670	
caa gat gcc cag gat caa atg aga aag atg ctt tgc caa aaa gaa tct	2300
Gln Asp Ala Gln Asp Gln Met Arg Lys Met Leu Cys Gln Lys Glu Ser	
675 680 685 690	
aat tac atc cgt ctt aaa agg gct aaa atg gac aag tct atg ttt gtg	2348
Asn Tyr Ile Arg Leu Lys Arg Ala Lys Met Asp Lys Ser Met Phe Val	
695 700 705	
aag ata aag aca cta gga ata gga gca ttt ggt gaa gtc tgt cta gca	2396
Lys Ile Lys Thr Leu Gly Ile Gly Ala Phe Gly Glu Val Cys Leu Ala	
710 715 720	
aga aaa gta gat act aag gct ttg tat gca aca aaa act ctt cga aag	2444
Arg Lys Val Asp Thr Lys Ala Leu Tyr Ala Thr Lys Thr Leu Arg Lys	
725 730 735	
aaa gat gtt ctt ctt cga aat caa gtc gct cat gtt aag gct gag aga	2492
Lys Asp Val Leu Leu Arg Asn Gln Val Ala His Val Lys Ala Glu Arg	
740 745 750	

**THIS PAGE BLANK (USPTO)**

gat atc ctg gct gaa gct gac aat gaa tgg gta gtt cgt cta tat tat	2540
Asp Ile Leu Ala Glu Ala Asp Asn Glu Trp Val Val Arg Leu Tyr Tyr	
755 760 765 770	
tca ttc caa gat aag gac aat tta tac ttt gta atg gac tac att cct	2588
Ser Phe Gln Asp Lys Asp Asn Leu Tyr Phe Val Met Asp Tyr Ile Pro	
775 780 785	
ggg ggt gat atg atg agc cta tta att aga atg ggc atc ttt cca gaa	2636
Gly Gly Asp Met Met Ser Leu Leu Ile Arg Met Gly Ile Phe Pro Glu	
790 795 800	
agt ctg gca cga ttc tac ata gca gaa ctt acc tgt gca gtt gaa agt	2684
Ser Leu Ala Arg Phe Tyr Ile Ala Glu Leu Thr Cys Ala Val Glu Ser	
805 810 815	
gtt cat aaa atg ggt ttt att cat aga gat att aaa cct gat aat att	2732
Val His Lys Met Gly Phe Ile His Arg Asp Ile Lys Pro Asp Asn Ile	
820 825 830	
ttg att gat cgt gat ggt cat att aaa ttg act gac ttt ggc ctc tgc	2780
Leu Ile Asp Arg Asp Gly His Ile Lys Leu Thr Asp Phe Gly Leu Cys	
835 840 845 850	
act ggc ttc aga tgg aca cac gat tct aag tac tat cag agt ggt gac	2828
Thr Gly Phe Arg Trp Thr His Asp Ser Lys Tyr Tyr Gln Ser Gly Asp	
855 860 865	
cat cca cgg caa gat agc atg gat ttc agt aat gaa tgg ggg gat ccc	2876
His Pro Arg Gln Asp Ser Met Asp Phe Ser Asn Glu Trp Gly Asp Pro	
870 875 880	
tca agc tgt cga tgt gga gac aga ctg aag cca tta gag cgg aga gct	2924
Ser Ser Cys Arg Cys Gly Asp Arg Leu Lys Pro Leu Glu Arg Arg Ala	
885 890 895	
gca cgc cag cac cag cga tgt cta gca cat tct ttg gtt ggg act ccc	2972
Ala Arg Gln His Gln Arg Cys Leu Ala His Ser Leu Val Gly Thr Pro	
900 905 910	
aat tat att gca cct gaa gtg ttg cta cga aca gga tac aca cag ttg	3020
Asn Tyr Ile Ala Pro Glu Val Leu Leu Arg Thr Gly Tyr Thr Gln Leu	
915 920 925 930	
tgt gat tgg tgg agt gtt ggt gtt att ctt ttt gaa atg ttg gtg gga	3068
Cys Asp Trp Trp Ser Val Gly Val Ile Leu Phe Glu Met Leu Val Gly	
935 940 945	
caa cct cct ttc ttg gca caa aca cca tta gaa aca caa atg aag gtt	3116
Gln Pro Pro Phe Leu Ala Gln Thr Pro Leu Glu Thr Gln Met Lys Val	
950 955 960	
atc aac tgg caa aca tct ctt cac att cca cca caa gct aaa ctc agt	3164
Ile Asn Trp Gln Thr Ser Leu His Ile Pro Pro Gln Ala Lys Leu Ser	
965 970 975	

**THIS PAGE BLANK (USPTO)**



```

cct gaa gct tct gat ctt att att aaa ctt tgc cga gga ccc gaa gat 3212
Pro Glu Ala Ser Asp Leu Ile Ile Lys Leu Cys Arg Gly Pro Glu Asp
    980                985                990

cgc tta ggc aag aat ggt gct gat gaa ata aaa gct cat cca ttt ttt 3260
Arg Leu Gly Lys Asn Gly Ala Asp Glu Ile Lys Ala His Pro Phe Phe
    995                1000                1005                1010

aaa aca att gac ttc tcc agt gac ctg aga cag cag tct gct tca tac 3308
Lys Thr Ile Asp Phe Ser Ser Asp Leu Arg Gln Gln Ser Ala Ser Tyr
                1015                1020                1025

att cct aaa atc aca cac cca aca gat aca tca aat ttt gat cct gtt 3356
Ile Pro Lys Ile Thr His Pro Thr Asp Thr Ser Asn Phe Asp Pro Val
                1030                1035                1040

gat cct gat aaa tta tgg agt gat gat aac gag gaa gaa aat gta aat 3404
Asp Pro Asp Lys Leu Trp Ser Asp Asp Asn Glu Glu Glu Asn Val Asn
                1045                1050                1055

gac act ctc aat gga tgg tat aaa aat gga aag cat cct gaa cat gca 3452
Asp Thr Leu Asn Gly Trp Tyr Lys Asn Gly Lys His Pro Glu His Ala
    1060                1065                1070

ttc tat gaa ttt acc ttc cga agg ttt ttt gat gac aat ggc tac cca 3500
Phe Tyr Glu Phe Thr Phe Arg Arg Phe Phe Asp Asp Asn Gly Tyr Pro
    1075                1080                1085                1090

tat aat tat ccg aag cct att gaa tat gaa tac att aat tca caa ggc 3548
Tyr Asn Tyr Pro Lys Pro Ile Glu Tyr Glu Tyr Ile Asn Ser Gln Gly
                1095                1100                1105

tca gag cag cag tcg gat gaa gat gat caa aac aca ggc tca gag att 3596
Ser Glu Gln Gln Ser Asp Glu Asp Asp Gln Asn Thr Gly Ser Glu Ile
                1110                1115                1120

aaa aat cgc gat cta gta tat gtt taacacacta gtaaataaat gtaatgagga 3650
Lys Asn Arg Asp Leu Val Tyr Val
    1125                1130

tttgtaaaag ggccctgaaat gcgagggtgtt ttgagggttct gagagtaaaa ttatgcaaatt 3710

atgacagagc tatatatgtg tgctctgtgt acaatatattt attttcctaa attatgggaa 3770

atccttttaa aatgttaatt tattccagcc gtttaaataca gtatttagaa aaaaattggt 3830

ataaggaaag taaattatga actgaatatt atagtcagtt cttggtactt aaagtactta 3890

aaataagtag tgctttgttt aaaaggagaa acctggtatc tatttggtata tatgctaaat 3950

aattttaaaa tacaagagtt tttgaaattt tttt 3984

```

&lt;210&gt; 2

&lt;211&gt; 1130

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

**THIS PAGE BLANK (USPTO)**

<400> 2  
Met Lys Arg Ser Glu Lys Pro Glu Gly Tyr Arg Gln Met Arg Pro Lys  
1 5 10 15  
Thr Phe Pro Ala Ser Asn Tyr Thr Val Ser Ser Arg Gln Met Leu Gln  
20 25 30  
Glu Ile Arg Glu Ser Leu Arg Asn Leu Ser Lys Pro Ser Asp Ala Ala  
35 40 45  
Lys Ala Glu His Asn Met Ser Lys Met Ser Thr Glu Asp Pro Arg Gln  
50 55 60  
Val Arg Asn Pro Pro Lys Phe Gly Thr His His Lys Ala Leu Gln Glu  
65 70 75 80  
Ile Arg Asn Ser Leu Leu Pro Phe Ala Asn Glu Thr Asn Ser Ser Arg  
85 90 95  
Ser Thr Ser Glu Val Asn Pro Gln Met Leu Gln Asp Leu Gln Ala Ala  
100 105 110  
Gly Phe Asp Glu Asp Met Val Ile Gln Ala Leu Gln Lys Thr Asn Asn  
115 120 125  
Arg Ser Ile Glu Ala Ala Ile Glu Phe Ile Ser Lys Met Ser Tyr Gln  
130 135 140  
Asp Pro Arg Arg Glu Gln Met Ala Ala Ala Ala Arg Pro Ile Asn  
145 150 155 160  
Ala Ser Met Lys Pro Gly Asn Val Gln Gln Ser Val Asn Arg Lys Gln  
165 170 175  
Ser Trp Lys Gly Ser Lys Glu Ser Leu Val Pro Gln Arg His Gly Pro  
180 185 190  
Pro Leu Gly Glu Ser Val Ala Tyr His Ser Glu Ser Pro Asn Ser Gln  
195 200 205  
Thr Asp Val Gly Arg Pro Leu Ser Gly Ser Gly Ile Ser Ala Phe Val  
210 215 220  
Gln Ala His Pro Ser Asn Gly Gln Arg Val Asn Pro Pro Pro Pro Pro  
225 230 235 240  
Gln Val Arg Ser Val Thr Pro Pro Pro Pro Pro Arg Gly Gln Thr Pro  
245 250 255  
Pro Pro Arg Gly Thr Thr Pro Pro Pro Pro Ser Trp Glu Pro Asn Ser  
260 265 270  
Gln Thr Lys Arg Tyr Ser Gly Asn Met Glu Tyr Val Ile Ser Arg Ile  
275 280 285  
Ser Pro Val Pro Pro Gly Ala Trp Gln Glu Gly Tyr Pro Pro Pro Pro  
290 295 300

**THIS PAGE BLANK (USPTO)**

Leu Asn Thr Ser Pro Met Asn Pro Pro Asn Gln Gly Gln Arg Gly Ile  
 305 310 315 320  
 Ser Ser Val Pro Val Gly Arg Gln Pro Ile Ile Met Gln Ser Ser Ser  
 325 330 335  
 Lys Phe Asn Phe Pro Ser Gly Arg Pro Gly Met Gln Asn Gly Thr Gly  
 340 345 350  
 Gln Thr Asp Phe Met Ile His Gln Asn Val Val Pro Ala Gly Thr Val  
 355 360 365  
 Asn Arg Gln Pro Pro Pro Pro Tyr Pro Leu Thr Ala Ala Asn Gly Gln  
 370 375 380  
 Ser Pro Ser Ala Leu Gln Thr Gly Gly Ser Ala Ala Pro Ser Ser Tyr  
 385 390 395 400  
 Thr Asn Gly Ser Ile Pro Gln Ser Met Met Val Pro Asn Arg Asn Ser  
 405 410 415  
 His Asn Met Glu Leu Tyr Asn Ile Ser Val Pro Gly Leu Gln Thr Asn  
 420 425 430  
 Trp Pro Gln Ser Ser Ser Ala Pro Ala Gln Ser Ser Pro Ser Ser Gly  
 435 440 445  
 His Glu Ile Pro Thr Trp Gln Pro Asn Ile Pro Val Arg Ser Asn Ser  
 450 455 460  
 Phe Asn Asn Pro Leu Gly Asn Arg Ala Ser His Ser Ala Asn Ser Gln  
 465 470 475 480  
 Pro Ser Ala Thr Thr Val Thr Ala Ile Thr Pro Ala Pro Ile Gln Gln  
 485 490 495  
 Pro Val Lys Ser Met Arg Val Leu Lys Pro Glu Leu Gln Thr Ala Leu  
 500 505 510  
 Ala Pro Thr His Pro Ser Trp Ile Pro Gln Pro Ile Gln Thr Val Gln  
 515 520 525  
 Pro Ser Pro Phe Pro Glu Gly Thr Ala Ser Asn Val Thr Val Met Pro  
 530 535 540  
 Pro Val Ala Glu Ala Pro Asn Tyr Gln Gly Pro Pro Pro Pro Tyr Pro  
 545 550 555 560  
 Lys His Leu Leu His Gln Asn Pro Ser Val Pro Pro Tyr Glu Ser Ile  
 565 570 575  
 Ser Lys Pro Ser Lys Glu Asp Gln Pro Ser Leu Pro Lys Glu Asp Glu  
 580 585 590  
 Ser Glu Lys Ser Tyr Glu Asn Val Asp Ser Gly Asp Lys Glu Lys Lys  
 595 600 605

**THIS PAGE BLANK (USPTO)**

Gln Ile Thr Thr Ser Pro Ile Thr Val Arg Lys Asn Lys Lys Asp Glu  
 610 615 620  
 Glu Arg Arg Glu Ser Arg Ile Gln Ser Tyr Ser Pro Gln Ala Phe Lys  
 625 630 635 640  
 Phe Phe Met Glu Gln His Val Glu Asn Val Leu Lys Ser His Gln Gln  
 645 650 655  
 Arg Leu His Arg Lys Lys Gln Leu Glu Asn Glu Met Met Arg Val Gly  
 660 665 670  
 Leu Ser Gln Asp Ala Gln Asp Gln Met Arg Lys Met Leu Cys Gln Lys  
 675 680 685  
 Glu Ser Asn Tyr Ile Arg Leu Lys Arg Ala Lys Met Asp Lys Ser Met  
 690 695 700  
 Phe Val Lys Ile Lys Thr Leu Gly Ile Gly Ala Phe Gly Glu Val Cys  
 705 710 715 720  
 Leu Ala Arg Lys Val Asp Thr Lys Ala Leu Tyr Ala Thr Lys Thr Leu  
 725 730 735  
 Arg Lys Lys Asp Val Leu Leu Arg Asn Gln Val Ala His Val Lys Ala  
 740 745 750  
 Glu Arg Asp Ile Leu Ala Glu Ala Asp Asn Glu Trp Val Val Arg Leu  
 755 760 765  
 Tyr Tyr Ser Phe Gln Asp Lys Asp Asn Leu Tyr Phe Val Met Asp Tyr  
 770 775 780  
 Ile Pro Gly Gly Asp Met Met Ser Leu Leu Ile Arg Met Gly Ile Phe  
 785 790 795 800  
 Pro Glu Ser Leu Ala Arg Phe Tyr Ile Ala Glu Leu Thr Cys Ala Val  
 805 810 815  
 Glu Ser Val His Lys Met Gly Phe Ile His Arg Asp Ile Lys Pro Asp  
 820 825 830  
 Asn Ile Leu Ile Asp Arg Asp Gly His Ile Lys Leu Thr Asp Phe Gly  
 835 840 845  
 Leu Cys Thr Gly Phe Arg Trp Thr His Asp Ser Lys Tyr Tyr Gln Ser  
 850 855 860  
 Gly Asp His Pro Arg Gln Asp Ser Met Asp Phe Ser Asn Glu Trp Gly  
 865 870 875 880  
 Asp Pro Ser Ser Cys Arg Cys Gly Asp Arg Leu Lys Pro Leu Glu Arg  
 885 890 895  
 Arg Ala Ala Arg Gln His Gln Arg Cys Leu Ala His Ser Leu Val Gly  
 900 905 910

**THIS PAGE BLANK (USPTO)**



Thr Pro Asn Tyr Ile Ala Pro Glu Val Leu Leu Arg Thr Gly Tyr Thr  
 915 920 925  
 Gln Leu Cys Asp Trp Trp Ser Val Gly Val Ile Leu Phe Glu Met Leu  
 930 935 940  
 Val Gly Gln Pro Pro Phe Leu Ala Gln Thr Pro Leu Glu Thr Gln Met  
 945 950 955 960  
 Lys Val Ile Asn Trp Gln Thr Ser Leu His Ile Pro Pro Gln Ala Lys  
 965 970 975  
 Leu Ser Pro Glu Ala Ser Asp Leu Ile Ile Lys Leu Cys Arg Gly Pro  
 980 985 990  
 Glu Asp Arg Leu Gly Lys Asn Gly Ala Asp Glu Ile Lys Ala His Pro  
 995 1000 1005  
 Phe Phe Lys Thr Ile Asp Phe Ser Ser Asp Leu Arg Gln Gln Ser Ala  
 1010 1015 1020  
 Ser Tyr Ile Pro Lys Ile Thr His Pro Thr Asp Thr Ser Asn Phe Asp  
 1025 1030 1035 1040  
 Pro Val Asp Pro Asp Lys Leu Trp Ser Asp Asp Asn Glu Glu Glu Asn  
 1045 1050 1055  
 Val Asn Asp Thr Leu Asn Gly Trp Tyr Lys Asn Gly Lys His Pro Glu  
 1060 1065 1070  
 His Ala Phe Tyr Glu Phe Thr Phe Arg Arg Phe Phe Asp Asp Asn Gly  
 1075 1080 1085  
 Tyr Pro Tyr Asn Tyr Pro Lys Pro Ile Glu Tyr Glu Tyr Ile Asn Ser  
 1090 1095 1100  
 Gln Gly Ser Glu Gln Gln Ser Asp Glu Asp Asp Gln Asn Thr Gly Ser  
 1105 1110 1115 1120  
 Glu Ile Lys Asn Arg Asp Leu Val Tyr Val  
 1125 1130

<210> 3  
 <211> 3213  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> CDS  
 <222> (1)..(2886)

<400> 3  
 gtg caa cat tca att aac cga aaa caa agc tgg aaa ggt tct aaa gag 48  
 Val Gln His Ser Ile Asn Arg Lys Gln Ser Trp Lys Gly Ser Lys Glu  
 1 5 10 15

**THIS PAGE BLANK (USPTO)**

tct cta gtt cct cag aga cac ggc cca tct cta gga gaa aat gtg gtt	96
Ser Leu Val Pro Gln Arg His Gly Pro Ser Leu Gly Glu Asn Val Val	
20 25 30	
tat cgt tct gaa agc ccc aac tca cag gcg gat gta gga aga cct ctg	144
Tyr Arg Ser Glu Ser Pro Asn Ser Gln Ala Asp Val Gly Arg Pro Leu	
35 40 45	
tct gga tcc ggc att gca gca ttt gct caa gct cac cca agc aat gga	192
Ser Gly Ser Gly Ile Ala Ala Phe Ala Gln Ala His Pro Ser Asn Gly	
50 55 60	
cag aga gtg aac ccc cca cca cca cct caa gtt agg agt gtt act cct	240
Gln Arg Val Asn Pro Pro Pro Pro Gln Val Arg Ser Val Thr Pro	
65 70 75 80	
cca cca cct ccg aga ggc cag acc cca cct ccc cga ggc acc act ccc	288
Pro Pro Pro Pro Arg Gly Gln Thr Pro Pro Pro Arg Gly Thr Thr Pro	
85 90 95	
cct ccc ccc tca tgg gaa cca agc tct cag aca aag cgc tac tct ggg	336
Pro Pro Pro Ser Trp Glu Pro Ser Ser Gln Thr Lys Arg Tyr Ser Gly	
100 105 110	
aac atg gag tac gta atc tcc cga atc tcc cct gtt cca cct ggg gcg	384
Asn Met Glu Tyr Val Ile Ser Arg Ile Ser Pro Val Pro Pro Gly Ala	
115 120 125	
tgg cag gag ggg tac cct cca cca cct ctt acc act tct ccc atg aat	432
Trp Gln Glu Gly Tyr Pro Pro Pro Pro Leu Thr Thr Ser Pro Met Asn	
130 135 140	
ccc cct agc cag gct cag agg gcc att agt tct gtt cca gtt ggt aga	480
Pro Pro Ser Gln Ala Gln Arg Ala Ile Ser Ser Val Pro Val Gly Arg	
145 150 155 160	
caa ccc atc atc atg cag agt act agc aaa ttt aac ttt aca cca ggg	528
Gln Pro Ile Ile Met Gln Ser Thr Ser Lys Phe Asn Phe Thr Pro Gly	
165 170 175	
cga cct gga gtt cag aat ggt ggt ggt cag tct gat ttt atc gtg cac	576
Arg Pro Gly Val Gln Asn Gly Gly Gly Gln Ser Asp Phe Ile Val His	
180 185 190	
caa aat gtc ccc act ggt tct gtg act cgg cag cca cca cct cca tat	624
Gln Asn Val Pro Thr Gly Ser Val Thr Arg Gln Pro Pro Pro Pro Tyr	
195 200 205	
cct ctg acc cca gct aat gga caa agc ccc tct gct tta caa aca ggg	672
Pro Leu Thr Pro Ala Asn Gly Gln Ser Pro Ser Ala Leu Gln Thr Gly	
210 215 220	
gct tct gct gct cca cca tca ttc gcc aat gga aac gtt cct cag tcg	720
Ala Ser Ala Ala Pro Pro Ser Phe Ala Asn Gly Asn Val Pro Gln Ser	
225 230 235 240	

**THIS PAGE BLANK (USPTO)**

atg atg gtg ccc aac agg aac agt cat aac atg gag ctt tat aat att	768
Met Met Val Pro Asn Arg Asn Ser His Asn Met Glu Leu Tyr Asn Ile	
245 250 255	
aat gtc cct gga ctg caa aca gcc tgg ccc cag tcg tct tct gct cct	816
Asn Val Pro Gly Leu Gln Thr Ala Trp Pro Gln Ser Ser Ser Ala Pro	
260 265 270	
gcg cag tca tcc cca agc ggt ggg cat gaa att cct aca tgg caa cct	864
Ala Gln Ser Ser Pro Ser Gly Gly His Glu Ile Pro Thr Trp Gln Pro	
275 280 285	
aac ata cca gtg agg tca aat tct ttt aat aac cca tta gga agt aga	912
Asn Ile Pro Val Arg Ser Asn Ser Phe Asn Asn Pro Leu Gly Ser Arg	
290 295 300	
gca agt cac tct gct aat tct cag cct tct gcc act aca gtc act gcc	960
Ala Ser His Ser Ala Asn Ser Gln Pro Ser Ala Thr Thr Val Thr Ala	
305 310 315 320	
atc aca ccc gct cct att caa cag ccc gtg aaa agc atg cgc gtc ctg	1008
Ile Thr Pro Ala Pro Ile Gln Gln Pro Val Lys Ser Met Arg Val Leu	
325 330 335	
aaa cca gag ctg cag act gct tta gcc cca acc cat cct tct tgg atg	1056
Lys Pro Glu Leu Gln Thr Ala Leu Ala Pro Thr His Pro Ser Trp Met	
340 345 350	
cca cag cca gtt cag act gtt cag cct acc cct ttt tct gag ggt aca	1104
Pro Gln Pro Val Gln Thr Val Gln Pro Thr Pro Phe Ser Glu Gly Thr	
355 360 365	
gct tca agt gtg cct gtc atc cca cct gtt gct gaa gct cca agc tat	1152
Ala Ser Ser Val Pro Val Ile Pro Pro Val Ala Glu Ala Pro Ser Tyr	
370 375 380	
caa ggt cca cca ccg cct tat cca aaa cat ctg cta cac caa aac cca	1200
Gln Gly Pro Pro Pro Tyr Pro Lys His Leu Leu His Gln Asn Pro	
385 390 395 400	
tct gtc cct cca tat gag tca gta agt aag ccc tgc aaa gat gaa cag	1248
Ser Val Pro Pro Tyr Glu Ser Val Ser Lys Pro Cys Lys Asp Glu Gln	
405 410 415	
cct agc tta ccc aag gaa gat gat agt gag aag agt gcg gac agt ggt	1296
Pro Ser Leu Pro Lys Glu Asp Asp Ser Glu Lys Ser Ala Asp Ser Gly	
420 425 430	
gac tct ggg gat aaa gaa aag aaa cag att aca act tca cct atc act	1344
Asp Ser Gly Asp Lys Glu Lys Lys Gln Ile Thr Thr Ser Pro Ile Thr	
435 440 445	
gtt cgg aaa aac aag aaa gat gaa gaa cga aga gag tct cgg att cag	1392
Val Arg Lys Asn Lys Lys Asp Glu Glu Arg Arg Glu Ser Arg Ile Gln	
450 455 460	

**THIS PAGE BLANK (USPTO)**

agt tac tcc cca cag gcc ttt aag ttc ttc atg gag cag cac gta gag	1440
Ser Tyr Ser Pro Gln Ala Phe Lys Phe Phe Met Glu Gln His Val Glu	
465 470 475 480	
aac gtc ctg aag tct cat cag cag cgt ctg cat cgg aag aag cag cta	1488
Asn Val Leu Lys Ser His Gln Gln Arg Leu His Arg Lys Lys Gln Leu	
485 490 495	
gaa aat gaa atg atg cgg gtt gga tta tct caa gat gcc cag gat caa	1536
Glu Asn Glu Met Met Arg Val Gly Leu Ser Gln Asp Ala Gln Asp Gln	
500 505 510	
atg aga aag atg ctt tgc cag aaa gag tct aac tat att cgt ctt aaa	1584
Met Arg Lys Met Leu Cys Gln Lys Glu Ser Asn Tyr Ile Arg Leu Lys	
515 520 525	
agg gct aaa atg gac aag tct atg ttt gta aag ata aag aca tta gga	1632
Arg Ala Lys Met Asp Lys Ser Met Phe Val Lys Ile Lys Thr Leu Gly	
530 535 540	
ata gga gcg ttt ggt gaa gtc tgt cta gca aga aaa gtc gat act aaa	1680
Ile Gly Ala Phe Gly Glu Val Cys Leu Ala Arg Lys Val Asp Thr Lys	
545 550 555 560	
gct ttg tat gca aca aag act ctt cga aag aaa gac gtt ctg ctc cga	1728
Ala Leu Tyr Ala Thr Lys Thr Leu Arg Lys Lys Asp Val Leu Leu Arg	
565 570 575	
aat cag gtg gct cat gtg aaa gcg gag agg gat atc cta gca gaa gcc	1776
Asn Gln Val Ala His Val Lys Ala Glu Arg Asp Ile Leu Ala Glu Ala	
580 585 590	
gac aat gag tgg gtg gtc cgc ctg tac tac tct ttc cag gac aag gac	1824
Asp Asn Glu Trp Val Val Arg Leu Tyr Tyr Ser Phe Gln Asp Lys Asp	
595 600 605	
aac ttg tac ttt gtg atg gac tac att cct ggg ggg gat atg atg agc	1872
Asn Leu Tyr Phe Val Met Asp Tyr Ile Pro Gly Gly Asp Met Met Ser	
610 615 620	
cta tta att aga atg ggc atc ttt cct gaa aat ctg gca cga ttc tac	1920
Leu Leu Ile Arg Met Gly Ile Phe Pro Glu Asn Leu Ala Arg Phe Tyr	
625 630 635 640	
ata gca gaa ctt acc tgt gca gtt gaa agt gtt cat aaa atg ggt ttt	1968
Ile Ala Glu Leu Thr Cys Ala Val Glu Ser Val His Lys Met Gly Phe	
645 650 655	
att cat aga gat att aaa cct gat aac att ttg att gac cgt gat ggc	2016
Ile His Arg Asp Ile Lys Pro Asp Asn Ile Leu Ile Asp Arg Asp Gly	
660 665 670	
cat att aaa ttg act gac ttt ggc ttg tgc act ggc ttc aga tgg aca	2064
His Ile Lys Leu Thr Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp Thr	
675 680 685	

**THIS PAGE BLANK (USPTO)**



cat gac tcc aag tac tac cag agt ggg gat cac cca cgg caa gat agc His Asp Ser Lys Tyr Tyr Gln Ser Gly Asp His Pro Arg Gln Asp Ser 690 695 700	2112
atg gat ttc agt aac gaa tgg gga gat cct tcc aat tgt cgg tgt ggg Met Asp Phe Ser Asn Glu Trp Gly Asp Pro Ser Asn Cys Arg Cys Gly 705 710 715 720	2160
gac aga ctg aag cca ctg gag cgg aga gct gct cgc cag cac cag cga Asp Arg Leu Lys Pro Leu Glu Arg Arg Ala Ala Arg Gln His Gln Arg 725 730 735	2208
tgt cta gcc cat tct ctg gtt ggg act ccc aat tat att gca cct gaa Cys Leu Ala His Ser Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu 740 745 750	2256
gtg cta ctg cga aca gga tat aca cag ctg tgt gac tgg tgg agt gtt Val Leu Leu Arg Thr Gly Tyr Thr Gln Leu Cys Asp Trp Trp Ser Val 755 760 765	2304
ggg gtt att ctt tgt gaa atg ttg gtg gga caa cct cct ttc ttg gca Gly Val Ile Leu Cys Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala 770 775 780	2352
caa acc cca tta gaa aca caa atg aag gtt atc atc tgg caa act tct Gln Thr Pro Leu Glu Thr Gln Met Lys Val Ile Ile Trp Gln Thr Ser 785 790 795 800	2400
cta cac atc cct cct caa gct aag ctg agt cct gaa gcc tct gac ctc Leu His Ile Pro Pro Gln Ala Lys Leu Ser Pro Glu Ala Ser Asp Leu 805 810 815	2448
att atc aaa ctg tgt cga gga cca gaa gac cgc ctc ggc aag aac ggt Ile Ile Lys Leu Cys Arg Gly Pro Glu Asp Arg Leu Gly Lys Asn Gly 820 825 830	2496
gct gat gag ata aag gct cat cca ttt ttt aag acc atc gat ttc tct Ala Asp Glu Ile Lys Ala His Pro Phe Phe Lys Thr Ile Asp Phe Ser 835 840 845	2544
agt gat ctg aga cag cag tct gct tca tac atc cct aaa atc acg cat Ser Asp Leu Arg Gln Gln Ser Ala Ser Tyr Ile Pro Lys Ile Thr His 850 855 860	2592
cca aca gat aca tcc aat ttc gac cct gtt gat cct gat aaa ttg tgg Pro Thr Asp Thr Ser Asn Phe Asp Pro Val Asp Pro Asp Lys Leu Trp 865 870 875 880	2640
agc gat ggc agc gag gag gaa aat atc agt gac act ctg agc gga tgg Ser Asp Gly Ser Glu Glu Glu Asn Ile Ser Asp Thr Leu Ser Gly Trp 885 890 895	2688
tat aaa aat ggg aag cac ccc gag cac gct ttc tat gag ttc acc ttt Tyr Lys Asn Gly Lys His Pro Glu His Ala Phe Tyr Glu Phe Thr Phe 900 905 910	2736

THIS PAGE BLANK (USPTO)

cgg agg ttt ttt gat gac aat ggc tac cca tat aat tat cca aag cct 2784  
 Arg Arg Phe Phe Asp Asp Asn Gly Tyr Pro Tyr Asn Tyr Pro Lys Pro  
           915                                  920                                  925

att gag tat gaa tac att cat tca cag ggc tca gaa caa cag tct gat 2832  
 Ile Glu Tyr Glu Tyr Ile His Ser Gln Gly Ser Glu Gln Gln Ser Asp  
           930                                  935                                  940

gaa gat gat caa cac aca agc tcc gat gga aac aac cga gat cta gtg 2880  
 Glu Asp Asp Gln His Thr Ser Ser Asp Gly Asn Asn Arg Asp Leu Val  
           945                                  950                                  955                                  960

tat gtt taataaacta ggagatcatt gtaagaattt gcaagaggcc tgaagtgcag 2936  
 Tyr Val

gggtttttga agttttgaga aaattatgca aatgtgacag agtttgtgtg ctctgtgtac 2996

aatatttttat tttcctaagt tatgggaaat tgttttataaa tgtaatttta ttccaccctt 3056

ttaattcagt aatttagaaa aaattgttat aaggaaagta aattatgaac tgagtattat 3116

agtcaattct tggtacttaa agtacttaaa aagagaagcc tggtatcttt tgtatatata 3176

ataaataatt ttaaaatccc aaaaaaaaaa aaaaaaa 3213

<210> 4

<211> 962

<212> PRT

<213> Mus musculus

<400> 4

Val Gln His Ser Ile Asn Arg Lys Gln Ser Trp Lys Gly Ser Lys Glu  
       1                                  5                                  10                                  15

Ser Leu Val Pro Gln Arg His Gly Pro Ser Leu Gly Glu Asn Val Val  
           20                                  25                                  30

Tyr Arg Ser Glu Ser Pro Asn Ser Gln Ala Asp Val Gly Arg Pro Leu  
           35                                  40                                  45

Ser Gly Ser Gly Ile Ala Ala Phe Ala Gln Ala His Pro Ser Asn Gly  
           50                                  55                                  60

Gln Arg Val Asn Pro Pro Pro Pro Pro Gln Val Arg Ser Val Thr Pro  
           65                                  70                                  75                                  80

Pro Pro Pro Pro Arg Gly Gln Thr Pro Pro Pro Arg Gly Thr Thr Pro  
                                   85                                  90                                  95

Pro Pro Pro Ser Trp Glu Pro Ser Ser Gln Thr Lys Arg Tyr Ser Gly  
           100                                  105                                  110

Asn Met Glu Tyr Val Ile Ser Arg Ile Ser Pro Val Pro Pro Gly Ala  
           115                                  120                                  125

Trp Gln Glu Gly Tyr Pro Pro Pro Pro Leu Thr Thr Ser Pro Met Asn  
           130                                  135                                  140

**THIS PAGE BLANK (USPTO)**

Pro Pro Ser Gln Ala Gln Arg Ala Ile Ser Ser Val Pro Val Gly Arg  
 145 150 155 160  
 Gln Pro Ile Ile Met Gln Ser Thr Ser Lys Phe Asn Phe Thr Pro Gly  
 165 170 175  
 Arg Pro Gly Val Gln Asn Gly Gly Gly Gln Ser Asp Phe Ile Val His  
 180 185 190  
 Gln Asn Val Pro Thr Gly Ser Val Thr Arg Gln Pro Pro Pro Pro Tyr  
 195 200 205  
 Pro Leu Thr Pro Ala Asn Gly Gln Ser Pro Ser Ala Leu Gln Thr Gly  
 210 215 220  
 Ala Ser Ala Ala Pro Pro Ser Phe Ala Asn Gly Asn Val Pro Gln Ser  
 225 230 235 240  
 Met Met Val Pro Asn Arg Asn Ser His Asn Met Glu Leu Tyr Asn Ile  
 245 250 255  
 Asn Val Pro Gly Leu Gln Thr Ala Trp Pro Gln Ser Ser Ser Ala Pro  
 260 265 270  
 Ala Gln Ser Ser Pro Ser Gly Gly His Glu Ile Pro Thr Trp Gln Pro  
 275 280 285  
 Asn Ile Pro Val Arg Ser Asn Ser Phe Asn Asn Pro Leu Gly Ser Arg  
 290 295 300  
 Ala Ser His Ser Ala Asn Ser Gln Pro Ser Ala Thr Thr Val Thr Ala  
 305 310 315 320  
 Ile Thr Pro Ala Pro Ile Gln Gln Pro Val Lys Ser Met Arg Val Leu  
 325 330 335  
 Lys Pro Glu Leu Gln Thr Ala Leu Ala Pro Thr His Pro Ser Trp Met  
 340 345 350  
 Pro Gln Pro Val Gln Thr Val Gln Pro Thr Pro Phe Ser Glu Gly Thr  
 355 360 365  
 Ala Ser Ser Val Pro Val Ile Pro Pro Val Ala Glu Ala Pro Ser Tyr  
 370 375 380  
 Gln Gly Pro Pro Pro Pro Tyr Pro Lys His Leu Leu His Gln Asn Pro  
 385 390 395 400  
 Ser Val Pro Pro Tyr Glu Ser Val Ser Lys Pro Cys Lys Asp Glu Gln  
 405 410 415  
 Pro Ser Leu Pro Lys Glu Asp Asp Ser Glu Lys Ser Ala Asp Ser Gly  
 420 425 430  
 Asp Ser Gly Asp Lys Glu Lys Lys Gln Ile Thr Thr Ser Pro Ile Thr  
 435 440 445

**THIS PAGE BLANK (USPTO)**

Val Arg Lys Asn Lys Lys Asp Glu Glu Arg Arg Glu Ser Arg Ile Gln  
 450 455 460  
 Ser Tyr Ser Pro Gln Ala Phe Lys Phe Phe Met Glu Gln His Val Glu  
 465 470 475 480  
 Asn Val Leu Lys Ser His Gln Gln Arg Leu His Arg Lys Lys Gln Leu  
 485 490 495  
 Glu Asn Glu Met Met Arg Val Gly Leu Ser Gln Asp Ala Gln Asp Gln  
 500 505 510  
 Met Arg Lys Met Leu Cys Gln Lys Glu Ser Asn Tyr Ile Arg Leu Lys  
 515 520 525  
 Arg Ala Lys Met Asp Lys Ser Met Phe Val Lys Ile Lys Thr Leu Gly  
 530 535 540  
 Ile Gly Ala Phe Gly Glu Val Cys Leu Ala Arg Lys Val Asp Thr Lys  
 545 550 555 560  
 Ala Leu Tyr Ala Thr Lys Thr Leu Arg Lys Lys Asp Val Leu Leu Arg  
 565 570 575  
 Asn Gln Val Ala His Val Lys Ala Glu Arg Asp Ile Leu Ala Glu Ala  
 580 585 590  
 Asp Asn Glu Trp Val Val Arg Leu Tyr Tyr Ser Phe Gln Asp Lys Asp  
 595 600 605  
 Asn Leu Tyr Phe Val Met Asp Tyr Ile Pro Gly Gly Asp Met Met Ser  
 610 615 620  
 Leu Leu Ile Arg Met Gly Ile Phe Pro Glu Asn Leu Ala Arg Phe Tyr  
 625 630 635 640  
 Ile Ala Glu Leu Thr Cys Ala Val Glu Ser Val His Lys Met Gly Phe  
 645 650 655  
 Ile His Arg Asp Ile Lys Pro Asp Asn Ile Leu Ile Asp Arg Asp Gly  
 660 665 670  
 His Ile Lys Leu Thr Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp Thr  
 675 680 685  
 His Asp Ser Lys Tyr Tyr Gln Ser Gly Asp His Pro Arg Gln Asp Ser  
 690 695 700  
 Met Asp Phe Ser Asn Glu Trp Gly Asp Pro Ser Asn Cys Arg Cys Gly  
 705 710 715 720  
 Asp Arg Leu Lys Pro Leu Glu Arg Arg Ala Ala Arg Gln His Gln Arg  
 725 730 735  
 Cys Leu Ala His Ser Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu  
 740 745 750

**THIS PAGE BLANK (USPTO)**



Val Leu Leu Arg Thr Gly Tyr Thr Gln Leu Cys Asp Trp Trp Ser Val  
 755 760 765  
 Gly Val Ile Leu Cys Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala  
 770 775 780  
 Gln Thr Pro Leu Glu Thr Gln Met Lys Val Ile Ile Trp Gln Thr Ser  
 785 790 795 800  
 Leu His Ile Pro Pro Gln Ala Lys Leu Ser Pro Glu Ala Ser Asp Leu  
 805 810 815  
 Ile Ile Lys Leu Cys Arg Gly Pro Glu Asp Arg Leu Gly Lys Asn Gly  
 820 825 830  
 Ala Asp Glu Ile Lys Ala His Pro Phe Phe Lys Thr Ile Asp Phe Ser  
 835 840 845  
 Ser Asp Leu Arg Gln Gln Ser Ala Ser Tyr Ile Pro Lys Ile Thr His  
 850 855 860  
 Pro Thr Asp Thr Ser Asn Phe Asp Pro Val Asp Pro Asp Lys Leu Trp  
 865 870 875 880  
 Ser Asp Gly Ser Glu Glu Glu Asn Ile Ser Asp Thr Leu Ser Gly Trp  
 885 890 895  
 Tyr Lys Asn Gly Lys His Pro Glu His Ala Phe Tyr Glu Phe Thr Phe  
 900 905 910  
 Arg Arg Phe Phe Asp Asp Asn Gly Tyr Pro Tyr Asn Tyr Pro Lys Pro  
 915 920 925  
 Ile Glu Tyr Glu Tyr Ile His Ser Gln Gly Ser Glu Gln Gln Ser Asp  
 930 935 940  
 Glu Asp Asp Gln His Thr Ser Ser Asp Gly Asn Asn Arg Asp Leu Val  
 945 950 955 960  
 Tyr Val

<210> 5  
 <211> 3155  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> CDS  
 <222> (1)..(2940)

<400> 5  
 atg aga gcc acc ccg aag ttt gga cct tat caa aaa gct ctc agg gaa 48  
 Met Arg Ala Thr Pro Lys Phe Gly Pro Tyr Gln Lys Ala Leu Arg Glu  
 1 5 10 15

**THIS PAGE BLANK (USPTO)**

atc cga tat tcc ctc ctg cct ttt gcc aac gag tca ggc act tcg gca	96
Ile Arg Tyr Ser Leu Leu Pro Phe Ala Asn Glu Ser Gly Thr Ser Ala	
20 25 30	
gct gca gag gtg aac cgg cag atg ctt cag gag ttg gtg aat gcg gca	144
Ala Ala Glu Val Asn Arg Gln Met Leu Gln Glu Leu Val Asn Ala Ala	
35 40 45	
tgt gac cag gag atg gct ggc aga gcg ctc acg cag acg ggc agt agg	192
Cys Asp Gln Glu Met Ala Gly Arg Ala Leu Thr Gln Thr Gly Ser Arg	
50 55 60	
agt atc gaa gct gcc ttg gag tac atc agt aag atg ggc tac ctg gac	240
Ser Ile Glu Ala Ala Leu Glu Tyr Ile Ser Lys Met Gly Tyr Leu Asp	
65 70 75 80	
ccc agg aat gag cag att gtg cga gtc atc aag cag acc tcc cca gga	288
Pro Arg Asn Glu Gln Ile Val Arg Val Ile Lys Gln Thr Ser Pro Gly	
85 90 95	
aag ggc ctg gcg tcc acc ccg gtg act cgg cgg ccc agt ttc gag ggc	336
Lys Gly Leu Ala Ser Thr Pro Val Thr Arg Arg Pro Ser Phe Glu Gly	
100 105 110	
aca ggg gaa gca ctc cca tcc tac cac cag ctg ggt ggt gca aac tac	384
Thr Gly Glu Ala Leu Pro Ser Tyr His Gln Leu Gly Gly Ala Asn Tyr	
115 120 125	
gag ggc ccc gcc gca ctg gag gag atg ccg cgg caa tat tta gac ttt	432
Glu Gly Pro Ala Ala Leu Glu Glu Met Pro Arg Gln Tyr Leu Asp Phe	
130 135 140	
ctc ttc cct gga gcc gga gcc gcc acc cac ggt gcc cag gct cac cag	480
Leu Phe Pro Gly Ala Gly Ala Gly Thr His Gly Ala Gln Ala His Gln	
145 150 155 160	
cat cct ccc aaa ggg tac agc aca gca gta gag cca agt gcg cac ttt	528
His Pro Pro Lys Gly Tyr Ser Thr Ala Val Glu Pro Ser Ala His Phe	
165 170 175	
ccg ggc aca cac tat ggt cgt ggt cat cta cta tcg gag cag tct ggg	576
Pro Gly Thr His Tyr Gly Arg Gly His Leu Leu Ser Glu Gln Ser Gly	
180 185 190	
tat ggg gtg cag cgc agt tcc tcc ttc cag aac aag acg cca cca gat	624
Tyr Gly Val Gln Arg Ser Ser Ser Phe Gln Asn Lys Thr Pro Pro Asp	
195 200 205	
gcc tat tcc agc atg gcc aag gcc cag ggt ggc cct ccc gcc agc ctc	672
Ala Tyr Ser Ser Met Ala Lys Ala Gln Gly Gly Pro Pro Ala Ser Leu	
210 215 220	
acc ttt cct gcc cat gct ggg ctg tac act gcc tcg cac cac aag ccg	720
Thr Phe Pro Ala His Ala Gly Leu Tyr Thr Ala Ser His His Lys Pro	
225 230 235 240	

**THIS PAGE BLANK (USPTO)**

gcg gct acc cca cct ggg gcc cac cca tta cat gtg ttg ggc acc cgg	768
Ala Ala Thr Pro Pro Gly Ala His Pro Leu His Val Leu Gly Thr Arg	
245 250 255	
ggt ccc acg ttt act ggc gaa agc tct gca cag gct gtg ctg gca ccg	816
Gly Pro Thr Phe Thr Gly Glu Ser Ser Ala Gln Ala Val Leu Ala Pro	
260 265 270	
tcc agg aac agc ctc aat gct gac ttg tac gag ctg ggc tcc acg gtg	864
Ser Arg Asn Ser Leu Asn Ala Asp Leu Tyr Glu Leu Gly Ser Thr Val	
275 280 285	
ccc tgg tct gca gct cca ctg gca cgc cgc gac tcg ctg cag aag cag	912
Pro Trp Ser Ala Ala Pro Leu Ala Arg Arg Asp Ser Leu Gln Lys Gln	
290 295 300	
ggt cta gaa gcc tcg cgg ccg cat gtg gct ttt cgg gct ggc ccc agc	960
Gly Leu Glu Ala Ser Arg Pro His Val Ala Phe Arg Ala Gly Pro Ser	
305 310 315 320	
agg acc aac tcc ttc aac aac cca caa cct gag ccc tca ctg ccc gcc	1008
Arg Thr Asn Ser Phe Asn Asn Pro Gln Pro Glu Pro Ser Leu Pro Ala	
325 330 335	
ccc aac acg gtc acc gcc gtg acg gcc gca cac atc ctt cac cct gtg	1056
Pro Asn Thr Val Thr Ala Val Thr Ala Ala His Ile Leu His Pro Val	
340 345 350	
aag agc gtg cgt gtg ctg cgg ccc gag ccc cag aca gcc gtg ggg ccc	1104
Lys Ser Val Arg Val Leu Arg Pro Glu Pro Gln Thr Ala Val Gly Pro	
355 360 365	
tcg cac ccc gcc tgg gtg gct gcg ccc aca gca cct gcc act gag agc	1152
Ser His Pro Ala Trp Val Ala Ala Pro Thr Ala Pro Ala Thr Glu Ser	
370 375 380	
ctg gag acg aag gag ggc agc gca ggc cca cac ccg ctg gat gtg gac	1200
Leu Glu Thr Lys Glu Gly Ser Ala Gly Pro His Pro Leu Asp Val Asp	
385 390 395 400	
tat ggc ggc tcc gag cgc agg tgc cca ccg cct ccg tat cca aag cac	1248
Tyr Gly Gly Ser Glu Arg Arg Cys Pro Pro Pro Pro Tyr Pro Lys His	
405 410 415	
ttg ctg ctg ccc agt aag tct gag cag tac agc gtg gac ctg gac agc	1296
Leu Leu Leu Pro Ser Lys Ser Glu Gln Tyr Ser Val Asp Leu Asp Ser	
420 425 430	
ctg tgc acc agt gtg cag cag agt ctg cga ggg ggc act gat cta gac	1344
Leu Cys Thr Ser Val Gln Gln Ser Leu Arg Gly Gly Thr Asp Leu Asp	
435 440 445	
ggg agt gac aag agc cac aaa ggt gcg aag gga gac aaa gct ggc aga	1392
Gly Ser Asp Lys Ser His Lys Gly Ala Lys Gly Asp Lys Ala Gly Arg	
450 455 460	

THIS PAGE BLANK (USPTO)

gac	aaa	aag	cag	att	cag	acc	tcc	ccg	gtg	cct	gtc	cgc	aag	aat	agc	1440
Asp	Lys	Lys	Gln	Ile	Gln	Thr	Ser	Pro	Val	Pro	Val	Arg	Lys	Asn	Ser	
465					470					475					480	
aga	gat	gaa	gag	aag	aga	gag	tct	cgc	atc	aag	agt	tac	tcc	cct	tat	1488
Arg	Asp	Glu	Glu	Lys	Arg	Glu	Ser	Arg	Ile	Lys	Ser	Tyr	Ser	Pro	Tyr	
				485					490					495		
gcc	ttc	aaa	ttc	ttc	atg	gag	caa	cac	gtg	gag	aat	gtc	atc	aaa	acc	1536
Ala	Phe	Lys	Phe	Phe	Met	Glu	Gln	His	Val	Glu	Asn	Val	Ile	Lys	Thr	
			500					505					510			
tac	cag	cag	aag	gtc	agc	cgg	agg	cta	cag	ctg	gag	cag	gaa	atg	gcc	1584
Tyr	Gln	Gln	Lys	Val	Ser	Arg	Arg	Leu	Gln	Leu	Glu	Gln	Glu	Met	Ala	
			515				520					525				
aaa	gct	ggg	ctc	tgt	gag	gcc	gag	cag	gag	cag	atg	agg	aag	atc	ctc	1632
Lys	Ala	Gly	Leu	Cys	Glu	Ala	Glu	Gln	Glu	Gln	Met	Arg	Lys	Ile	Leu	
	530					535					540					
tac	cag	aag	gag	tct	aac	tac	aac	cgg	ctg	aag	agg	gcc	aag	atg	gac	1680
Tyr	Gln	Lys	Glu	Ser	Asn	Tyr	Asn	Arg	Leu	Lys	Arg	Ala	Lys	Met	Asp	
545					550					555					560	
aag	tcc	atg	ttt	gtg	aaa	atc	aag	act	cta	ggc	atc	ggg	gcc	ttt	ggg	1728
Lys	Ser	Met	Phe	Val	Lys	Ile	Lys	Thr	Leu	Gly	Ile	Gly	Ala	Phe	Gly	
				565					570					575		
gaa	gtg	tgc	ctc	gct	tgt	aag	ctg	gac	act	cac	gct	ctg	tac	gcc	atg	1776
Glu	Val	Cys	Leu	Ala	Cys	Lys	Leu	Asp	Thr	His	Ala	Leu	Tyr	Ala	Met	
			580					585					590			
aag	act	ctc	agg	aag	aag	gat	gtc	ctg	aac	cgg	aat	caa	gtg	gcc	cat	1824
Lys	Thr	Leu	Arg	Lys	Lys	Asp	Val	Leu	Asn	Arg	Asn	Gln	Val	Ala	His	
			595				600					605				
gtc	aag	gct	gag	agg	gac	atc	ctg	gct	gaa	gca	gac	aat	gag	tgg	gtg	1872
Val	Lys	Ala	Glu	Arg	Asp	Ile	Leu	Ala	Glu	Ala	Asp	Asn	Glu	Trp	Val	
	610					615					620					
gtc	aaa	ctc	tac	tac	tcc	ttc	cag	gac	aag	gac	agc	ctg	tac	ttt	gtg	1920
Val	Lys	Leu	Tyr	Tyr	Ser	Phe	Gln	Asp	Lys	Asp	Ser	Leu	Tyr	Phe	Val	
625					630					635					640	
atg	gac	tac	ata	cca	ggc	ggg	gat	atg	atg	agc	ctg	ctg	atc	agg	atg	1968
Met	Asp	Tyr	Ile	Pro	Gly	Gly	Asp	Met	Met	Ser	Leu	Leu	Ile	Arg	Met	
				645					650					655		
gag	gtc	ttc	cct	gag	cac	ctg	gcc	cgc	ttc	tac	att	gca	gag	ttg	acc	2016
Glu	Val	Phe	Pro	Glu	His	Leu	Ala	Arg	Phe	Tyr	Ile	Ala	Glu	Leu	Thr	
			660					665					670			
ctg	gcc	att	gaa	agt	gtc	cac	aag	atg	ggc	ttt	atc	cac	cgg	gac	atc	2064
Leu	Ala	Ile	Glu	Ser	Val	His	Lys	Met	Gly	Phe	Ile	His	Arg	Asp	Ile	
		675					680					685				

**THIS PAGE BLANK (USPTO)**



aag cct gac aac ata ctc atc gac ctg gat ggt cat att aag ctg aca	2112
Lys Pro Asp Asn Ile Leu Ile Asp Leu Asp Gly His Ile Lys Leu Thr	
690 695 700	
gat ttt ggc ctc tgc act gga ttc agg tgg act cac aat tcc aag tac	2160
Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp Thr His Asn Ser Lys Tyr	
705 710 715 720	
tac cag aaa ggg aac cac atg aga cag gac agc atg gag ccc ggt gac	2208
Tyr Gln Lys Gly Asn His Met Arg Gln Asp Ser Met Glu Pro Gly Asp	
725 730 735	
ctc tgg gac gat gtt tcc aac tgt cgc tgt gga gac agg tta aag acc	2256
Leu Trp Asp Asp Val Ser Asn Cys Arg Cys Gly Asp Arg Leu Lys Thr	
740 745 750	
ctg gag cag agg gcg cag aag cag cac cag agg tgc ctg gca cat tct	2304
Leu Glu Gln Arg Ala Gln Lys Gln His Gln Arg Cys Leu Ala His Ser	
755 760 765	
ctt gtc ggg aca cca aat tac atc gct ccg gag gtg ctt ctc cgc aaa	2352
Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu Val Leu Leu Arg Lys	
770 775 780	
ggg tac acg cag ctc tgt gac tgg tgg agc gtc ggt gtg att ctc ttt	2400
Gly Tyr Thr Gln Leu Cys Asp Trp Trp Ser Val Gly Val Ile Leu Phe	
785 790 795 800	
gag atg ctg gtt ggg cag ccg cct ttc ttg gcc ccc acc ccc aca gag	2448
Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala Pro Thr Pro Thr Glu	
805 810 815	
acg cag ctg aag gtg atc aac tgg gag agc acg ctg cat atc cct acg	2496
Thr Gln Leu Lys Val Ile Asn Trp Glu Ser Thr Leu His Ile Pro Thr	
820 825 830	
cag gtg agg ctc agc gct gag gcc cga gac ctc atc acg aag ctg tgc	2544
Gln Val Arg Leu Ser Ala Glu Ala Arg Asp Leu Ile Thr Lys Leu Cys	
835 840 845	
tgc gcg gct gac tgc cgc ctg ggc agg gat ggg gca gat gac ctc aag	2592
Cys Ala Ala Asp Cys Arg Leu Gly Arg Asp Gly Ala Asp Asp Leu Lys	
850 855 860	
gca cac ccg ttc ttc aac acc atc gac ttt tcc cgt gac atc cga aag	2640
Ala His Pro Phe Phe Asn Thr Ile Asp Phe Ser Arg Asp Ile Arg Lys	
865 870 875 880	
cag gct gca ccc tac gtc ccc acc atc agc cac ccc atg gac acc tcc	2688
Gln Ala Ala Pro Tyr Val Pro Thr Ile Ser His Pro Met Asp Thr Ser	
885 890 895	
aat ttt gac ccg gtg gat gaa gaa agc ccc tgg cac gag gcc agc gga	2736
Asn Phe Asp Pro Val Asp Glu Glu Ser Pro Trp His Glu Ala Ser Gly	
900 905 910	

**THIS PAGE BLANK (USPTO)**

gag agc gcc aag gcc tgg gac acg ctg gcc tcc ccc agc agc aag cat 2784  
 Glu Ser Ala Lys Ala Trp Asp Thr Leu Ala Ser Pro Ser Ser Lys His  
           915                                  920                                  925

cca gag cac gcc ttc tat gag ttc acc ttc cgc agg ttc ttc gat gac 2832  
 Pro Glu His Ala Phe Tyr Glu Phe Thr Phe Arg Arg Phe Phe Asp Asp  
           930                                  935                                  940

aac ggc tat ccc ttc cgg tgc ccg aag ccc tca gag ccc gca gag agt 2880  
 Asn Gly Tyr Pro Phe Arg Cys Pro Lys Pro Ser Glu Pro Ala Glu Ser  
           945                                  950                                  955                                  960

gca gac cca ggg gat gcg gac ttg gaa ggt gcg gcc gag ggc tgc cag 2928  
 Ala Asp Pro Gly Asp Ala Asp Leu Glu Gly Ala Ala Glu Gly Cys Gln  
                                   965                                  970                                  975

ccg gtg tac gtg taagcctcag ttaaccacaa ctgaggagaaa cccaaaatga 2980  
 Pro Val Tyr Val  
                                   980

gattttctttt cagaagacaa actcaagctt aggaatcctt catttttagt tctggtaaata 3040

gggcaacagg aagagtcaac atgatttcaa attagccctc tgaggacctt cactgcatta 3100

aaacagtatt ttttaaaaaa ttagtacagt atggaaagag cacttatttt gggggg 3155

<210> 6

<211> 980

<212> PRT

<213> Mus musculus

<400> 6

Met Arg Ala Thr Pro Lys Phe Gly Pro Tyr Gln Lys Ala Leu Arg Glu  
       1                                  5                                  10                                  15

Ile Arg Tyr Ser Leu Leu Pro Phe Ala Asn Glu Ser Gly Thr Ser Ala  
                                   20                                  25                                  30

Ala Ala Glu Val Asn Arg Gln Met Leu Gln Glu Leu Val Asn Ala Ala  
                                   35                                  40                                  45

Cys Asp Gln Glu Met Ala Gly Arg Ala Leu Thr Gln Thr Gly Ser Arg  
                                   50                                  55                                  60

Ser Ile Glu Ala Ala Leu Glu Tyr Ile Ser Lys Met Gly Tyr Leu Asp  
                                   65                                  70                                  75                                  80

Pro Arg Asn Glu Gln Ile Val Arg Val Ile Lys Gln Thr Ser Pro Gly  
                                   85                                  90                                  95

Lys Gly Leu Ala Ser Thr Pro Val Thr Arg Arg Pro Ser Phe Glu Gly  
                                   100                                  105                                  110

Thr Gly Glu Ala Leu Pro Ser Tyr His Gln Leu Gly Gly Ala Asn Tyr  
                                   115                                  120                                  125

**THIS PAGE BLANK (USPTO)**

Glu Gly Pro Ala Ala Leu Glu Glu Met Pro Arg Gln Tyr Leu Asp Phe  
 130 135 140  
 Leu Phe Pro Gly Ala Gly Ala Gly Thr His Gly Ala Gln Ala His Gln  
 145 150 155 160  
 His Pro Pro Lys Gly Tyr Ser Thr Ala Val Glu Pro Ser Ala His Phe  
 165 170 175  
 Pro Gly Thr His Tyr Gly Arg Gly His Leu Leu Ser Glu Gln Ser Gly  
 180 185 190  
 Tyr Gly Val Gln Arg Ser Ser Ser Phe Gln Asn Lys Thr Pro Pro Asp  
 195 200 205  
 Ala Tyr Ser Ser Met Ala Lys Ala Gln Gly Gly Pro Pro Ala Ser Leu  
 210 215 220  
 Thr Phe Pro Ala His Ala Gly Leu Tyr Thr Ala Ser His His Lys Pro  
 225 230 235 240  
 Ala Ala Thr Pro Pro Gly Ala His Pro Leu His Val Leu Gly Thr Arg  
 245 250 255  
 Gly Pro Thr Phe Thr Gly Glu Ser Ser Ala Gln Ala Val Leu Ala Pro  
 260 265 270  
 Ser Arg Asn Ser Leu Asn Ala Asp Leu Tyr Glu Leu Gly Ser Thr Val  
 275 280 285  
 Pro Trp Ser Ala Ala Pro Leu Ala Arg Arg Asp Ser Leu Gln Lys Gln  
 290 295 300  
 Gly Leu Glu Ala Ser Arg Pro His Val Ala Phe Arg Ala Gly Pro Ser  
 305 310 315 320  
 Arg Thr Asn Ser Phe Asn Asn Pro Gln Pro Glu Pro Ser Leu Pro Ala  
 325 330 335  
 Pro Asn Thr Val Thr Ala Val Thr Ala Ala His Ile Leu His Pro Val  
 340 345 350  
 Lys Ser Val Arg Val Leu Arg Pro Glu Pro Gln Thr Ala Val Gly Pro  
 355 360 365  
 Ser His Pro Ala Trp Val Ala Ala Pro Thr Ala Pro Ala Thr Glu Ser  
 370 375 380  
 Leu Glu Thr Lys Glu Gly Ser Ala Gly Pro His Pro Leu Asp Val Asp  
 385 390 395 400  
 Tyr Gly Gly Ser Glu Arg Arg Cys Pro Pro Pro Pro Tyr Pro Lys His  
 405 410 415  
 Leu Leu Leu Pro Ser Lys Ser Glu Gln Tyr Ser Val Asp Leu Asp Ser  
 420 425 430

**THIS PAGE BLANK (USPTO)**

Leu Cys Thr Ser Val Gln Gln Ser Leu Arg Gly Gly Thr Asp Leu Asp  
 435 440 445  
 Gly Ser Asp Lys Ser His Lys Gly Ala Lys Gly Asp Lys Ala Gly Arg  
 450 455 460  
 Asp Lys Lys Gln Ile Gln Thr Ser Pro Val Pro Val Arg Lys Asn Ser  
 465 470 475 480  
 Arg Asp Glu Glu Lys Arg Glu Ser Arg Ile Lys Ser Tyr Ser Pro Tyr  
 485 490 495  
 Ala Phe Lys Phe Phe Met Glu Gln His Val Glu Asn Val Ile Lys Thr  
 500 505 510  
 Tyr Gln Gln Lys Val Ser Arg Arg Leu Gln Leu Glu Gln Glu Met Ala  
 515 520 525  
 Lys Ala Gly Leu Cys Glu Ala Glu Gln Glu Gln Met Arg Lys Ile Leu  
 530 535 540  
 Tyr Gln Lys Glu Ser Asn Tyr Asn Arg Leu Lys Arg Ala Lys Met Asp  
 545 550 555 560  
 Lys Ser Met Phe Val Lys Ile Lys Thr Leu Gly Ile Gly Ala Phe Gly  
 565 570 575  
 Glu Val Cys Leu Ala Cys Lys Leu Asp Thr His Ala Leu Tyr Ala Met  
 580 585 590  
 Lys Thr Leu Arg Lys Lys Asp Val Leu Asn Arg Asn Gln Val Ala His  
 595 600 605  
 Val Lys Ala Glu Arg Asp Ile Leu Ala Glu Ala Asp Asn Glu Trp Val  
 610 615 620  
 Val Lys Leu Tyr Tyr Ser Phe Gln Asp Lys Asp Ser Leu Tyr Phe Val  
 625 630 635 640  
 Met Asp Tyr Ile Pro Gly Gly Asp Met Met Ser Leu Leu Ile Arg Met  
 645 650 655  
 Glu Val Phe Pro Glu His Leu Ala Arg Phe Tyr Ile Ala Glu Leu Thr  
 660 665 670  
 Leu Ala Ile Glu Ser Val His Lys Met Gly Phe Ile His Arg Asp Ile  
 675 680 685  
 Lys Pro Asp Asn Ile Leu Ile Asp Leu Asp Gly His Ile Lys Leu Thr  
 690 695 700  
 Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp Thr His Asn Ser Lys Tyr  
 705 710 715 720  
 Tyr Gln Lys Gly Asn His Met Arg Gln Asp Ser Met Glu Pro Gly Asp  
 725 730 735

**THIS PAGE BLANK (USPTO)**



Leu Trp Asp Asp Val Ser Asn Cys Arg Cys Gly Asp Arg Leu Lys Thr  
                     740                    745                    750  
 Leu Glu Gln Arg Ala Gln Lys Gln His Gln Arg Cys Leu Ala His Ser  
                     755                    760                    765  
 Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu Val Leu Leu Arg Lys  
                     770                    775                    780  
 Gly Tyr Thr Gln Leu Cys Asp Trp Trp Ser Val Gly Val Ile Leu Phe  
                     785                    790                    795                    800  
 Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala Pro Thr Pro Thr Glu  
                     805                    810                    815  
 Thr Gln Leu Lys Val Ile Asn Trp Glu Ser Thr Leu His Ile Pro Thr  
                     820                    825                    830  
 Gln Val Arg Leu Ser Ala Glu Ala Arg Asp Leu Ile Thr Lys Leu Cys  
                     835                    840                    845  
 Cys Ala Ala Asp Cys Arg Leu Gly Arg Asp Gly Ala Asp Asp Leu Lys  
                     850                    855                    860  
 Ala His Pro Phe Phe Asn Thr Ile Asp Phe Ser Arg Asp Ile Arg Lys  
                     865                    870                    875                    880  
 Gln Ala Ala Pro Tyr Val Pro Thr Ile Ser His Pro Met Asp Thr Ser  
                     885                    890                    895  
 Asn Phe Asp Pro Val Asp Glu Glu Ser Pro Trp His Glu Ala Ser Gly  
                     900                    905                    910  
 Glu Ser Ala Lys Ala Trp Asp Thr Leu Ala Ser Pro Ser Ser Lys His  
                     915                    920                    925  
 Pro Glu His Ala Phe Tyr Glu Phe Thr Phe Arg Arg Phe Phe Asp Asp  
                     930                    935                    940  
 Asn Gly Tyr Pro Phe Arg Cys Pro Lys Pro Ser Glu Pro Ala Glu Ser  
                     945                    950                    955                    960  
 Ala Asp Pro Gly Asp Ala Asp Leu Glu Gly Ala Ala Glu Gly Cys Gln  
                     965                    970                    975  
 Pro Val Tyr Val  
                     980

<210> 7  
 <211> 5720  
 <212> DNA  
 <213> Drosophila melanogaster  
  
 <220>  
 <221> CDS  
 <222> (1103) .. (4399)

**THIS PAGE BLANK (USPTO)**

<400> 7  
atctagcacg acggcagcaa caaaaccacg aattaatttt actaaattta agccaaacgc 60  
gcatcggaaa tgcctgaaaa tgcgattgaa tgcacgcgaa aagtgatggg ttgcgaacgc 120  
gagtgaatca agtgaaaata cgtcggcaaa tatcagcgaa ttgtcgtcaa aaggcaagga 180  
aaaacgggaga aaaagaggaa aagcaataag tgccgtgtgt gggaaacgcg aaaaaggcga 240  
gaacaaagag gcgaaaagcg aggaaattgc gtggaaaacg tggaaaacgc gaagaagcga 300  
agctccaagt tggccgccat cgattcgtgc gtaggatcaa ttaagattcc gagtggtcga 360  
gaatcggctc aaatcaaatt aaaatcaact aatatttttg tattcagata ttcaaattga 420  
attcattcat cgcttgcgac ttttattcgg atctgccaac tatttttgaa tttgaattgt 480  
gtgtctgcgg ctggcgcaga atctctgata aagcagagga ataaaatcgg aagaacaaca 540  
aatacaaata caaatgaaat gcggggagca gtatttacat gccaaatgaa tgctggatag 600  
gcgaaagggg gggtttctct tataatgcaa atgtgaatgt gaatgcgaat gcgaatgcga 660  
gtggaagaat tcccggcgcg agtgataaat aatccgacga caaacaagc agaagcctac 720  
accgcgagaa agagcagcgc aaacacaatt atctttattg agagcaacaa tatcaagatc 780  
gagataataa agcatcctaa aaccgcgcgc ttagttcgtt ttagtctcgc cacggatata 840  
gatattcaaa ggcaaaaagg tgggtgcggc atcgccagac aaacaagtaa agcatctatt 900  
tcatacaaaa caaccaatta aataataata aaaataataa taatcgtaga gaggcagagc 960  
caaatcaaat tcccggcgcg cgatgtgcc cagtgtgtgt gcgtgtgtgt gtgtgtgtgc 1020  
tgtgtgtgc tgtgcgagtg ttagtgtgcg gagcatttct gtgatatgag tgctaaatgc 1080  
cacagggcga agcagcagca tc atg cat cca gcg ggc gaa aaa agg ggc ggt 1132  
Met His Pro Ala Gly Glu Lys Arg Gly Gly  
1 5 10  
cgc ccc aat gat aaa tac acg gcg gaa gcc ctc gag agc atc aag cag 1180  
Arg Pro Asn Asp Lys Tyr Thr Ala Glu Ala Leu Glu Ser Ile Lys Gln  
15 20 25  
gac cta acc cga ttt gaa gta caa aat aac cat agg aat aat cag aat 1228  
Asp Leu Thr Arg Phe Glu Val Gln Asn Asn His Arg Asn Asn Gln Asn  
30 35 40  
tac aca cct ctg cga tac acg gcg acc aac gga cgc aac gat gca ctt 1276  
Tyr Thr Pro Leu Arg Tyr Thr Ala Thr Asn Gly Arg Asn Asp Ala Leu  
45 50 55  
act cct gac tat cac cac gcc aag cag ccg atg gag ccg cca ccc tcc 1324  
Thr Pro Asp Tyr His His Ala Lys Gln Pro Met Glu Pro Pro Pro Ser  
60 65 70

**THIS PAGE BLANK (USPTO)**

gcc tct cct gct ccg gac gtg gtc ata ccg ccg ccg ccc gcc att gta	1372
Ala Ser Pro Ala Pro Asp Val Val Ile Pro Pro Pro Pro Ala Ile Val	
75 80 85 90	
ggc cag ccc gga gcc ggc tcc ata tcc gta tcc ggt gtg ggc gtt gga	1420
Gly Gln Pro Gly Ala Gly Ser Ile Ser Val Ser Gly Val Gly Val Gly	
95 100 105	
gtg gtg ggt gtg gcg aac gga cgt gtg cca aag atg atg acg gcc cta	1468
Val Val Gly Val Ala Asn Gly Arg Val Pro Lys Met Met Thr Ala Leu	
110 115 120	
atg cca aac aaa ctg atc cgg aag ccg agc atc gaa cgg gac acg gcg	1516
Met Pro Asn Lys Leu Ile Arg Lys Pro Ser Ile Glu Arg Asp Thr Ala	
125 130 135	
agc agt cac tac ctg cgc tgc agt ccg gct ctg gac tcc gga gcc ggt	1564
Ser Ser His Tyr Leu Arg Cys Ser Pro Ala Leu Asp Ser Gly Ala Gly	
140 145 150	
agc tcc cga tcg gac agc ccc cat tcg cac cac acc cac cag ccg agc	1612
Ser Ser Arg Ser Asp Ser Pro His Ser His His Thr His Gln Pro Ser	
155 160 165 170	
tcg agg acg gtg ggt aat cca ggt gga aat ggt gga ttt tct ccg tcg	1660
Ser Arg Thr Val Gly Asn Pro Gly Gly Asn Gly Gly Phe Ser Pro Ser	
175 180 185	
cca agc ggt ttc agt gag gtg gct cca ccg gcg ccg ccg cca cgc aat	1708
Pro Ser Gly Phe Ser Glu Val Ala Pro Pro Ala Pro Pro Pro Arg Asn	
190 195 200	
ccc acc gcc tcc agc gcg gcc acg ccc cca ccg cca gtg ccg ccc acc	1756
Pro Thr Ala Ser Ser Ala Ala Thr Pro Pro Pro Pro Val Pro Pro Thr	
205 210 215	
agc cag gcg tac gtg aag cgg cga tca ccg gcc ctg aac aac cgc ccg	1804
Ser Gln Ala Tyr Val Lys Arg Arg Ser Pro Ala Leu Asn Asn Arg Pro	
220 225 230	
ccg gcg ata gcg cca ccc act cag cga ggc aac tca cct gta ata acc	1852
Pro Ala Ile Ala Pro Pro Thr Gln Arg Gly Asn Ser Pro Val Ile Thr	
235 240 245 250	
caa aac ggg ctg aag aac ccg cag cag cag ttg acg cag cag ctg aag	1900
Gln Asn Gly Leu Lys Asn Pro Gln Gln Gln Leu Thr Gln Gln Leu Lys	
255 260 265	
tcc ctg aac cta tac cca ggc gga ggc agt gga gca gtg gtg gag cca	1948
Ser Leu Asn Leu Tyr Pro Gly Gly Ser Gly Ala Val Val Glu Pro	
270 275 280	
ccg ccg ccc tac cta att caa ggc gga gcc gga gga gca gca ccg ccg	1996
Pro Pro Pro Tyr Leu Ile Gln Gly Gly Ala Gly Gly Ala Ala Pro Pro	
285 290 295	

**THIS PAGE BLANK (USPTO)**

ccg cca cca ccc agt tac acg gcc tcc atg cag tcg cgg cag tcg ccc Pro Pro Pro Pro Ser Tyr Thr Ala Ser Met Gln Ser Arg Gln Ser Pro 300 305 310	2044
aca caa tcc caa caa tcg gac tac agg aaa tcc ccg agc agt ggg ata Thr Gln Ser Gln Gln Ser Asp Tyr Arg Lys Ser Pro Ser Ser Gly Ile 315 320 325 330	2092
tac tcg gcc acc tcg gcg ggc tcg ccg agc ccc ata act gtg tcg ctg Tyr Ser Ala Thr Ser Ala Gly Ser Pro Ser Pro Ile Thr Val Ser Leu 335 340 345	2140
ccg ccg gcg ccg ctg gcg aag cca caa cca cga gtc tac cag gcc agg Pro Pro Ala Pro Leu Ala Lys Pro Gln Pro Arg Val Tyr Gln Ala Arg 350 355 360	2188
agt cag cag ccg atc atc atg cag agt gtg aag agc acg cag gtc caa Ser Gln Gln Pro Ile Ile Met Gln Ser Val Lys Ser Thr Gln Val Gln 365 370 375	2236
aag ccc gtg ctg caa aca gca gtg gcg cgc caa tcg cca tcg agt gcc Lys Pro Val Leu Gln Thr Ala Val Ala Arg Gln Ser Pro Ser Ser Ala 380 385 390	2284
tcg gcc agc aat tca cca gtc cac gtg ctg gcc gct cca ccc tct tac Ser Ala Ser Asn Ser Pro Val His Val Leu Ala Ala Pro Pro Ser Tyr 395 400 405 410	2332
cct cag aag tcc gcg gca gtg gtg cag cag cag caa cag gca gca gcg Pro Gln Lys Ser Ala Ala Val Val Gln Gln Gln Gln Gln Ala Ala Ala 415 420 425	2380
gcg gcc cac cag cag cag cat cag cac cag caa tcc aaa cca cca acg Ala Ala His Gln Gln Gln His Gln His Gln Gln Ser Lys Pro Pro Thr 430 435 440	2428
cca acc aca ccg ccc ttg gtg ggt ctg aac agc aag ccc aat tgc ctg Pro Thr Thr Pro Pro Leu Val Gly Leu Asn Ser Lys Pro Asn Cys Leu 445 450 455	2476
gag cca ccg tcc tat gcc aag agc atg cag gcc aag gcg gcc acg gtg Glu Pro Pro Ser Tyr Ala Lys Ser Met Gln Ala Lys Ala Ala Thr Val 460 465 470	2524
gta cag cag cag caa cag cag cag caa caa cag cag gtc cag cag cag Val Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Val Gln Gln Gln 475 480 485 490	2572
cag gtg caa cag cag cag caa cag cag caa cag caa ctg cag gcc ttg Gln Val Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Leu Gln Ala Leu 495 500 505	2620
agg gtg ctc cag gca cag gct cag agg gag cgg gat caa cgg gag cgg Arg Val Leu Gln Ala Gln Ala Gln Arg Glu Arg Asp Gln Arg Glu Arg 510 515 520	2668

**THIS PAGE BLANK (USPTO)**



gaa cgg gat cag cag aag ctg gcc aac gga aat cct ggc cgg cag atg	2716
Glu Arg Asp Gln Gln Lys Leu Ala Asn Gly Asn Pro Gly Arg Gln Met	
525 530 535	
ctt ccg ccg ccg ccc tat cag agc aac aac aac aac aac agc gag atc	2764
Leu Pro Pro Pro Pro Tyr Gln Ser Asn Asn Asn Asn Asn Ser Glu Ile	
540 545 550	
aaa ccg ccg agc tgc aac aac aac aac ata cag ata agc aac agc aac	2812
Lys Pro Pro Ser Cys Asn Asn Asn Asn Ile Gln Ile Ser Asn Ser Asn	
555 560 565 570	
ctg gcg acg aca cca ccc att ccg cct gcc aaa tac aat aac aac tcc	2860
Leu Ala Thr Thr Pro Pro Ile Pro Pro Ala Lys Tyr Asn Asn Asn Ser	
575 580 585	
tcc aac acg ggc gcg aat agc tcg ggc ggc agc aac gga tcc acc ggc	2908
Ser Asn Thr Gly Ala Asn Ser Ser Gly Gly Ser Asn Gly Ser Thr Gly	
590 595 600	
acc acc gcc tcc tcg tcg acc agc tgc aag aag atc aag cac gcc tcg	2956
Thr Thr Ala Ser Ser Ser Thr Ser Cys Lys Lys Ile Lys His Ala Ser	
605 610 615	
ccc atc ccg gag cgc aag aag atc tcc aag gag aag gag gag gag cgc	3004
Pro Ile Pro Glu Arg Lys Lys Ile Ser Lys Glu Lys Glu Glu Glu Arg	
620 625 630	
aag gag ttc cgc atc agg cag tac tcg ccg caa gcc ttc aag ttc ttc	3052
Lys Glu Phe Arg Ile Arg Gln Tyr Ser Pro Gln Ala Phe Lys Phe Phe	
635 640 645 650	
atg gag cag cac ata gag aac gtg atc aag tcg tat cgc cag cgc acg	3100
Met Glu Gln His Ile Glu Asn Val Ile Lys Ser Tyr Arg Gln Arg Thr	
655 660 665	
tat cgc aag aat cag ctg gag aag gag atg cac aaa gtg gga ctg ccc	3148
Tyr Arg Lys Asn Gln Leu Glu Lys Glu Met His Lys Val Gly Leu Pro	
670 675 680	
gat cag acc caa atc gag atg agg aaa atg ctg aac caa aag gag agc	3196
Asp Gln Thr Gln Ile Glu Met Arg Lys Met Leu Asn Gln Lys Glu Ser	
685 690 695	
aac tac att cga ttg aag cgc gcc aag atg gac aag agc atg ttc gtc	3244
Asn Tyr Ile Arg Leu Lys Arg Ala Lys Met Asp Lys Ser Met Phe Val	
700 705 710	
aaa ctg aag ccc att gga gtg ggt gca ttt ggc gag gta acg ctg gtg	3292
Lys Leu Lys Pro Ile Gly Val Gly Ala Phe Gly Glu Val Thr Leu Val	
715 720 725 730	
agc aaa atc gat acc tcg aac cat ttg tat gcg atg aaa acc ctg cgg	3340
Ser Lys Ile Asp Thr Ser Asn His Leu Tyr Ala Met Lys Thr Leu Arg	
735 740 745	

**THIS PAGE BLANK (USPTO)**

aaa gcg gac gtt ctc aag cgg aat cag gtg gca cac gtg aag gcc gag	3388
Lys Ala Asp Val Leu Lys Arg Asn Gln Val Ala His Val Lys Ala Glu	
750 755 760	
agg gat atc ctc gcg gaa gcc gac aat aac tgg gtg gtg aag ttg tac	3436
Arg Asp Ile Leu Ala Glu Ala Asp Asn Asn Trp Val Val Lys Leu Tyr	
765 770 775	
tac agc ttc cag gac aag gat aat ctg tac ttt gtg atg gac tac ata	3484
Tyr Ser Phe Gln Asp Lys Asp Asn Leu Tyr Phe Val Met Asp Tyr Ile	
780 785 790	
cca ggt ggt gat ctg atg tcg ctg ctc atc aaa ctg ggc att ttc gag	3532
Pro Gly Gly Asp Leu Met Ser Leu Leu Ile Lys Leu Gly Ile Phe Glu	
795 800 805 810	
gag gaa ctg gcc aga ttc tac atc gcc gag gtc acc tgc gcc gtg gac	3580
Glu Glu Leu Ala Arg Phe Tyr Ile Ala Glu Val Thr Cys Ala Val Asp	
815 820 825	
agc gtt cac aaa atg ggc ttc att cac aga gac atc aag cct gac aac	3628
Ser Val His Lys Met Gly Phe Ile His Arg Asp Ile Lys Pro Asp Asn	
830 835 840	
ata ctc atc gat agg gac gga cac ata aag ctc acc gac ttt ggc ctg	3676
Ile Leu Ile Asp Arg Asp Gly His Ile Lys Leu Thr Asp Phe Gly Leu	
845 850 855	
tgc acg gga ttc cga tgg acg cac aac tcg aag tac tac cag gag aac	3724
Cys Thr Gly Phe Arg Trp Thr His Asn Ser Lys Tyr Tyr Gln Glu Asn	
860 865 870	
ggc aat cac tcg cgc cag gac tcg atg gag ccc tgg gag gaa tac tcc	3772
Gly Asn His Ser Arg Gln Asp Ser Met Glu Pro Trp Glu Glu Tyr Ser	
875 880 885 890	
gag aac gga ccg aag ccc acc gtg ctg gag agg cga cgg atg cgc gat	3820
Glu Asn Gly Pro Lys Pro Thr Val Leu Glu Arg Arg Arg Met Arg Asp	
895 900 905	
cac caa aga gtc ctg gcc cac tcg ctg gtg ggc acc ccg aac tac ata	3868
His Gln Arg Val Leu Ala His Ser Leu Val Gly Thr Pro Asn Tyr Ile	
910 915 920	
gct ccc gag gtg ctg gag agg agt ggg tac acg cag ctg tgc gac tac	3916
Ala Pro Glu Val Leu Glu Arg Ser Gly Tyr Thr Gln Leu Cys Asp Tyr	
925 930 935	
tgg agc gtg ggc gtc atc ctt tac gag atg ctg gtg ggt cag ccg ccc	3964
Trp Ser Val Gly Val Ile Leu Tyr Glu Met Leu Val Gly Gln Pro Pro	
940 945 950	
ttt ctg gcc aac agt ccg ctg gaa acg caa caa aag gtc atc aac tgg	4012
Phe Leu Ala Asn Ser Pro Leu Glu Thr Gln Gln Lys Val Ile Asn Trp	
955 960 965 970	

**THIS PAGE BLANK (USPTO)**

gag aaa acg ctg cat att ccg ccg cag gcc gag tta tcc cgc gag gct 4060  
 Glu Lys Thr Leu His Ile Pro Pro Gln Ala Glu Leu Ser Arg Glu Ala  
 975 980 985

acg gac ttg ata agg agg ctg tgt gcg tcg gct gac aag cgg ctg ggc 4108  
 Thr Asp Leu Ile Arg Arg Leu Cys Ala Ser Ala Asp Lys Arg Leu Gly  
 990 995 1000

aag agc gtg gac gag gtc aag agc cac gac ttc ttc aag ggc atc gac 4156  
 Lys Ser Val Asp Glu Val Lys Ser His Asp Phe Phe Lys Gly Ile Asp  
 1005 1010 1015

ttt gcg gac atg cgg aag cag aaa gcg ccc tac ata ccg gaa atc aag 4204  
 Phe Ala Asp Met Arg Lys Gln Lys Ala Pro Tyr Ile Pro Glu Ile Lys  
 1020 1025 1030

cac cca acg gac aca tcc aac ttt gat ccc gtg gat ccg gag aag ctg 4252  
 His Pro Thr Asp Thr Ser Asn Phe Asp Pro Val Asp Pro Glu Lys Leu  
 1035 1040 1045 1050

cgc tcg aat gac tcc acc atg agc agc ggc gat gat gtc gac cag aat 4300  
 Arg Ser Asn Asp Ser Thr Met Ser Ser Gly Asp Asp Val Asp Gln Asn  
 1055 1060 1065

gac cgc act ttc cac ggc ttt ttc gaa ttt acc ttc cgt cgc ttc ttc 4348  
 Asp Arg Thr Phe His Gly Phe Phe Glu Phe Thr Phe Arg Arg Phe Phe  
 1070 1075 1080

gac gac aag cag ccg ccg gat atg acg gac gat cag gcg ccg gtt tac 4396  
 Asp Asp Lys Gln Pro Pro Asp Met Thr Asp Asp Gln Ala Pro Val Tyr  
 1085 1090 1095

gtc tgaaatggat gctctccatg tgcccaacac caacaccccg cccccgaatc 4449  
 Val

attgttagtc aaatagtcac aaaaagggga tagaaaccat tgagtgggct tgcattgtaa 4509

aggaagcgtg gctatagaat gaaactatct atatacatta tataaattat aggagacagt 4569

agagggcggga gctacgtata tacatacaaa taatatacat atatttgata tatatatata 4629

tatatatgcc gtagggcatg aactgaataa atataaaacg gagccgagta gagatgaaac 4689

gagaggagcg agtcaggacc ttcgaccttt aactgaacat agtatatcct tgtgcactac 4749

tactccacaa caaatatata tttttaaaatt gttagaattc aaaagggacc aactggaaat 4809

cgaacctttc tgggtgctcaa agcaaagcaa agcaaagcaa aacaaaacgc cttaaactaa 4869

atgagacgcg aatttaccca accacttcac tcctctcctt tctccacctc cgatcggtgg 4929

ccggattcga actcagcagg ctgggtgcat ccggccatcc cattgacttc ccattcagaa 4989

ttgagattgc gaggtgtgcg atggagaacg aacggagacc aaaagtcgca cggcagcgat 5049

ataagcgggt cttataagcc taatctaaat ctaaactggg agaacaggac ctatgtatgt 5109

cctgctatcc aattcgtcta tcaactgctct tcactctgtgt acgaccccca cccccccct 5169

**THIS PAGE BLANK (USPTO)**

ccccatccaa aagaacaaac ttagacgtag cctatgtgaa aagctagcaa tgtagacca 5229  
 acttggtgaa tgccaaatga aattgttttag cccacgaggg aaaacgcggg ggaaattcaa 5289  
 cacttattct ctgatagcaa acggaaaaga aagaaagaaa aaaaaaaca gaaacagtac 5349  
 gagaaaattg taatcttctt aatgtaatat tgtaaagaac acgttaattg taatctatgc 5409  
 tagagttgtg tagcgcccta agatgttttt tagtttatag accgctaacc gtaatctagt 5469  
 ttaattccta acactaagcg agagtacagt acattgggtt ttttgtttgt cgtagggttcg 5529  
 ttggaaaatg cttaacggga aacgatttgt ttttctcttt aattagcttc agtttgatg 5589  
 tgcgtgtgtt tttattatga cttatatata gtccatctga atattcgtgg atggagccta 5649  
 ttttaaagt gagatcgagc taattgaagg aaatacaaac aaactctgtg tgccttgcc 5709  
 aattagttta c 5720

<210> 8  
 <211> 1099  
 <212> PRT  
 <213> *Drosophila melanogaster*

<400> 8  
 Met His Pro Ala Gly Glu Lys Arg Gly Gly Arg Pro Asn Asp Lys Tyr  
 1 5 10 15  
 Thr Ala Glu Ala Leu Glu Ser Ile Lys Gln Asp Leu Thr Arg Phe Glu  
 20 25 30  
 Val Gln Asn Asn His Arg Asn Asn Gln Asn Tyr Thr Pro Leu Arg Tyr  
 35 40 45  
 Thr Ala Thr Asn Gly Arg Asn Asp Ala Leu Thr Pro Asp Tyr His His  
 50 55 60  
 Ala Lys Gln Pro Met Glu Pro Pro Pro Ser Ala Ser Pro Ala Pro Asp  
 65 70 75 80  
 Val Val Ile Pro Pro Pro Pro Ala Ile Val Gly Gln Pro Gly Ala Gly  
 85 90 95  
 Ser Ile Ser Val Ser Gly Val Gly Val Gly Val Val Gly Val Ala Asn  
 100 105 110  
 Gly Arg Val Pro Lys Met Met Thr Ala Leu Met Pro Asn Lys Leu Ile  
 115 120 125  
 Arg Lys Pro Ser Ile Glu Arg Asp Thr Ala Ser Ser His Tyr Leu Arg  
 130 135 140  
 Cys Ser Pro Ala Leu Asp Ser Gly Ala Gly Ser Ser Arg Ser Asp Ser  
 145 150 155 160

**THIS PAGE BLANK (USPTO)**



Pro His Ser His His Thr His Gln Pro Ser Ser Arg Thr Val Gly Asn  
 165 170 175  
 Pro Gly Gly Asn Gly Gly Phe Ser Pro Ser Pro Ser Gly Phe Ser Glu  
 180 185 190  
 Val Ala Pro Pro Ala Pro Pro Pro Arg Asn Pro Thr Ala Ser Ser Ala  
 195 200 205  
 Ala Thr Pro Pro Pro Pro Val Pro Pro Thr Ser Gln Ala Tyr Val Lys  
 210 215 220  
 Arg Arg Ser Pro Ala Leu Asn Asn Arg Pro Pro Ala Ile Ala Pro Pro  
 225 230 235 240  
 Thr Gln Arg Gly Asn Ser Pro Val Ile Thr Gln Asn Gly Leu Lys Asn  
 245 250 255  
 Pro Gln Gln Gln Leu Thr Gln Gln Leu Lys Ser Leu Asn Leu Tyr Pro  
 260 265 270  
 Gly Gly Gly Ser Gly Ala Val Val Glu Pro Pro Pro Pro Tyr Leu Ile  
 275 280 285  
 Gln Gly Gly Ala Gly Gly Ala Ala Pro Pro Pro Pro Pro Pro Ser Tyr  
 290 295 300  
 Thr Ala Ser Met Gln Ser Arg Gln Ser Pro Thr Gln Ser Gln Gln Ser  
 305 310 315 320  
 Asp Tyr Arg Lys Ser Pro Ser Ser Gly Ile Tyr Ser Ala Thr Ser Ala  
 325 330 335  
 Gly Ser Pro Ser Pro Ile Thr Val Ser Leu Pro Pro Ala Pro Leu Ala  
 340 345 350  
 Lys Pro Gln Pro Arg Val Tyr Gln Ala Arg Ser Gln Gln Pro Ile Ile  
 355 360 365  
 Met Gln Ser Val Lys Ser Thr Gln Val Gln Lys Pro Val Leu Gln Thr  
 370 375 380  
 Ala Val Ala Arg Gln Ser Pro Ser Ser Ala Ser Ala Ser Asn Ser Pro  
 385 390 395 400  
 Val His Val Leu Ala Ala Pro Pro Ser Tyr Pro Gln Lys Ser Ala Ala  
 405 410 415  
 Val Val Gln Gln Gln Gln Gln Ala Ala Ala Ala His Gln Gln Gln  
 420 425 430  
 His Gln His Gln Gln Ser Lys Pro Pro Thr Pro Thr Thr Pro Pro Leu  
 435 440 445  
 Val Gly Leu Asn Ser Lys Pro Asn Cys Leu Glu Pro Pro Ser Tyr Ala  
 450 455 460

**THIS PAGE BLANK (USPTO)**

Lys Ser Met Gln Ala Lys Ala Ala Thr Val Val Gln Gln Gln Gln Gln  
 465 470 475 480  
 Gln Gln Gln Gln Gln Gln Val Gln Gln Gln Gln Val Gln Gln Gln Gln  
 485 490 495  
 Gln Gln Gln Gln Gln Gln Leu Gln Ala Leu Arg Val Leu Gln Ala Gln  
 500 505 510  
 Ala Gln Arg Glu Arg Asp Gln Arg Glu Arg Glu Arg Asp Gln Gln Lys  
 515 520 525  
 Leu Ala Asn Gly Asn Pro Gly Arg Gln Met Leu Pro Pro Pro Pro Tyr  
 530 535 540  
 Gln Ser Asn Asn Asn Asn Asn Ser Glu Ile Lys Pro Pro Ser Cys Asn  
 545 550 555 560  
 Asn Asn Asn Ile Gln Ile Ser Asn Ser Asn Leu Ala Thr Thr Pro Pro  
 565 570 575  
 Ile Pro Pro Ala Lys Tyr Asn Asn Asn Ser Ser Asn Thr Gly Ala Asn  
 580 585 590  
 Ser Ser Gly Gly Ser Asn Gly Ser Thr Gly Thr Thr Ala Ser Ser Ser  
 595 600 605  
 Thr Ser Cys Lys Lys Ile Lys His Ala Ser Pro Ile Pro Glu Arg Lys  
 610 615 620  
 Lys Ile Ser Lys Glu Lys Glu Glu Glu Arg Lys Glu Phe Arg Ile Arg  
 625 630 635 640  
 Gln Tyr Ser Pro Gln Ala Phe Lys Phe Phe Met Glu Gln His Ile Glu  
 645 650 655  
 Asn Val Ile Lys Ser Tyr Arg Gln Arg Thr Tyr Arg Lys Asn Gln Leu  
 660 665 670  
 Glu Lys Glu Met His Lys Val Gly Leu Pro Asp Gln Thr Gln Ile Glu  
 675 680 685  
 Met Arg Lys Met Leu Asn Gln Lys Glu Ser Asn Tyr Ile Arg Leu Lys  
 690 695 700  
 Arg Ala Lys Met Asp Lys Ser Met Phe Val Lys Leu Lys Pro Ile Gly  
 705 710 715 720  
 Val Gly Ala Phe Gly Glu Val Thr Leu Val Ser Lys Ile Asp Thr Ser  
 725 730 735  
 Asn His Leu Tyr Ala Met Lys Thr Leu Arg Lys Ala Asp Val Leu Lys  
 740 745 750  
 Arg Asn Gln Val Ala His Val Lys Ala Glu Arg Asp Ile Leu Ala Glu  
 755 760 765

**THIS PAGE BLANK (USPTO)**

Ala Asp Asn Asn Trp Val Val Lys Leu Tyr Tyr Ser Phe Gln Asp Lys  
 770 775 780  
 Asp Asn Leu Tyr Phe Val Met Asp Tyr Ile Pro Gly Gly Asp Leu Met  
 785 790 795 800  
 Ser Leu Leu Ile Lys Leu Gly Ile Phe Glu Glu Glu Leu Ala Arg Phe  
 805 810 815  
 Tyr Ile Ala Glu Val Thr Cys Ala Val Asp Ser Val His Lys Met Gly  
 820 825 830  
 Phe Ile His Arg Asp Ile Lys Pro Asp Asn Ile Leu Ile Asp Arg Asp  
 835 840 845  
 Gly His Ile Lys Leu Thr Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp  
 850 855 860  
 Thr His Asn Ser Lys Tyr Tyr Gln Glu Asn Gly Asn His Ser Arg Gln  
 865 870 875 880  
 Asp Ser Met Glu Pro Trp Glu Glu Tyr Ser Glu Asn Gly Pro Lys Pro  
 885 890 895  
 Thr Val Leu Glu Arg Arg Arg Met Arg Asp His Gln Arg Val Leu Ala  
 900 905 910  
 His Ser Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu Val Leu Glu  
 915 920 925  
 Arg Ser Gly Tyr Thr Gln Leu Cys Asp Tyr Trp Ser Val Gly Val Ile  
 930 935 940  
 Leu Tyr Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala Asn Ser Pro  
 945 950 955 960  
 Leu Glu Thr Gln Gln Lys Val Ile Asn Trp Glu Lys Thr Leu His Ile  
 965 970 975  
 Pro Pro Gln Ala Glu Leu Ser Arg Glu Ala Thr Asp Leu Ile Arg Arg  
 980 985 990  
 Leu Cys Ala Ser Ala Asp Lys Arg Leu Gly Lys Ser Val Asp Glu Val  
 995 1000 1005  
 Lys Ser His Asp Phe Phe Lys Gly Ile Asp Phe Ala Asp Met Arg Lys  
 1010 1015 1020  
 Gln Lys Ala Pro Tyr Ile Pro Glu Ile Lys His Pro Thr Asp Thr Ser  
 025 1030 1035 1040  
 Asn Phe Asp Pro Val Asp Pro Glu Lys Leu Arg Ser Asn Asp Ser Thr  
 1045 1050 1055  
 Met Ser Ser Gly Asp Asp Val Asp Gln Asn Asp Arg Thr Phe His Gly  
 1060 1065 1070

**THIS PAGE BLANK (USPTO)**

Phe	Phe	Glu	Phe	Thr	Phe	Arg	Arg	Phe	Phe	Asp	Asp	Lys	Gln	Pro	Pro
	1075						1080					1085			
Asp	Met	Thr	Asp	Asp	Gln	Ala	Pro	Val	Tyr	Val					
1090							1095								

**THIS PAGE BLANK (USPTO)**



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19068

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(C) : Please See Extra Sheet.  
US CL : 424/130.1; 536/23.5; 514/1, 2, 44; 800/3, 13, 14, 21, 25  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1; 536/23.5; 514/1, 2, 44; 800/3, 13, 14, 21, 25

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WEST, STN, MEDLINE, CAPLUS, BIOSIS, SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/30402 A1 (YALE UNIVERSITY) 03 October 1996, entire document, especially pages 158-163.	1-5
Y		6-113
Y	WO 95/31722 A1 (LIGAND PHARMACEUTICALS, INC.) 23 November 1995, entire document, especially page 50.	6-37
Y, P	TAO et al. Human homologue of the Drosophila melanogaster lats tumor suppressor modulates CDC2 activity, Nature Genetics, February 1999, Vol 21, No. 2, page 177-181, entire document.	68-113

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 OCTOBER 1999

Date of mailing of the international search report

16 DEC 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHIN-LIN CHEN

Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT****International application No.**  
**PCT/US99/19068****C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

<b>Category*</b>	<b>Citation of document, with indication, where appropriate, of the relevant passages</b>	<b>Relevant to claim No.</b>
<b>A, P</b>	<b>ST. JOHN et al. Mice Deficient of Lats1 Develop Soft-Tissue Sarcomas, Ovarian Tumors and Pituitary Dysfunction, Nature Genetics, February 1999, Vol 21, No. 2, page 182-186, entire document.</b>	<b>1-37</b>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19068

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/19068

**A. CLASSIFICATION OF SUBJECT MATTER:**  
**IPC (6):**

**A61K 39/395; C07H 21/04; A01N 61/00, 37/18, 43/04; C12N 5/00, 15/00**